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Abstract 
Optimization of buprenorphine dosing in pregnant women 
Hongfei Zhang, PhD 
University of Pittsburgh, 2019 
The primary objective of this work was to optimize buprenorphine (BUP) dosing based on 
exposure in treating opioid addiction in pregnant women. A combination of clinical 
pharmacokinetic study and modeling and simulation was used to accomplish this. 
The clinical study evaluated BUP pharmacokinetics (PK) during pregnancy and postpartum. Up 
to 3 studies were performed in each participant during 1st-, 2nd -half of pregnancy, and postpartum. 
At each study visit, multiple blood samples and specific pharmacodynamics measurements were 
collected. Plasma concentrations of BUP were quantified using UPLC-MS/MS. In this study BUP 
exposure was lower during pregnancy compared to postpartum.  
A physiologically-based pharmacokinetic (PBPK) model of intravenous and sublingual BUP was 
developed and verified using 14 independent BUP PK studies. This PBPK model predicted 
decreased BUP exposure during pregnancy compared to postpartum, consistent with the 
observations from the clinical study. 
Non-linear mixed effects modeling using a first-order conditional estimation with interaction to 
analyze changes in BUP PK in pregnant women was conducted. Buprenorphine PK data were 
well-characterized by a two-compartment model with first-order absorption with enterohepatic 
recirculation and first-order elimination. The model estimated population apparent clearance 
(CL/F) of BUP in a typical pregnant woman was 469 L/h. Pregnancy was associated with a 1.64-
folds increase in CL/F of BUP compared to postpartum period. A pharmacodynamic (PD) analysis 
showed that the average area under curves of COWS scores during pregnancy were significantly 
greater than postpartum period following administration of BUP, which is consistent with the 
v 
observed lower buprenorphine exposure during pregnancy. The relationship between pupillary 
diameters and BUP concentration was described by a sigmoidal Emax model with a hypothetical 
effect compartment. The calculated IC50 of BUP concentration for pupillary diameter changes was 
not significantly different during pregnant and postpartum, suggesting that there may not be any 
significant change in the sensitivity and /or number of µ-opioid receptors in the brain in pregnant 
women compared to non-pregnant women. 
Overall, the clinical observations and the two different modeling approaches demonstrated that 
BUP exposure is decreased during pregnancy and this alteration in BUP exposure is associated a 
decreased response to BUP in pregnancy.  
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1 
 Introduction 
1.1 Pain - Treatment of pain - Opioids 
Pain is one of the most prevalent public health problems. Pain can originate from diseases, 
or surgical, diagnostic and therapeutic procedures. A national Health Survey of 8,781 adults 
showed that 55.7% of the participants reported pain in the previous 3 months [1]. In addition, it is 
estimated that up to 71% of the patients experienced pain during their stay in the intensive care 
unit [2]. Pain contributes significantly to morbidity, mortality and disability of humans. Inadequate 
pain control can compromise recovery, and negatively impact patient outcomes both physically 
and psychologically. Pain is one of the sources of stress and agitation in patients. Accordingly, the 
use of analgesics for treating pain in patients is common.  
The pathophysiology of pain is complex. The process of pain includes transduction, 
transmission, modulation, and perception. The nociceptive pain starts from the activation of 
peripheral pain receptors, A-delta and C fiber. These afferent nerves translate noxious stimulation 
into nociceptive impulses, and these impulses are sent along the sensory tracks to the spinal cord 
and then to the brain. The modulation occurring at the gate of the dorsal horn is the process of 
lessening or amplifying the pain-related neural signal by the body. The final perception of pain is 
regulated by the transduction, transmission, modulation, and psychological aspect of the individual 
[3, 4]. Pain has sensory and emotional components. As a result, every patient experiences pain in 
a unique manner.  
Due to the complicated pathophysiology as well as subjective and emotional nature of pain, 
the management of pain is a challenge in clinic practice. Prescription opioids are commonly used 
2 
in the treatment of pain. Opioids are substances that bind to opioid receptors and the binding can 
be antagonized by naloxone [5]. Opioids can be either endogenous opiate alkaloids or exogenous 
chemicals [6]. The term of opioids generally refers to a group of drugs that are naturally derived 
such as morphine and codeine, semi-synthetics such as hydrocodone and oxycodone, or synthetic 
chemicals like fentanyl. Because of their effectiveness in relieving pain, opioid medications are 
the first-line of therapy for treating moderate to severe pain [7, 8].  
Opioids can simulate the effect of endorphins, endogenous opioids, to lessen the effects of 
painful stimuli by interacting with opioid receptors distributed throughout the central nervous 
system [9-12].  After binding to opioid receptors, opioids can also cause euphoric effects through 
their involvement in the dopaminergic brain regions involved in the reward system. Moreover, the 
euphoric effects may be intensified when the medication is taken in ways other than those 
prescribed – crushing, snorting, injecting, or combining with alcohol or other drugs [13-15]. 
Opioids are safe when taken as prescribed for a short time period. However, prolonged use may 
lead to dependence and addiction, as well as tolerance. The impact of opioids on the brain are 
complex [16, 17]. After entering the brain, exogenous opiates bind to mu-opioid receptors and 
activate the mesolimbic reward system. The activation of mesolimbic reward system results in the 
release of dopamine, which causes euphoria. Repeated exposure to opioids makes the brain cells 
less responsive and higher doses are needed to generate the same amount of dopamine, which is 
the process of tolerance. Another effect of opioid binding to µ-opioid receptor is the suppression 
of the release of noradrenaline. With repeated doses of opioids, the activities of neurons are 
upregulated to maintain normal levels of noradrenaline [16, 17]. When opioids are suddenly 
stopped, the effect on the inhibition of noradrenaline release is removed. The excessive release of 
noradrenaline results in irritability, anxiety, and jitter, as well as other withdrawal symptoms. The 
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long-term use of opioids can result in damage to the brain and lead to compulsive drug-seeking, 
which is addiction. Addiction leads to drug overdose. Death due to drug overdose has become a 
nationwide public health crisis in the United States [18-20]. In 2016 and 2017, death involving an 
opioid contributed to almost 70% of the total drug overdose related deaths [21].  
1.2 Current treatments of opioid addiction 
Psychosocial intervention alone or pharmacological intervention alone are associated with poor 
outcomes for patients with opioid addiction [22]. Currently, the most effective treatment for opioid 
addiction is medication-assisted treatment, which combines counseling, behavioral therapies with 
the use of medications. Several medications have been approved by the Food and Drug 
Administration (FDA) for treating opioid addiction including full agonist, partial agonist, and 
antagonist of mu-opioid receptor.  
1.2.1  Full agonist of mu-opioid receptor 
Methadone 
The use of methadone as a maintenance therapy to treat opioid addition can be traced back 
to 1960’s [23]. Many clinical studies have demonstrated the effectiveness of methadone 
maintenance interventions in reducing illicit opioid use, suppressing drug withdrawal, and 
minimizing craving [24-28]. Methadone is currently recognized as the standard of care for treating 
opioid addiction. Methadone, a racemic mixture of the R- and S- enantiomers is a synthetic agonist 
of mu-opioid receptor. Methadone binds to mu-, delta-, and kappa- opioid receptors with similar 
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pharmacological properties like morphine [29, 30]. Methadone blocks the binding of opioids with 
the receptors. As with other long-acting opioids, methadone has a better safety profile, for 
example, less severe abstinence syndrome, than short-acting opioids, such as heroin and morphine 
[31-33]. 
Following oral administration, the absolute bioavailability of methadone is approximately 
80% with marked interindividual variability (range from 41 – 100%) [34-36]. It is estimated that 
the first-pass metabolism of methadone in the intestinal tract is around 20%, with cytochrome P450 
(CYP) 3A4 being the primary enzyme for methadone metabolism [37, 38]. The mean time for peak 
plasma concentration ranges from 2.5 to 4 hours [39-41]. At steady-state, the volume of 
distribution of methadone is 5.9 and 3.3 L/kg for the R- and S- methadone, respectively [42]. As 
a basic drug, methadone is highly bound to alpha-1-acid glycoprotein in plasma (88%) [43, 44]. 
Methadone is mainly metabolized via N-demethylation to inactive metabolites by CYP3A4, 
CYP2B6 and CYP2C19 in the liver [45-47]. In addition, there is a limited amount of methadone 
that is eliminated as the parent drug through renal excretion. The renal elimination of methadone 
is urine pH dependent, and the renal clearance can contribute to the total body clearance from 1 to 
35% as urine pH varies from 7.8 to 5.2 [48, 49]. The total body clearance of methadone is 
approximately 8 L/h and the terminal half-life of methadone is 32 hours following intravenous 
administration in healthy subjects [45]. 
Levo-alpha-acetyl-methodol (LAAM) 
Levo-alpha-acetylmethodol, also known as levomethadyl acetate is a synthetic opioid with 
a structure similar to methadone. Compared to other mu opioid receptor agonists, LAAM has an 
extraordinary long duration of action due to its long half-life and active metabolites [50-52]. Many 
studies have shown that LAAM has similar or better efficacy compared to methadone in preventing 
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withdrawal symptoms induced by cessation of morphine or heroin [53-57]. LAAM was approved 
by the FDA as a pharmacotherapy for opioid dependence in the year 1993. However, due to its 
potential risks for serious and possibly life-threatening proarrhythmic side effect, LAAM has been 
removed from the market in the United states in the year 2003 [58]. 
1.2.2  Partial agonist of mu-opioid receptor 
Buprenorphine 
Buprenorphine is a semi-synthetic derivative of the alkaloid thebaine. Initially, 
buprenorphine was used as an opioid analgesic for treating moderate to severe pain. In 2002, 
buprenorphine was approved for the treatment of opioid addiction by the FDA. 
In comparison with morphine and methadone, buprenorphine has a very unique 
pharmacological profile. Buprenorphine has high binding affinity to mu opioid receptor but low 
intrinsic activity. In mouse mu receptor, transfected Chinese hamster ovary (mMOR-CHO) cells, 
the inhibitory constant (Ki), a parameter that reflects binding affinity of buprenorphine and 
morphine are 0.38 and 286 nM, respectively [59]. However, using [D-Ala2, N-Me4, Gly5-ol]-
enkephalin (DMGO) as a reference to measure the intrinsic activity of mu opioid receptor agonist 
binding effect, an in vitro study found that the maximal stimulation of G-protein activation by 
buprenorphine and morphine are 43 and 106%, respectively [60]. In addition to in vitro studies, 
the bell-shaped dose response curve of anti-nociception effect in animal studies, the ceiling effects 
of subjective measurements of agonist effect and minimal respiratory depression of buprenorphine 
at high doses in clinical studies all support buprenorphine as a partial mu-opioid receptor agonist 
[61, 62]. Besides binding to mu-opioid receptor, buprenorphine also binds to other opioid 
receptors. The Ki values are 0.08, 0.8 and 4.5 nM for the binding affinity to mu-, delta-, and kappa- 
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opioid receptors, respectively [63]. Buprenorphine has no intrinsic activity (antagonist) on the 
delta-opioid receptor and very low activity on the kappa-opioid receptor [60, 63, 64]. 
Buprenorphine has a very low oral bioavailability due to its extensive first-pass 
metabolism, therefore buprenorphine is administered through parenteral, sublingual, transmucosal, 
subcutaneous or transdermal routes and not orally [65]. The pharmacokinetic characteristics of the 
formulations of BUP are summarized in Table 1. High interindividual variability in buprenorphine 
pharmacokinetics following sublingual administration has been reported in multiple clinical 
studies. In a dose-escalation trial of sublingual buprenorphine conducted by Ciraulo et al., the 
coefficients of variation in the maximum plasma concentration (Cmax) and area under curve (AUC) 
ranged from 40 – 64% [66]. The plasma peak concentrations ranged from 1.93 to 7.2 ng/mL, and 
the AUC0-96 varied from 9.24 to 35.57 ng∙h/mL following single 4 mg sublingual administration 
of buprenorphine in 6 participants in the clinical study reported by Kuhlman et al [67]. Although 
the absorption after sublingual administration is rapid, the observed time to reach plasma peak 
concentration (Tmax) varied from less than 1 to 6 hrs [68, 69]. The relatively long time for plasma 
peak concentration after sublingual administration may be due to slow release of buprenorphine 
from the buccal tissue depot [69]. Several factors might impact the absorption and bioavailability 
of buprenorphine from the sublingual formulation. First of all, only unionized form of 
buprenorphine that can cross mucous membrane beneath the tongue, diffuses into the capillaries 
and enters into the venous circulation. Buprenorphine is a basic drug (pKa1 = 9.62, pKa2 = 8.31) 
[70]. Currently, no study has evaluated the associations between the bioavailability of BUP and 
the pH in the oral cavity with sublingual BUP. However, an in vivo clinical study has demonstrated 
that the bioavailability of methadone was improved from 34 to 75% when the pH of oral cavity 
was changed from 6.5 to 8.5 [71]. The normal pH range for oral cavity is around 7.4, but eating or 
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drinking acidic food can decrease the pH of saliva and mouth, and therefore can decrease the 
absorption of sublingual buprenorphine. Also, a high percent of BUP in the saliva that is swallowed 
during the sublingual administration is subjected to extensive first-pass metabolism leading to low 
oral bioavailability of BUP. Buprenorphine is a lipophilic drug with a logarithm of the octanol to 
water partition coefficient (LogP) of 4.98 [70]. Due to its high lipophilicity, buprenorphine readily 
penetrates into tissues. In plasma, buprenorphine is highly bound (96%) to alpha and beta globulin 
[72]. The apparent volume of distribution at steady state of buprenorphine following intravenous 
administration is 335 L [67]. Buprenorphine has a variable plasma elimination half-life as shown 
in Table 1-1 with different formulations. The long half-life reported after subcutaneous injection 
is due to the slow and continuous release and absorption of buprenorphine from the depot tissue 
into the body. Following sublingual or transmucosal administration, the half-life is commonly 
reported in the range of 24-42 hours. 
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Table 1-1 Pharmacokinetic characteristics of different buprenorphine formulations approved by the FDA 
Formulation Indication Dosage Strength Absolute Bioavailability (%) 
Tmax 
(hrs) 
Mean plasma 
elimination 
half-life  
Reference 
Buccal film Severe pain 75, 150, 300, 450, 600, 750, 900 µg 46-65 0.5-4 27.6 hrs 
Belbuca 
Label [73] 
Injection 
(Intravenous/intramuscular) 
Moderate to 
severe pain 0.3 mg/ 1 mL 100 0.25 [74] 1.2 – 7.2 hrs 
Buprenex 
Label [75] 
Transdermal system 
Moderate to 
severe chronic 
pain 
5, 10, 15,  
20 µg /hrs 15 72  
26 hrs (upon 
removal of 
path)  
Butrans 
Lable [76] 
Buccal film 
(buprenorphine/naloxone) 
 
 
 
 
 
Maintenance 
treatment of 
opioid 
dependence 
2.1 mg/0.3 mg 
4.2 mg/0.7 mg 
6.3 mg/1 mg 
Not reported 
(Bunavail has a 
higher 
bioavailability than 
Suboxone) 
0.5 – 4.02 
[74] 14.6 – 27.5 hrs 
Bunavail 
Label [77] 
Sublingual tablet 2, 8 mg 30-55 [67, 78] 1.28 - 1.84 31-35 hrs Subtex Label [79] 
Sublingual tablet 
(buprenorphine/naloxone) 
1.4 mg/ 0.36 mg 
5.7 mg /1.4 mg 
40% higher than 
Suboxone [80, 81] 1.75 24 - 42 hrs 
Zubsolv 
Label [82] 
Sublingual film 
(buprenorphine/naloxone) 
2 mg/ 0.5 mg, 
8 mg /2 mg, 
16 mg /4 mg 
 46 – 51 [74] 1.25 – 1.72 35 - 37 hrs 
Suboxone 
Label [72], 
Cassipa 
Label [83] 
Implanted subdermal 
administration 
Low-to-
moderate opioid 
use disorder 
74.2 mg/ 24 weeks Not reported 12 
13.7 - 23.8 hrs 
(upon removal 
implants) [84] 
Probuphine 
Label [85] 
Subcutaneous injection 
(Extended-release) 
Moderate to 
severe opioid use 
disorder 
100 mg/0.5 mL 
300 mg/1.5 mL Not reported 24 43 – 60 days 
Sublocade 
Label [86] 
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Plasma clearance of BUP is around 50 L/h after an intravenous injection in healthy 
volunteers [74, 78, 87, 88]. The blood clearance of buprenorphine is approximate 80 L/hr (the 
blood to plasma ratio of buprenorphine is 0.6 [89]). Comparing BUP blood clearance with (the 
hepatic blood blow in healthy subjects (1.5 L/min), the estimated BUP hepatic extraction ratio is 
approximate 0.9, which indicates BUP to be a high hepatic clearance drug. For a high clearance 
drug given by oral route, the blood flow, the intrinsic clearance and the unbound fraction of a drug 
in blood will affect its oral clearance. Buprenorphine is N-dealkylated in the liver to 
norbuprenorphine, primarily by CYP3A4, which is further conjugated to norbuprenorphine 
glucuronide [90, 91]. A portion of BUP can also be directly conjugated to buprenorphine 
glucuronide. Overall, in addition to CYP3A4, and CYP2C8, and Uridine 5'-diphospho-
glucuronosyltransferases (UGT1A1, UGT1A3, and UG2B7) are also involved in buprenorphine 
metabolism. In vitro study have shown that the N-dealkylated metabolite, norbuprenorphine has 
high affinity to the mu-opioid receptor that is comparable to that of the parent compound (Ki = 
0.07 nM) [92]. The high potency of norbuprenorphine to mu-opioid receptor might be a concern 
for respiratory depression, a common side effect caused by opioid agonists. However, both in vitro 
and in vivo studies have shown that norbuprenorphine is a substrate of P-glycoprotein 1 (P-gp) 
efflux transporter and the exposure of norbuprenorphine in the brain is minimal [93, 94]. In 
contrast, P-gp mediated transport of buprenorphine is very limited [93]. Although buprenorphine 
glucuronide and norbuprenorphine glucuronide have been shown in vitro to be biologically active, 
they are expected to have minimal clinical impact due to their high hydrophilicity and poor 
penetration into the brain [95].  
With regards to the excretion of buprenorphine, a mass balance study has shown that 
following intravenous dosing of buprenorphine, a total of 69% and 30% of the radioactivity was 
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recovered in the feces and urine, respectively. The unconjugated buprenorphine and 
norbuprenorphine in feces probably comes from the hydrolysis of the conjugates of buprenorphine 
and norbuprenorphine that are secreted through the bile into the intestine [96]. 
1.2.3  Antagonist of mu-opioid receptor 
Naltrexone 
Naltrexone shows a much higher affinity to mu-opioid receptor than other opioids, 
including heroin, morphine, methadone and buprenorphine (Ki = 0.3 nM) [97]. Naltrexone 
competes with other opioid agonists and occupies opioid receptors due to its higher affinity [98]. 
As a consequence, naltrexone blocks the euphoric effect of opioid agonists. Naltrexone can 
precipitate withdrawal symptom in patients who are physically dependent on opioids [99, 100]. 
Naltrexone has both oral and injectable long-acting sustained release formulations. Despite its 
effective blockage of opioids, clinical utility of naltrexone is hampered by poor patient retention, 
especially for its oral formulations [101]. The oral bioavailability of naltrexone ranges from 5 to 
40% due to first pass metabolism. Naltrexone has a low extent binding to plasma protein 
(approximate 20%) and relative large apparent volume of distribution (1350 liters) [102]. The half-
life of naltrexone is approximately 6 hours. After administration, naltrexone is extensively 
metabolized by dihydrodiol dehydrogenase, a cytosolic enzyme [103]. The major metabolite of 
naltrexone is 6-β-naltrexone, which also shows antagonistic effect at the mu-opioid receptor [104, 
105]. The active metabolite, 6-beta-naltrexone has a much longer half-life (24.96 hrs) compared 
to its parent naltrexone (6 hrs) [106, 107]. 
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Naloxone 
Naloxone is a very potent (Ki = 2.3 nM ) mu-opioid receptor antagonist [108]. Naloxone 
is able to reverse the effects of opioid agonists, such as respiratory depression, by competitively 
occupying opioid receptors [109, 110]. After injection, the onset of action of naloxone occurs 
generally within 2 minutes. Naloxone has no effect following oral administration. Naloxone is 
directly conjugated to form its major metabolite, naloxone-3-glucuronide. A portion of 
administered dose also undergoes to N-dealkylation [111]. The mean plasma elimination half-life 
of naloxone is around 2 hours [112]. Due to its short half-life, naloxone is not used as a 
maintenance treatment of opioid addiction. Many studies have demonstrated that naloxone has no 
impact on the pharmacokinetics of buprenorphine [69, 88, 113]. Therefore, another clinical utility 
of naloxone is to prevent intravenous misuse of buprenorphine. Naloxone is added to 
buprenorphine sublingual formulation, as in Suboxone. Naloxone has minimal absorption 
following sublingual administration; however, it antagonizes the effects of opioid agonists when 
patients crush and inject the combination formulation. 
1.2.4  Non-opioid Treatment 
In 2018, the FDA approved lofexidine to facilitate abrupt opioid discontinuation by 
mitigating opioid withdrawal symptoms in adults. As an alpha-2 adrenergic agonist, lofexidine 
decreases norepinephrine release, thereby, lessens the withdrawal syndrome when patients stop 
taking opioid agonists [114, 115].  Lofexidine is not a treatment for opioid use disorder, but can 
be used as a treatment for management of opioid withdrawal symptoms during detoxification. The 
standard treatment duration of lofexidine is up to 14 days. After oral administration, the peak 
plasma concentration of lofexidine is observed around 3 to 5 hours [116]. The terminal elimination 
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half-life of lofexidine at steady state is 17-22 hours [116]. Lofexidine is extensively metabolized 
by CYP2D6 to form its major metabolite, 2,6-dichlorophenol [117]. Both lofexidine and its 
metabolites are mainly excreted via the kidney [117]. 
In conclusion, the current treatment for opioid addiction can be grouped into 3 categories, 
abstinence-based treatment (antagonist of µ-opioid receptor), maintenance-based treatment 
(agonist of µ-opioid receptor), and adjuvant treatment to facilitate abstinence of opioid (non-
opioids). Although abstinence from opioid is the ultimate goal for treating opioid addiction, high 
rate of relapse in abstinence-based treatment has been reported [118]. The most effective approach 
for treating opioid addiction would be to gradually decrease methadone or buprenorphine-based 
maintenance treatment to abstinence. However, there is no clear consensus on how long a patient 
should receive the maintenance-based treatment before detoxification, as this approach is also 
associated with high rate of relapse [118]. 
1.3 Physiological changes during pregnancy  
Pregnancy is a very unique status that induces many anatomical and physiological changes 
in the body to accommodate the development and growth of the fetus. These maternal changes and 
adaptations in pregnant women occur gradually, bound by certain limits without maternal damage 
and revert to nonpregnant baseline several weeks after delivery. The causal mechanism of all of 
these changes has not been totally understood, but many studies have found associations between 
regulation of hormones and physiological changes during pregnancy [119-121]. The summary of 
physiological changes during pregnancy are shown in Table 1-2.
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Table 1-2. Physiological changes during pregnancy 
System Parameter Non-pregnant Pregnant (near term) 
Placenta Blood flow (mL/min) [122] 0 600-700  
Uterine Uterine artery blood flow 
(mL/min) [123] 
50-100 500-1000 
Cardiovasular Cardiac output (L/min) [124] 4.8 7.2 
Stroke volume (mL) [124] 65 82 
Heart rate (beats/min) [124] 75 88 
Plasma Volume (L) [125] 2.6 3.5 
Liver Hepatic artery blood flow (L/min) [126] 0.57 1.06 
Portal vein (L/min) [126] 1.25 1.92 
Renal Glomerular filtration rate [mL/min] 
[127] 
99 151 
Serum creatinine (mg/dL) [125] 0.7 0.5 
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1.3.1  Uterus  
Uterus is the place where the fetus undergoes development and growth during the entire 
gestation. During pregnancy, uterus contains fetus, placenta and the amniotic sac. In order to 
provide nutrition, space and protection to the fetus, there is marked increase in uterine size and 
weight throughout the gestation. For example, uterine artery blood flow gradually increases from 
50-100 ml/min in non-pregnant state to 500 – 1000 ml/min at 16th gestational week [123].  
1.3.2  Placenta and fetus 
Placenta is a temporary organ that develops in the uterus during pregnancy and is expelled 
from the body upon the birth of the baby. Placenta serves as an interface, which connects the fetus 
via the umbilical cord to the uterine wall on the maternal side. Placenta plays a critical role in the 
development and growth of the fetus. Placenta together with the umbilical cord are critical for the 
exchange of substances between the maternal and the fetal sides, e.g. diffusion of oxygen and 
carbon dioxide, supplying nutrients to fetus, and removal of waste products from the fetus. 
Placenta provides immunity to the fetus by transferring maternal immunoglobulins to the fetus. 
Placenta also serves as an endocrine organ by secretion of hormones that are essential for the 
development and growth of the fetus [128]. 
Although placenta is covered by a thick layer of syncytiotrophoblast and is considered to 
be a barrier separating maternal blood and fetal capillary endothelium, many substances can cross 
the placental barrier through passive diffusion, carrier-mediated transport or transcytosis [129]. Of 
the three mechanisms, passive diffusion is the predominate method of passage of chemicals 
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transplacentally for most lipophilic substances with molecular weight less than 600 Da, such as 
midazolam and paracetamol  [128]. Both ATP-binding cassette (ABC) and solute carrier (SLC) 
family transporters are expressed in the placenta. For example, P-gp, also known as multidrug 
resistance protein 1 (MDR1), breast cancer resistance protein (BCRP) and multidrug resistance-
associated protein 2 (MRP2) are identified in apical membrane of the trophoblast to efflux 
substrates from the syncytiotrophoblast to the maternal side. Whereas, MRP1 is found in the 
basolateral membrane of the trophoblast to transport substances to the fetal side. SLC transporter 
family members such as organic cation transporters (OCTs), organic anion transporters (OATs), 
and organic anion transporting polypeptides (OATPs) have also been identified in placenta 
recently (Figure 1-1) [130]. 
Besides transporters, several drug metabolizing enzymes have also been identified in the 
placenta. CYP1A, UGT1A and UGT2B are expressed in human placenta in the 1st trimester. The 
activities of UGT1A, UGT2B and CYP1A are significantly increased in the placenta of mothers 
who are smokers [131]. Other studies have also found that the types and abundance of CYPs are 
variable at different gestational ages and are impacted by maternal disease and social behavior 
[132, 133]. In full term placenta, CYP1A1, 2E1, 3A4, 3A5, 3A7, and 4B1 have been detected at 
the protein level. Unlike phase I enzymes, enzymes involved in phase II metabolism is less well 
studied in the placenta. The presence of UGT1 and UGT2 have been identified in both 1st trimester 
and full-term placenta. In vitro study has found that enzymes that are responsible for sulfation 
might also exist in placenta [134]. A summary of the enzymes in human placenta are shown in 
Table 1-3.  
Many studies have reported the presence of CYP1A1, CYP1B1, CYP2C8, CYP2D6, 
CYP2E1, CYP3A4, CYP3A5, and CYP3A7 in the fetus [135]. Although these enzymes are present 
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in the placenta and the fetus, the metabolic contribution of these enzymes to the clearance of drug 
administered to the mother is expected to be minimal due to the small size of the fetus and the low 
abundance of enzymes in the placenta [135]. 
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Figure 1-1. Drug transporters in placenta 
Modified from reference [130] 
BCRP, breast cancer resistance protein; MRP, multidrug resistance-associated protein, CRP, 
breast cancer resistance protein; BSA, – bisphenol A; CNT1, concentrative nucleoside transporter 
1; ENTs, equilibrative nucleoside transporters; MATE1, multidrug and toxin extrusion protein 1; 
MRP1, multidrug resistance-associated protein 1; OATP2B1, organic anion-transporting 
polypeptide 2B1; OATP4A1, organic anion-transporting polypeptide 4A1; OCT3, organic cation 
transporter 3. 
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Table 1-3. Enzymes identified in human placenta ([131, 134-136]) 
Enzyme 1st trimester  Full-term  
CYP1A1 +  +  
CYP2B6 ? + 
CYP2C8 ? + 
CYP2E1 -   +  
CYP3A4/5 +  +  
CYP3A7 +  +  
CYP4B1 +  +  
UGT1A +  +  
UGT2B4 + +  
UGT2B7 +  +  
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1.3.3  Cardiovascular system 
In pregnant women, profound changes have been seen in the cardiovascular system 
including changes in blood volume, blood component, and systemic hemodynamics. During 
pregnancy, the total blood volume and the plasma volume increases by 40-50% [137]. Whereas, 
the increase of erythrocyte volume is less than the increase in the total blood volume and plasma 
volume (20 -30%) depending on iron supplementation [137]. The increases are linear within the 
first 6 weeks of gestational age and then gradually reach a plateau during 28 – 32 weeks of 
gestation. Normally, these parameters return to baseline by 6 weeks postpartum [137]. The 
increase in blood volume in the body is to adapt to the demands of blood and oxygen from the 
feto-placental unit, as well as to prepare for potential blood loss at delivery. As there is a difference 
between the increases in plasma volume and erythrocyte volume, physiologic anemia is observed 
in pregnancy. Hematocrit decreases by 15 to 20 % compared to the value in nonpregnant women. 
Usually, the decline in erythrocyte volume occurs at 4 weeks after conception, and gradually 
reaches a maximum around 28 to 32 gestational weeks, and thereafter the hematocrit increases 
slightly before delivery [138]. Plasma protein levels also decrease during pregnancy. The 
concentration of plasma albumin decreases from 4.1 – 5.3 (non-pregnant adult), to 3.1 – 5.1, 2.6 – 
4.5, and 2.3 – 4.2 g/dL at the 1st, 2nd, and 3rd trimester, respectively [139]. The concentration of 
plasma α1-acid glycoprotein decreases from 0.74 (non-pregnant adult), to 0.73, 0.58, and 0.60 g/L 
at the 1st, 2nd, and 3rd trimester, respectively [140]. 
Cardiac output is the product of stroke volume and heart rate. In pregnancy, both stroke 
volume and heart rate are increased, which leads to an increase of cardiac output by 50% [124]. 
The cardiac output increases dramatically during 1st trimester and reaches a maximum at the end 
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of 2nd trimester [124]. The increase in cardiac output leads to an increase in blood flow to various 
tissues and organs, such as uterus, liver and kidney. 
1.3.4  Liver 
Liver is the largest solid organ in the body and plays critical roles in synthesis, metabolism 
and secrection. During pregnancy, portal vein blood flow is increased from 1.25 to 1.92 L/min and 
hepatic arterial blood flow is increased from 0.57 to 1.06 L/min [126]. Pregnancy has no or 
minimal impact on the size or structure of liver [141]. However, changes have been observed in 
the hepatic excretory, synthetic, and metabolic functions [141, 142]. Bacq et al. evaluated the 
changes of liver functions during pregnancy by comparing liver function tests in 103 healthy 
pregnant women and 103 age matched non-pregnant controls [143]. In the study, they observed 
that at fasting state, the serum concentrations of albumin, total and free bilirubin were significantly 
decreased, whereas, the serum concentration of aspartate transaminase (AST) and alanine 
transaminase (ALT) and serum concentration of total bile acid were not significantly changed 
during pregnancy [143]. Pregnancy induced changes in the activities of drug metabolizing 
enzymes are summarized in the section 1.4.3. 
1.3.5  Renal system 
During pregnancy, the renal system undergoes significant changes both in structure and 
function to adapt to the changes in cardiovascular system. The length of both kidneys increases by 
1-1.5 cm with an increase in blood volume [144]. The renal blood flow increases by 35-60% [145]. 
The glomerular filtration rate (GFR) is dramatically increased in the 1st trimester and its reaches a 
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maximum of 180 ml/min around 16 weeks.  Then GFR is maintained at the peak level until the 
36th weeks of gestation [146].   
1.4 Impacts of pregnancy on the pharmacokinetics of drugs 
Pregnancy induces many physiological changes including the development of placental-
fetal compartment, increase in renal glomerular filtration rate, body volume and hepatic portal 
blood flow, as well as alterations in drug metabolizing enzyme and transporter mediated drug 
disposition [125, 145, 147]. These pregnancy-induced physiological changes can impact drug 
absorption, distribution, metabolism, and elimination [148].  
1.4.1  Absorption 
Absorption is the movement of a drug from the site of administration to the bloodstream. 
For an orally administered drug, absorption is the process of the movement of a drug from the gut 
lumen into the enterocyte in the gut wall. In other words, the fraction of the administered dose that 
is not lost in the feces nor decomposed in the gut lumen is the fraction that is absorbed (Fa). The 
primary mechanisms involved in movement of a drug molecule across the cell membrane include 
passive diffusion, protein-mediated transport, and endocytosis/exocytosis [149]. Passive diffusion 
is an important and the most common means by which many drugs cross cell membranes. The 
process of passive diffusion is driven by the concentration gradient of a drug on either side of cell 
membranes. Protein-mediated transport can be either passive (facilitated diffusion) or active. In 
the process of facilitated diffusion, the carrier proteins transport drugs in the direction of 
22 
concentration gradient with no energy requirement. For the means of active transport, the 
translocation of drugs is against a concentration gradient and the process is associated with energy 
expenditure [150]. Endocytosis/exocytosis also needs energy and is an important transport 
mechanism for large macromolecules such as protein drugs. Active transport plays an important 
role in drug transport by regulating movement of drug molecule across cell membrane. Multiple 
drug transporters are present in the intestinal epithelia such as efflux transporters like MDR1, 
BCRP, and MRP2, and uptake transporters like organic anion transporting polypeptide (OATP), 
Peptide (PEPT) 1, and monocarboxylate (MCT) 1 [151-153]. Several studies have shown that 
polymorphism in MDR1 is associated with altered absorption of digoxin and fexofenadine [154, 
155]. Changes in absorption due to transporters result in alterations in systemic exposure of drugs 
and may lead to toxicity or underdosing. The impact of pregnancy on the regulation of drug uptake 
or efflux transporters has not been well studied.  
Additionally, the gastric motility and emptying, food, as well as diseases that affect 
gastrointestinal physiology could also impact drug absorption. During pregnancy, the decrease in 
gastric emptying and intestinal motility may result in a decrease in drug absorption rate.  
After a drug is absorbed into the intestinal wall, it is transported through the portal vein 
into the liver. From the liver, the drug is carried to the inferior vena cava, then to the heart, lung 
and systemic circulation [156]. Due to the presence of enzymes in the gut and liver, a drug may 
undergo extensive first-pass (presystem) metabolism before reaching the systemic circulation after 
oral administration. The overall systemic availability (bioavailability, F) of a drug after oral 
administration is the product of the fraction being absorbed (Fa), the fraction escaping metabolism 
in the gut wall (Fg), and the fraction escaping metabolism in the liver (Fh). The bioavailability of a 
drug used during pregnancy may be decreased or increased depending on how the activity of 
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metabolic enzymes involved in the biotransformation of a drug are altered during pregnancy in the 
gut and liver. For examples, if a drug is a substrate of CYP3A, the bioavailability of the drug for 
oral administration may be decreased due to the increase in the activity of CYP3A4 during 
pregnancy, such as the case with midazolam [157]. Bioavailability can also be altered by changes 
in uptake and efflux transporters in the gut wall. F = Fa × Fg × Fh. 
1.4.2  Distribution 
After a drug enters the body, it distributes to various tissues. The extent of a drug 
distribution in the body is determined by its lipid solubility (LogP), pKa, and partition between 
plasma and tissues (Kp). The partitioning of a drug between plasma and tissue is affected by 
fraction of the drug that is bound to plasma because only the unbound drug can cross cell 
membranes. The volume distribution (V) is a useful indicator to characterize the extent of drug 
distribution throughout the body. Volume of distribution is an apparent parameter that relates 
amount of drug available in the body to its concentrations in blood or plasma. A drug with a volume 
of distribution of 3 – 5 L implies that most of the administered dose stays within the vascular 
system and may be highly bound to plasm proteins. For drugs that have large volume of 
distribution, most of the administered dose stays outside of the vascular system and the drug may 
be highly bound to the tissues.  
Pregnancy increases body fat, total body water, plasma volume, and blood volume. 
Pregnancy decreases plasma protein concentrations. In pregnancy, the plasma concentration of 
albumin decreases up to 13% compared to nonpregnant women [125]. The level of alpha1-acid 
glycoprotein (AAG), which binds basic drugs, is also decreased during pregnancy. As a result of 
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the decrease in plasma protein concentrations, unbound fraction of a drugs will be increased. The 
apparent volume of distribution of a drug can be calculated as follows 
𝑉𝑉 =  𝑉𝑉𝑃𝑃 +  𝑓𝑓𝑓𝑓,𝑃𝑃𝑓𝑓𝑓𝑓,𝑇𝑇 × 𝑉𝑉𝑇𝑇 
Where V is the apparent volume of distribution of drug, Vp is the plasma volume, VT is the 
total body water minus the plasma volume, fu,P is the ratio of unbound and total drug concentrations 
in plasma, fu,T is the ratio of unbound and total drug concentrations in tissues. 
Therefore, the increase in plasma volume, total body water and a decrease in plasma protein 
concentration during pregnancy can lead to an increased volume of distribution of certain drugs. 
1.4.3 Metabolism 
After entering the systemic circulation, a drug is eliminated from the body by metabolism 
and/or excretion of the parent drug. Drug metabolizing enzymes are widely expressed in various 
tissues and organs such as the intestinal tract, placenta and kidney, but the liver is the organ that is 
primarily responsible for the metabolism of most drugs. The hepatic clearance of a drug is 
influenced by hepatic intrinsic clearance, hepatic blood flow and unbound fraction of drug in the 
blood. The intrinsic clearance of a drug is determined by the affinity of the drug molecule and the 
drug metabolizing enzymes, and the abundance of the enzymes. The hepatic extraction ratio (E), 
characterizes the fraction of the drug that is extracted during single passage, and can be calculated 
as ((Ca-Cv)/Ca), where, Ca is the drug concentration in the arterial blood flow before entering the 
liver; Cv is the drug concentration the in venous blood leaving the liver. For low clearance drugs 
(CL ≤ 300 mL/min) or drugs with low extraction ratio (E ≤ 0.2), hepatic clearance after intravenous 
administration is determined by intrinsic clearance and unbound fraction of drug in plasma. For 
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high clearance drugs (CL ≥ 1050 mL/min) or drugs with high extraction ratio (E ≥ 0.7), hepatic 
clearance after intravenous administration is determined by hepatic blood flow. For intermediate 
clearance drugs, hepatic blood flow, intrinsic clearance and the unbound fraction of drug in plasma 
will determine the hepatic clearance. 
The effect of pregnancy on hepatic metabolism is drug specific. For a high clearance drug 
administered by intravenous route, the hepatic clearance is increased due to a significant increase 
in hepatic blood flow in pregnancy. For a low clearance drug administered by intravenous route, 
the hepatic clearance is impacted by the changes in specific enzyme activities (intrinsic clearance) 
and unbound fraction of the drugs in plasma. During pregnancy, the metabolism of drugs mediated 
by cytochrome P-450 (CYP) 2C9, CYP2D6, CYP3A4, UGT1A4, and UGT2B7 are increased, 
whereas the metabolism of substrates of CYP1A2 and CYP2C19 are decreased [158]. The 
mechanism of the changes in the enzyme activities during pregnancy is not completed understood, 
but many studies have reported association between the activity of drug metabolizing enzymes and 
hormones levels [158, 159]. The potential mechanism may involve changes in the expression and 
/or activities of drug metabolizing enzymes that are regulated by different transcriptional factors 
which are modulated by the altered levels of circulating hormones in the blood during pregnancy 
[158]. Table 1-4 summarized pregnancy induced changes in drug metabolizing enzyme activities.  
1.4.2 Excretion 
Kidney is one of the primary organs that eliminate parent drugs and metabolites from the 
body. The mechanisms of renal excretion include glomerular filtration, tubular secretion and 
reabsorption. Numerous endogenous and exogenous substances undergo glomerular filtration with 
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or without secretion and reabsorption. The filtration and reabsorption are passive processes, 
whereas, secretion is mediated by drug transporters. Normally, only unbound drugs can be filtered 
by the nephrons. For a drug with filtration as the only mechanism of renal clearance, the renal 
clearance is a product of the glomerular filtration rate (GFR) and the unbound fraction (fu). The 
GFR is increased from 97 ml/min in non-pregnant women to 180 ml/min in pregnancy women 
[146]. Also, as mentioned before, the unbound fraction of a drug is increased due to the decrease 
of plasma protein concentration. The renal clearance of a drug such as cefazolin and lithium are 
known to be increased in pregnancy. (Table 1-5). 
In addition to the increase in renal filtration, clinical evidence of increase in active secretion 
has also been reported in pregnant women. Using digoxin as a probe, Hebert et al. reported an 
increase in the renal secretion of digoxin mediated by P-gp (1.97-fold at 3rd trimester in 
comparison to postpartum period) [157]. The renal secretion of metformin increased to 1.53- and 
1.34-fold at 2nd and 3rd trimesters. The observed increase in metformin secretion may due to the 
enhanced activity of renal OCT2 [160]. However, metformin is not a specific substrate for OCT2. 
It is also a substrate of renal OCT1, and the multidrug and excursion pump (MATE). The observed 
results might be confounded by the other factors as well.  
In summary, pregnancy induces many anatomical and physiological changes. These 
changes may have extensive impacts on absorption, distribution, metabolism and elimination of 
drugs used in pregnancy. The alteration of drug pharmacokinetics may result in changes in efficacy 
and toxicity of drugs used in pregnant women. Many clinical studies have reported significant 
changes in systemic exposure of certain drugs used during pregnancy [161-163]. Table 1-5 shows 
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the summary of pregnancy induced physiological changes and potential impacts on 
pharmacokinetics of drugs. 
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Table 1-4. Pregnancy induced changes in drug metabolizing enzyme activities 
Isoform of 
Enzyme 
Clinical Probe        Gestation vs Postpartum Example of clinical evidence Reference 
  1st 
Trimester 
2nd 
Trimester 
3rd 
Trimester 
  
CYP1A2 Caffeine ↓ ↓ ↓ The increase in 
metabolic/parent of renal 
excretion 
[164] 
 Caffeine ↓ ↓ ↓ The decrease of oral clearance 
of caffeine  
[165] 
CYP2C19 Proguanil   ↓ Plasma concentration of 
cycloguanil (CYP2C19 
mediated biotransformation of 
proguanil) decreased by 42% 
of its value at postpartum. 
[166] 
CYP2D6 dextromethorphan ↑ ↑ ↑ The increase in 
dextromethorphan O-
demethylation 
[165] 
 Metoprolol   ↑ CLiv increased 2.12-fold [167] 
CYP3A Midazolam   ↑ Unbound CL/F increased 2.1-
fold 
[157] 
 dextromethorphan ↑ ↑ ↑ The increase in 
dextromethorphan N-
demethylation 
[165] 
UGT1A4 lamotrigine   ↑ The decrease in plasma 
concentration of lamotrigine 
[168] 
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Table 1-5. The summary of pregnancy induced physiological changes and potential impacts on pharmacokinetics of drugs 
Pharmacokinetic 
characteristics 
Pregnancy induced 
physiological change 
Potential impacts to drug 
pharmacokinetics 
                                Example  
Absorption ↓ gastric emptying and 
gastrointestinal motility, 
↑ in gastric pH  
↑ in gastrointestinal blood 
flow  
Alterations of transporters  
Alterations of enzymes  
↓ or ↑ rate of absorption 
↓ or ↑ bioavailability 
 
Midazolam Cmax decreased by 28% at 3rd trimester compared with 
postpartum period [137]. 
The urinary recovery of metoprolol and its metabolites were higher 
during pregnancy than postpartum [167]. 
Distribution ↑ in total body water and 
fat 
↓ in plasma protein 
concentration 
↑ in volume of 
distribution 
 
The volume of distribution of metoprolol following intravenous 
administration were increased to 1.78-fold during pregnancy [167]. 
Metabolism ↑ in cardiac output 
↑  in portal vein and hepatic 
blood flow 
Alterations of enzymes 
Alterations of transporters 
↑ or ↓ in metabolism 
 
The decreased clearance of caffeine mediated by CYP1A2 in 
pregnancy [164]. 
The increase in the clearance of metoprolol mediated by CYP2D6 at 
3rd trimester [167]. 
Excretion ↑ in renal blood flow 
↓ in plasma protein 
concentration 
Alterations of enzymes 
Alterations of transporters 
↑ in renal filtration 
↑ or ↓ in renal active 
secretion 
The systemic exposure of cefazolin after intravenous administration 
of same dose was 70% of that value of postpartum [169].  
In pregnancy, the clearance of lithium was approximately 2 times of 
that value at postpartum [170]. 
The unbound renal secretion of digoxin was increased from 58 
(postpartum) to 109 mL/min (28 – 32 weeks gestation) [171] due to 
the induction of P-gp activity during pregnancy. 
The renal secretion of amoxicillin was increased from 0.167 
(postpartum) to 280 L/min (2nd trimester) due to the induction of 
OAT1 activity during pregnancy. 
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1.5 The prediction of pregnancy induced pharmacokinetic changes of drugs based on 
Biopharmaceutics Classification System 
The Biopharmaceutics Classification System (BCS) was first introduced by Amidon et al. 
[172]. Based on aqueous solubility and permeability of drugs, the BCS classified drugs into four 
categories as follows.  
Class 1: High solubility and high permeability 
Class 2: Low solubility and high permeability 
Class 3: High solubility and low permeability 
Class 4: Low solubility and low permeability 
According to the FDA guidance, a drug is considered highly soluble when the highest 
strength of a drug product is soluble in 250 mL or less of aqueous media within the pH range of 1 
- 6.8 at 37 ± 1°C; and highly permeable when the extent of absorption of a drug product in humans 
is at least 85 % of the administered dose based on a mass balance determination or in comparison 
to an intravenous reference dose [173]. Alternatively, drugs with the lowest solubility in aqueous 
solution being > 200 µg/mL over a pH range of 1–7.5 at 37°C would be considered as to be highly 
soluble [174]. Benet suggested that the cutoff values for low and high permeability to be < 2.0 or 
≥ 3.5 × 10-6 cm/s, respectively, when artificial membrane permeability assay is used to measure 
the permeability of a drug [174]. The BCS system is widely used to establish in vitro - in vivo 
correlations and to predict absorption of a drug product. In 2004, Wu and Benet extended the BCS 
to a Biopharmaceutics Drug Disposition Classification System (BDDCS) to predict the overall in 
vivo drug disposition based on solubility and permeability of drugs [175]. The BDDCS classified 
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drugs into four categories as same as BCS. In BDDCS, drugs with high permeability categorized 
to class 1 and 2 of BCS undergoes extensive metabolism by enzymes, whereas, drugs with low 
permeability categorized to class 3 and 4 of BCS, are eliminated primarily by renal and /or biliary 
excretion as unchanged drugs [175]. With regard to the involvement of transporters in the 
disposition of drugs, for drugs in the class 1 of BCS (high solubility and high permeability), the 
effects of transporters are minimal in both gut and liver, but the impacts of transporters might be 
seen in class 2, 3 and 4 of BCS [174]. 
Based on the physiological changes induced by pregnancy as described in previous sections, we 
predicted that the metabolism of drugs in BCS class 1 and 2 may be increased due to the increase 
in hepatic elimination capacity, whereas the clearance of drugs in BCS class 3 and 4 may be 
increased due to the increase in renal clearance. No study has reported the aqueous solubility of 
BUP, however, the solubility of BUP in water should be minimal due to its high lipophilicity (LogP 
= 4.98) [70]. The permeability of BUP in a Caco-2 cell membrane system is 44.7 × 10-6 cm/s [176]. 
Buprenorphine can be classified as a BCS class 2 drug with low solubility and high permeability. 
As a BCS class 2 drug, BUP undergoes extensive hepatic metabolism with minimal renal 
elimination of the parent drug. The increase in hepatic elimination capacity in pregnancy will 
increase BUP clearance during pregnancy.  
1.6 Pharmacotherapy of opioid use disorder in pregnant women  
The 2010 National Survey on Drug Use and Health by the National Institutes of Health 
(NIH) on drug abuse reported a 47% increase in illicit drug use during pregnancy since 2002 (4.4% 
in 2010 versus 3% in 2002 between the ages of 15 and 44 of pregnant women) [177]. The term 
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"illicit" refers to the use of illegal drugs, including marijuana, and the misuse of prescription 
medications, such as cocaine, benzodiazepines, and opiates. During the last decade, Marijuana use 
has increased 62% in reproductive-aged women [178]. The use of opioids during pregnancy can 
result in a drug withdrawal syndrome in the newborns called neonatal abstinence syndrome (NAS). 
Since 2000, there has been a five-fold increase in the number of babies born with NAS [179].  
Maternal opioid use is associated with increased obstetrical complications, such as 
maternal death, cardiac arrest, intrauterine growth restriction and placental abruption [180]. 
Moreover, antepartum use of opioids results in neonatal abstinence syndrome (NAS), birth defect, 
stillbirth, and preterm labor [181, 182]. It would be ideal to abstain from opioids throughout the 
course of pregnancy. However, there are risks associated with stopping opioids in pregnant women 
as the mother may undergoes intense withdrawal during detoxification. Also, the stress derived 
from the abstinence in the mother may result in intrauterine stress, which may lead to preterm 
labor, as well as impact the development and growth of the fetus [183]. Successful detoxification 
have been reported in several studies [183-185]. However, analysis has found that there were high 
rates of relapse in these patients [186]. Therefore, detoxification is not a common treatment option 
in pregnant women with opioid use disorder. Any decision regarding detoxification should be 
made after full evaluation of the history and severity of substance use disorder in patients and for 
the best outcomes for both the mother and the fetus.  
Currently, the most common treatments for opioid use disorder in pregnant women are 
medication-assisted maintenance therapy using long-acting µ-opioid receptor agonists such as 
methadone or buprenorphine [187]. Methadone has been used for decades and many studies have 
shown the effectiveness of methadone for treating opioid use disorder in pregnant women. Altered 
metabolism of methadone in pregnant women has been reported by several investigations [188-
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190]. For example, Pond et al. studies the PK of methadone at 20 – 34 (phase I), 35 – 40 weeks of 
gestation (phase II), 1 – 4 weeks (phase III), 8 – 9 weeks (Phase IV) at postpartum in 9 pregnant 
women who were receiving methadone maintenance therapy. The apparent clearance of 
methadone was significantly higher during pregnancy than postpartum (311 (phase I) and 256 
(phase II) ml/min vs 161 (phase III) and 155 (phase IV) ml/min) [189]. Wolff et al. have also 
reported alteration in the metabolism of methadone in pregnancy. In the study, they found that the 
weight adjusted clearance of methadone were 0.17, 0.19, 0.21, and 0.11 L/hr/kg at 1st, 2nd, 3rd 
trimester and postpartum, respectively[190]. Despite patients taking higher dose of methadone 
during pregnancy, the trough plasm concentrations and plasma exposures (as measured by AUC) 
of methadone were lower during pregnancy [190]. The higher maternal methadone dose has been 
correlated with higher incidence of NAS [191]. Albright et al. studied changes in methadone dose 
in a single cohort longitudinal study in 139 pregnant women [192]. There was a gradual increase 
in methadone dose over gestation, and the mean increase in methadone dose was 24 mg [192]. It 
has been reported that 60 - 80% of newborns undergo NAS after intrauterine exposure to 
methadone [193]. However, most of the studies were performed in a small cohort, and are 
nonrandomized or had no control population.  
As a pharmacotherapy approved by the FDA for opioid addition, buprenorphine has 
comparable efficacy to methadone [194-196]. Recently, studies have found that buprenorphine 
crosses placenta and buprenorphine exposed neonates may have less severity and lower incidence 
of NAS [136, 182, 197]. Buprenorphine-exposed neonates require, on an average, 89% less 
morphine to treat neonatal abstinence syndrome, a 43% shorter hospital stay, and a 58% shorter 
duration of medical treatment for neonatal abstinence syndrome compared to methadone [198]. 
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These results support the use of buprenorphine as a potential first-line medication for pregnant 
opioid-dependent women. 
1.7 The current dosing issue of buprenorphine in pregnancy  
In order to evaluate the safety and efficacy of maternal and prenatal exposure to 
buprenorphine and methadone, Jones et al conducted a double blinded and double randomized 
clinical study. In the study they found that 28 of 86 (33%) patients in the buprenorphine group 
terminated treatment early compared to 16 of 80 patient (18%) in the methadone group. Seventy 
one percent of the dropout was due to patient dissatisfaction with the buprenorphine treatment. 
However, in non-pregnant population, there were no significant difference in patient retention 
between the intermediate and high dose buprenorphine group and methadone groups during opioid 
maintenance treatment based on a meta-analysis of 31 clinical studies [199]. In addition, analysis 
in a Pennsylvania state Medicaid program among 2361 pregnant women receiving buprenorphine 
treatment have found that 40% of these patients had low-to-moderate adherence, early 
discontinuation, or showed declining adherence. Lower BUP daily dose has been found to be a 
factor that is associated with early discontinuation [200]. As limited data are available on the 
alterations of buprenorphine pharmacokinetics and pharmacodynamics during pregnancy, the 
dosing regimen of buprenorphine in pregnant women are commonly based on the 
recommendations in non-pregnant women and men.  
Clinical observations in Magee Womens Hospital Pittsburgh indicate an increase in 
buprenorphine dose requirement during pregnancy [201]. Another clinical study that compared the 
efficacy of buprenorphine and methadone in pregnant women showed 30% of the patients 
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converted to buprenorphine failed at start, and 71% of them to dropout because of dissatisfaction 
with buprenorphine [202]. On the published studies, the reported doses of buprenorphine given to 
pregnant women ranged from 0.4-24 mg/day [203]. We speculate that the lack of clear consensus 
and the broad dose range may result in dosing bias by individual physician and in turn affect the 
retention of pregnant women in buprenorphine therapy. As mentioned before, both intrinsic 
clearance and hepatic blood flow can impact buprenorphine clearance. We predict that pregnancy 
is associated with increased clearance and decreased exposure of buprenorphine due to enhanced 
cardiac output, hepatic blood flow, and increased expression and activities of CYP3A4, UGT1A1, 
and UGT1A3 [165, 204, 205]. Therefore, a better understanding of pregnancy-medicated changes 
in pharmacokinetics of buprenorphine, as well as the relationship of buprenorphine 
pharmacokinetics and pharmacodynamics are critical to optimize dosing of buprenorphine in 
pregnant women. Another challenge in dosing buprenorphine in pregnant women is the need to 
balance drug exposure in the mother and the fetus. When using buprenorphine as maintenance 
treatment in pregnant women, the treatment goal is to maximally inhibit drug withdrawal, craving 
and illicit opioid use with a minimum drug exposure to the fetus.   
1.8 The pharmacokinetic and pharmacodynamic relationship of buprenorphine 
The Clinical Opioid Withdrawal Scale (COWS) is a common tool used in clinical practice 
to assess opioid withdrawal. The COWS has both subjective and objective components. For 
example, the patients are asked about the presence of gastrointestinal upset, bone or joint aches, 
etc. during evaluation of the severity of drug withdrawal. Therefore, the COWS score is highly 
impacted by patients’ responses to certain questions and can be manipulated by the patients. More 
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studies are needed to further validate the reliability of COWS for detecting withdrawal. As a 
maintenance therapy to treat opioid substance dependence, buprenorphine has to cross the brain–
blood barrier and bind to mu-opioid receptors in the brain. The ideal marker to assess opioid 
withdrawal would be buprenorphine concentration in the brain and mu-opioid receptor occupancy. 
Greenwald et al. have studied the mu-opioid receptor occupancy in the brains of heroin-dependent 
patients using positron emission tomography (PET) scan and suggested that 50% mu-opioid 
receptor occupancy is needed to suppress drug withdrawal symptoms in patients [206]. However, 
it is not feasible to measure buprenorphine brain concentration or the occupancy of mu-opioid 
receptor in pregnant women. We would like to explore objective physiological measurements, 
mediated by mu-opioid receptor binding in brain, as a surrogate to mu-opioid receptor occupancy 
in order to optimize buprenorphine dosing in pregnant women. 
Pupillary size is determined by the dilation or constriction of iris through sympathetic and 
parasympathetic nervous system. Opioids induced pupillary constriction has been observed in 
human, rabbits and dogs and pupillary dilation are seen in rats, mice, and cats. It has been shown 
that opioid induced miosis and mydriasis are opioid receptor-mediated as the effects can be 
blocked by mu-opioid receptor antagonist, naloxone [207]. Currently, the exact site of action is 
not clear, but it is believed that the site of action should be within the brain as no pupillary effect 
was observed by intraocular administration of an opioid like morphine. In addition, the effective 
dose of morphine that causes changes in pupillary size following an intracerebroventricular 
injection was one hundredth of the intravenous dose [208, 209]. The possible mechanism of the 
pupillary constriction by opioids may be through the suppression of the inhibitory process of 
Edinger-Westphal nucleus, a place in midbrain that regulates signal to iris muscle resulting in 
pupillary constriction [210]. Several studies have reported that pupillary constriction is correlated 
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with opioid concentration in plasma and higher plasma opioid concentrations result in more 
pronounced effects on pupillary constriction [211-215]. Use of pupillometry as a marker to 
optimize dosage of opioids for pain management has been reported [216, 217]. Multiple clinical 
studies and our preliminary in-house data in pregnant women have demonstrated that 
buprenorphine can induce pupillary constriction [212, 213]. So, we plan to evaluate the association 
between the plasma concentration of buprenorphine and pupillary diameter in pregnant women 
maintained on buprenorphine.   
1.9 Difficulty in performing pharmacokinetic studies in pregnant women and alternative 
approaches to evaluate pharmacokinetics in pregancy 
Given that anatomical and physiological changes during pregnancy, the pharmacokinetics 
of several drugs are expected to be altered in pregnant women. Modulations in pharmacokinetics 
of drugs may result in toxicity or lack of efficacy. To study the pharmacokinetics of a drug, a 
sufficient number of blood samples should be collected to determine the time course of absorption, 
distribution, metabolism and excretion from each subject. Usually, a pharmacokinetic study 
requires 9-12 blood samples from each subject over a 3-5 half-lives of a drug. Such intensive blood 
sampling and the long duration of a PK study adds another practical difficulty in studying PK of 
drugs in pregnant women. Several approaches may be considered as an alternative to a full PK 
study in pregnant women. 
Limited sampling strategy has been proposed by many investigators. In these studies, drug 
concentrations at a single time point or abbreviated blood sampling period are used to estimate 
drug exposures within a dosing interval. For example, Mathew et al. reported a two-point limited 
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sampling strategy for tacrolimus in stable renal transplant patients. They found that combining the 
whole blood concentration of tacrolimus at trough and at 1.5 hrs after a dose, or trough and 4 hrs 
after dose it was possible to estimate AUC0–12 of tacrolimus (Regression coefficient was 0.951) 
[218].  
The trough concentration (concentration before the next dose) of a drug at steady state 
often shows good correlation with drug exposure during a dosing interval, therefore, determination 
of trough concentration is a common approach used in therapeutic drug monitoring. In our previous 
study, we found the trough concentrations of BUP to be correlated well with BUP exposure (as 
measured by AUC) at steady state during the dosing interval of 12 hrs (Figure 1-2) [201].  
 
 
Figure 1-2. Relationship between buprenorphine trough concentration and overall 
exposure (AUC0-12) at steady state in pregnant women [201] 
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Physiological-based pharmacokinetic (PBPK) modeling is a sophisticated PK modeling 
approach that incorporates every major tissue type as a separate physiological compartment. Organ 
size, organ composition, blood flow, abundance and relative expression of drug metabolizing 
enzymes and drug transporters, genetic variants of drug disposition proteins, differences between 
sexes, age dependent ontogeny and other physiological parameters are incorporated when 
performing PBPK modeling [219]. Physiologically-based pharmacokinetic modeling has been 
successfully applied to answer some clinical pharmacological questions such as the alteration of 
PK in pediatric patients and drug-drug interaction. Recently, several PBPK models have been 
developed to estimate the exposure of opioids such as morphine, methadone and fentanyl in 
patients [220-223]. Ke et al. have developed a pregnancy PBPK model in which gestational age 
associated with physiological changes such as cardiac output, GFR and the activities of drug 
metabolizing enzymes were incorporated into the non-pregnant PBPK model [220]. This PBPK 
model has successfully predicted an approximate 50 % decrease in the AUC and Cmax of 
methadone in the 2nd and 3rd trimester compared to the postpartum period [220]. The PBPK 
modeling approach provides us an alternative to predict pharmacokinetic alteration of a drug in 
special patient populations such as pregnant women by incorporating longitudinal physiological 
changes. 
Population PK modeling has the ability to combine and analyze data from limited sampling 
in each patient. Data from several subjects are pooled together and modeled simultaneously, so 
there is no need for a full PK sampling in each individual. This feature is one of the advantages of 
utilizing population PK analysis in pregnant women. Due to two layers of random effects 
(parameter level and dependent variable level), variance estimation in a population 
pharmacokinetic modeling analysis is more precise than traditional PK analysis. Additionally, 
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population PK modeling is a powerful pharmacostatistical methodology to identify and quantify 
sources of variability in drug disposition in particular patient population. Population derived 
pharmacokinetic parameters such as clearance and volume of distribution, as well as associations 
between patient characteristics and differences in pharmacokinetics can be used to guide 
prescribing for individual patients. Using population PK/PD modeling, we can study the changes 
in response to a drug with altered drug PK profiles in different circumstances in patients, which is 
critical for a decision to change the dosing regimen in patients. 
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1.10 Hypothesis and Objectives 
The goal of this study was to optimize buprenorphine dosing in treating opioid addiction 
in pregnant women through a better understanding of the effect of pregnancy on BUP exposure. 
Between 2000 and 2009, the rate of opioid use in pregnant women had increased nearly 5-folds. 
Maternal opioid use is associated with increased obstetrical complications and also results in 
neonatal abstinence syndrome. During this period, there was a five-fold increase in the number of 
babies born with NAS. The efficacy of buprenorphine in suppressing withdrawal symptoms 
appears to be comparable to methadone. Additionally, neonates may have less severe and a lower 
incidence of NAS after exposure to buprenorphine compared to methadone. Due to abuse potential, 
patients are required to go to the clinic daily to receive methadone as a maintenance treatment. As 
a partial mu-opioid receptor agonist, buprenorphine has less abuse potential compared to 
methadone. Upon the approval of Drug Addiction Treatment Act 2000, buprenorphine has been 
used as an office-based treatment for opioid addiction since 2002. As an office-based treatment, 
qualified physicians can prescribe buprenorphine to patients for treatment of opioid addiction bi-
weekly or monthly. As a result, receiving buprenorphine as maintenance treatment of opioid 
dependence is more convenient for patients than methadone, which can potentially improve patient 
compliance and retention. However, a large cohort of clinical trial that compared the efficacy of 
buprenorphine and methadone in pregnant women reported that 30% of the patients converted to 
buprenorphine failed at start, and 71% of them dropout due to dissatisfaction with buprenorphine. 
This is likely due to the lack of clear consensus on buprenorphine dosing in pregnant women as 
the current dosage regimen is based on the recommendations in non-pregnant women and men. It 
is well known that pregnancy is associated with various physiological changes that can potentially 
alter buprenorphine disposition and brain distribution and impact on the efficacy of buprenorphine 
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in treating opioid addiction. Use of medications during pregnancy without titration of its dose to 
account for pregnancy induced altered physiological condition may lead to therapeutic failure or 
drug related toxicities. As of today, limited information is known about pregnancy mediated 
changes in the pharmacokinetics and pharmacodynamics of buprenorphine. We hypothesize that 
model-based analysis can predict alterations in the clearance and exposure of drugs used during 
pregnancy and can substitute for drug exposure studies which are difficult to perform in pregnant 
women. Buprenorphine will be used as an example to illustrate the applications of model-based 
analysis to predict changes in drug clearance across different trimesters in pregnancy. 
Through the proposed experiments, we systematically evaluated the impact of pregnancy 
induced physiological changes on the alterations of pharmacokinetics and pharmacodynamics of 
buprenorphine. This hypothesis was tested through five specific aims. First, we established and 
validated a simple and sensitive ultra-performance liquid chromatography - tandem mass 
spectrometer (UPLC-MS/MS) assay for quantification of buprenorphine and three primary 
metabolites (norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide) 
in patient plasma samples. Using this assay, we measured the plasma concentrations of 
buprenorphine and its three metabolites in pregnant women at different trimesters of pregnancy. 
Additionally, we compared the alterations of buprenorphine pharmacokinetics, as well as the 
modulations of biotransformation of buprenorphine via N-demethylation and glucuronidation in a 
small cohort (Chapter 2).  Second, we built and validated robust PBPK models using Simcyp® 
population simulator for intravenous and sublingual buprenorphine in non-pregnant subjects. The 
proposed PBPK model predicted the time course of buprenorphine systemic exposure with 
different dosing regimen of buprenorphine in non-pregnant subjects (Chapter 3). Third, we 
developed a full physiologically-based pharmacokinetic (PBPK) model for buprenorphine in 
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pregnant women, to predict changes in buprenorphine exposure at different stages of pregnancy, 
and to demonstrate the utility of PBPK modelling in optimizing buprenorphine pharmacotherapy 
during pregnancy. In this study, anatomical and gestational changes in physiological parameters 
were incorporated. Buprenorphine plasma concentrations measured in pregnant women vs time 
profiles were used to verify the model predicted buprenorphine plasma concentrations (Chapter 
4). Fourth, we developed a population PK model to evaluate the changes in buprenorphine PK 
during pregnancy and to identify potential patient covariates that may influence buprenorphine PK 
during pregnancy in an attempt to optimize dosing of buprenorphine in pregnant women (Chapter 
5). The final aim was to evaluate the relationships between pharmacokinetics and 
pharmacodynamics of buprenorphine in pregnant women. Clinical Opioid Withdrawal Scale score 
over a dose interval were compared between pregnancies and postpartum. A population 
pharmacokinetic/pharmacodynamic model was developed to describe the time course of the 
changes of pupillary diameter following sublingual administration of buprenorphine in pregnant 
women (Chapter 6). The pharmacokinetic/pharmacodynamic analysis helped us to understand if 
the alteration in the pharmacokinetics of BUP is associated with a modulation of the 
pharmacodynamics of BUP in pregnant women. 
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 Development and Validation of a Sensitive Ultra-Performance Liquid 
Chromatography-Tandem Mass Spectrometric Assay for Simultaneous Determination of 
Buprenorphine and Three Metabolites in Human Plasma: Application in a Clinical 
Pharmacokinetic Study in Pregnant Women 
2.1 Abstract 
Introduction: Opioid use disorder has been increased 5-fold in pregnant women. Recently, 
buprenorphine, a maintenance therapy approved by the FDA, has been increasingly used in 
pregnant women for treating opioid use disorder. Pregnancy is associated with anatomic and 
physiological changes, which may lead to altered pharmacokinetics of drugs.  
Methods: By developing and validating a sensitive and reliable analytical method to 
simultaneously determine concentrations of BUP and its three metabolites in human plasma 
samples to evaluate the alterations in buprenorphine pharmacokinetics in pregnant women. 
Results: A rapid, sensitive, and selective method for the determination of buprenorphine 
and its three metabolites, norbuprenorpine, buprenorphine glucuronide, and norbuprenorphine 
glucuronide, in human plasma using ultra performance liquid chromatography with tandem mass 
spectrometry (UPLC–MS/MS) was developed and validated. Plasma samples (200 µL) were 
processed by protein precipitation prior to chromatography. Deuterated labelled buprenorphine-
D4, norbuprenorphine-D3, buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide-
D3 were used as the internal standards (IS). Chromatographic separation was performed using 
Acquity UPLC Ethylene Bridged Hybrid (BEH) C18 1.7 µm column (2.1x100 mm) with a mobile 
phase consisting of [A] 5% acetonitrile in water containing ammonium acetate (2 mM) and formic 
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acid (0.1%), and [B] acetonitrile containing ammonium acetate (2 mM) and formic acid (0.1%) 
delivered at a flow rate of 0.3 mL/min in a gradient elution. The total run-time was 7 min, with 
buprenorphine, norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide 
eluting at 3.3, 1.64, 1.35, and 0.84 min, respectively. The analytes were detected by a XEVO TQS 
mass spectrometer in positive electron spray ionization (ESI) mode using multiple reaction 
monitoring (MRM). The assay was linear over the range of 0.05 – 100 ng/mL for buprenorphine, 
0.2 – 100 ng/mL for norbuprenorphine, 0.2-200 ng/mL for buprenorphine glucuronide and 
norbuprenorphine glucuronide. The intra-day and inter-day accuracies expressed as percentage of 
the nominal concentrations were within 98.2-108.0 %. The intra-day and inter-day precision 
determined by the coefficient of variations were within 9 %. No significant matrix effects were 
observed for buprenorphine or the three metabolites in plasma samples. Buprenorphine and the 
three metabolites were stable under various storage and experimental conditions. This validated 
method was successfully applied to a clinical pharmacokinetic study after sublingual 
administration of buprenorphine to pregnant women at different trimesters and postpartum and 
were able to quantify buprenorphine, norbuprenorphine, buprenorphine glucuronide and 
norbuprenorphine glucuronide in plasma samples. We observed a lower exposure of 
buprenorphine and higher AUC ratios of metabolites to parents during pregnancy compared to 
postpartum.  
Conclusions: The AUC ratios of metabolites to parents demonstrated that CYP- and UGT- 
mediated buprenorphine metabolism were altered during pregnancy compared to postpartum, 
which may partially explain the lower exposure of buprenorphine during pregnancy.  
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2.2 Introduction 
Currently, the standard of care for treating opioid addiction is methadone. Many clinical 
studies have demonstrated the effectiveness of methadone maintenance interventions in reducing 
illicit opioid use, by suppressing drug withdrawal, and craving [24-28]. The use of methadone as 
a maintenance therapy to treat opioid addition can be traced back to 1960’s [23]. Due to safety 
concerns, methadone treatment must be practiced in a highly structured clinic. Also, daily visit to 
the clinic is required for patients in a methadone treatment program.  
Buprenorphine is a semisynthetic opioid agent and has been indicated as a medication-
assisted treatment for opioid dependence since 2002 by the FDA. Although buprenorphine is a 
relatively new pharmacotherapy for treating opioid addiction, it has unique pharmacological 
properties that make buprenorphine an appealing alternative to methadone treatment. 
Buprenorphine has a high affinity and low intrinsic activity for mu opioid receptors, which makes 
it less addictive than methadone and other opioids [60]. As a mixed agonist-antagonist at µ-opioid 
receptor, buprenorphine exhibits a ceiling effect for respiratory depression [61, 62]. These distinct 
pharmacological attributes render buprenorphine with enhanced safety compared to methadone. 
Unlike methadone treatment, buprenorphine is offered as an office-based treatment for opioid use 
disorder. Under the approval of the Drug Addiction Treatment Act of 2000, qualified physicians 
can prescribe buprenorphine for opioid addiction in office-based settings, which significantly 
improves accessibility of buprenorphine to patients as a maintenance therapy for treating opioid 
use disorder [224]. 
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In addition, buprenorphine use in pregnancy may lead to a decreased incidence of NAS 
compared to methadone. Jone et al. conducted a double-blind, double-dummy clinical study that 
randomized 175 pregnant opioid dependent women to either buprenorphine or methadone 
maintenance groups. The results showed that buprenorphine treatment was superior to methadone 
based on less morphine requirement to treat neonatal abstinence syndrome, shorter hospital stay, 
and shorter duration of medical treatment for neonatal abstinence syndrome in buprenorphine-
exposed neonates [202].  However, in this study there was a significantly higher dropout rate in 
the buprenorphine arm than in the methadone treatment group. Approximate 71% of the subjects 
dropout from buprenorphine treatment due to patient dissatisfaction on buprenorphine [202]. 
As there is limited information available about the impact of pregnancy on the 
pharmacokinetics and pharmacodynamics of buprenorphine, the current dosing regimen of 
buprenorphine in pregnant women is based on the recommendations for non-pregnant patients. 
However, pregnancy is associated with various physiological changes that may impact 
buprenorphine clearance during pregnancy. Buprenorphine undergoes extensive gut and hepatic 
metabolism through N-dealkylation to norbuprenorphine primarily mediated by CYP3A4 and 
CYP2C8 [90, 91]. Norbuprenorphine is further conjugated to norbuprenorphine glucuronide 
through UGT1A1 and UGT1A3. A portion of buprenorphine is directly conjugated to 
buprenorphine glucuronide mediated by UGT1A1, UGT1A3, and UG2B7. Figure 2-1 shows the 
metabolic pathway of buprenorphine in human. After sublingual administration, changes in hepatic 
blood follow, intrinsic clearance and the unbound fraction of buprenorphine in plasma will affect 
the clearance of buprenorphine.
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Figure 2-1. Buprenorphine metabolic pathway 
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Pregnancy is associated with increased cardiac output, hepatic and portal vein blood flow, 
increased unbound fraction of drugs, as well as increased activities of CYP3A4 and UGT1A4 [137, 
167, 168]. Therefore, we predict that buprenorphine systemic exposure will be decreased due to 
an increase in the total body clearance of buprenorphine in pregnant women. Our pilot study 
documented lower exposure of BUP during pregnancy [201]. Further research is needed to 
characterize the pharmacokinetic profile of buprenorphine in a larger number of pregnant women 
and to study the association between pharmacokinetics and pharmacodynamics of buprenorphine 
in pregnant women. 
In order to evaluate the alterations in buprenorphine pharmacokinetics during pregnancy, 
it was necessary to develop a sensitive and specific assay method for the determination of 
buprenorphine and its metabolites in human plasma. Simultaneous quantification of buprenorphine 
and its three metabolites have been reported in microsome, human umbilical cord, meconium, and 
urine samples [225-228]. To date, multiple methods have been reported using LC-MS/MS to 
quantify buprenorphine and norbuprenorphine, but only two methods have been reported 
simultaneous quantification of buprenorphine and three of its metabolites in plasma samples [229-
232]. Both of these methods use solid phase extraction for sample preparation [233, 234]. Solid 
phase extraction is expensive and time consuming for analyzing large batches of biological 
samples from clinical pharmacokinetic studies. Low recovery of norbuprenorphine glucuronide 
was also seen in both of the reported methods. In addition, the method reported by Regina et al. 
required a large volume of plasma (750 µL), which may not be practical in a pregnant woman and 
the neonates for a full clinical pharmacokinetic study with multiple sampling points [234]. This is 
the first report of a method using simple protein precipitation for plasma sample processing that is 
specific and sensitive for BUP and three of its metabolites. 
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The objective of this study was to develop a rapid, highly sensitive and reproducible UPLC-
MS/MS analytical method to quantify concentrations of buprenorphine and three of its metabolites 
in human plasma and to apply this method to process large batches of human plasma samples from 
clinical pharmacokinetic studies in pregnant women.  
2.3 Materials and methods 
2.3.1  Chemicals and Reagents 
Chemical structures of buprenorphine, norbuprenorphine, buprenorphine glucuronide, 
norbuprenorphine glucuronide and respective deuterated internal standards, buprenorphine-D4, 
norbuprenorphine-D3, buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide-D3 
are shown in Figure 2-2. They were purchased from Sigma-Aldrich (St. Louis, MO). Ammonium 
acetate (99.9999 trace metals basis) and OptimaTM LC/MS grade acetonitrile, formic acid, 
methanol and water were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Human plasma 
was procured from central blood bank of Pittsburgh (Pittsburgh, PA, USA). 
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Figure 2-2. Chemical structure of buprenorphine (A), buprenorphine-D4 (B), norbuprenorphine (C), norbuprenorphine-D3 
(D), buprenorphine-3-β-D-glucuronide (E), buprenorphine-D4-3-β-D-glucuronide (F), norbuprenorphine glucuronide (G), 
norbuprenorphine glucuronide-D3 (H)
                                                                          
(A)                                                  (B)                                                       (C)                                                 (D) 
                               
               
                           (E)                                                   (F)                                                         (G)                                                (H) 
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2.3.2  Chromatographic Conditions 
The UPLC system used for the analysis of buprenorphine and three  of its metabolites was 
a Waters Acquity H class model (Waters Corporation, MA, USA). Separation of all components 
of interest was achieved on Acquity UPLC BEH C18 1.7 µm, 2.1 x 100 mm column. The mobile 
phase A was 5% acetonitrile in water containing ammonium acetate (2 mM) and formic acid 
(0.1%) and mobile phase B was 95% acetonitrile in water containing ammonium acetate (2 mM) 
and formic acid (0.1%) at a flow rate of 0.3 mL/min. A sample volume of 2 µL was injected on 
column. A gradient method for the mobile phase was used to separate buprenorphine and its three 
metabolites. The gradient started at 25% of B, maintained for 1.0 min, then increasing to 35% of 
B from 1.0 min to 1.1 min, maintaining for 2 min, then increased to 100% of B from 3.1 to 4.1 
min, maintaining for 2 min, and decreased to 25% of B from 5.1 to 5.2 min, then maintained at 
25% of B until 7 min. The gradient method is summarized in Table 2-1. The total run time for each 
injection was 7 mins. 
 
Table 2-1. Gradient method used to separate buprenorphine and three metabolites 
Run Time (min) Mobile Phase A % Mobile Phase B % 
Up to 1.0  75 25 
1.1 65 35 
3.1 65 35 
4.1 0 100 
5.1 0 100 
5.2 75 25 
7 75 25 
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2.3.3  Mass Spectrometric Conditions 
Mass spectrometric analysis was carried out using a XEVO TQS triple quadrupole mass 
spectrometer (Waters, Milford, MA, USA) with positive electric spray ionization mode using 
multiple reaction monitoring (MRM). Multiple reaction monitoring used the precursor to product 
ion pairs for quantification of compounds used by MRM are summarized in Table 2-2.  
The settings of MRM were as follows: capillary voltage, 2.8 kV; source temperature, 
150°C; desolvation temperature, 500°C; cone gas flow, 150 L/h; desolvation gas flow, 800 L/h. 
The LC–MS system was controlled by Masslynx® software version 4.1, and data were collected 
with the same software. 
 
Table 2-2. The ion pairs for multiple reaction monitoring 
Compound Parent (m/z) Daughter (m/z) 
Buprenorphine 467.99 396.18 
Buprenorphine-D4 472.22 400.15 
Norbuprenorphine 414.02 101.00 
Norbuprenorphine-D3 417.27 101.07 
Buprenorphine-3-β-D-glucuronide 644.10 468.22 
Buprenorphine-D4-3-β-D-glucuronide 648.10 472.2 
Norbuprenorphine glucuronide 590.10 414.22 
Norbuprenorphine glucuronide-D3 593.10 417.21 
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2.3.4  Standards and quality control samples preparation 
A stock solution of buprenorphine, norbuprenorphine, buprenorphine glucuronide, 
norbuprenorphine glucuronide at a concentration of 100 µg/mL was prepared in 100% methanol 
and was used to spike human blank plasma to obtain 0.05, 0.1, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, 
50.0, 100.0 ng/mL of buprenorphine, 0.2, 0.5, 1.0, 2.0, 5.0, 10.0, 20.0, 50.0, 100.0 ng/mL of 
norbuprenorphine, and 0.2, 0.4, 1.0, 2.0, 4.0, 10.0, 20.0, 40.0, 100.0, 200.0 ng/mL of 
buprenorphine glucuronide and norbuprenorphine glucuronide as calibration standards. Quality 
control samples were prepared independently by separately spiking buprenorphine, 
norbuprenorphine, buprenorphine glucuronide, norbuprenorphine glucuronide stock solutions at a 
concentration of 100 µg/mL into blank human plasma to obtain QC samples at concentrations of 
0.1, 0.2, 4, 40, 80 ng/mL for buprenorphine, 0.2, 4, 40, 80 ng/mL for norbuprenorphine and 0.4, 
8, 80 and 160 ng/mL for buprenorphine glucuronide, norbuprenorphine glucuronide. The stock 
solutions of the deuterated compounds, buprenorphine-D4, norbuprenorphine-D3, buprenorphine-
D4-3-β-D-glucuronide, norbuprenorphine glucuronide-D3 at concentrations of 100 µg/mL were 
mixed and diluted with 50% methanol in water at concentration of 10 ng/mL, and used as working 
internal standards solution. These stock solutions, calibration standards, QC samples and internal 
standards were frozen at –80°C in safe-lock tubes.  
2.3.5  Plasma samples preparation 
Daily calibration standards, QC samples, and clinical plasma samples were thawed at room 
temperature. Plasma concentrations of buprenorphine, norbuprenorphine, buprenorphine 
glucuronide, norbuprenorphine glucuronide were determined by UPLC-MS/MS. Calibration 
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standards and QC samples were prepared by spiking blank human plasma with stock solution as 
described in section 2.3.3. Twenty µL of mixed internal standards (buprenorphine-D4, 
norbuprenorphine-D3, buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide-D3 at 
10 ng/mL in 50% methanol) were added to 200 μL of plasma sample in an Eppendorf 
microcentrifuge tube. To this, 800 μL of 100% acetonitrile (ACN) were added as a protein 
precipitation solution. The tube was vortexed for 30s, then followed with centrifugation at 15,000 
rpm for 15min at room temperature. The supernatant was transferred to a glass tube and was dried 
under a stream of air. The dried residues were reconstituted in 100 μL of mobile phase (consisting 
of 2B:1A), vortexed for 30s, and then transferred to an Eppendorf microcentrifuge tube. The tube 
was centrifuged at 15,000 rpm for 15min at room temperature. The supernatant was transferred to 
a sample vial for injection. Two μL of the solution was injected on the column. 
2.3.6  Bioanalytical method validation 
The UPLC-MS/MS method was developed and validated according to the guidance of 
bioanalytical method validation by the FDA in 2013 [235]. 
 
Selectivity  
The selectivity was evaluated by analyzing drug-free human plasma from six individuals 
in order to exclude potential interference in the assay with buprenorphine and its three metabolites 
from any endogenous substances in plasma. 
 
Calibration curves  
The calibration curves were generated by plotting the response ratio of buprenorphine to 
buprenorphine-D4, norbuprenorphine to norbuprenorphine-D3, buprenorphine-3-β-D-glucuronide 
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to buprenorphine-D4-3-β-D-glucuronide, norbuprenorphine glucuronide to norbuprenorphine 
glucuronide-D3 against nominal concentration of the corresponding four analytes in plasma 
samples. The calibration curves were fit by linear regression using weighing factor of 1/x2. 
Concentration of analytes in the unknown plasma samples were calculated from their peak area 
ratios and the calibration curve. The deviations of back calculated concentrations from the nominal 
concentrations of QC samples were used to check the assay performance over the concentration 
ranges on each sample run day. The acceptance criteria of accuracy and precision of QC samples 
are described below.   
 
Accuracy and precision   
Accuracy was investigated by intra- and inter-day coefficient of variation (CV). Quality 
control samples (0.1, 0.2, 4, 40, 80 ng/mL for buprenorphine, 0.2, 4, 40, 80 ng/mL for 
norbuprenorphine; 0.4, 8, 80, 160 ng/mL for buprenorphine glucuronide and norbuprenorphine 
glucuronide) were tested. For intra-day accuracy, five samples of each concentration were 
analyzed on a single day; for inter-day accuracy, a total of five samples of each concentration were 
measured on three consecutive days. The back-calculated concentrations should be between 85% 
and 115% of the nominal concentrations.  
 
Precision was evaluated by intra- and inter-day reproducibility. Quality control samples 
(0.1, 0.2, 4, 40, 80 ng/mL for buprenorphine, 0.2, 4, 40, 80 ng/mL for norbuprenorphine; 0.4, 8, 
80, 160 ng/mL for buprenorphine glucuronide and norbuprenorphine glucuronide) were tested. For 
intra-day precision, five samples of each concentration were assayed on a single day; for inter-day 
precisions, a total of five samples of each concentration were determined on three consecutive 
days. The intra-day and inter-day coefficient of variation should be within 15%. 
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Extraction recovery and matrix effects  
The extraction recovery of buprenorphine and three of its metabolites was performed by 
comparing the responses obtained from extracted QC samples (0.1, 0.2, 4, 40, 80 ng/mL for 
buprenorphine, 0.2, 4, 40, 80 ng/mL for norbuprenorphine; 0.4, 8, 80, 160 ng/mL for 
buprenorphine glucuronide and norbuprenorphine glucuronide) with the responses obtained from 
extracted blank human plasma spiked with buprenorphine, norbuprenorphine, buprenorphine 
glucuronide and norbuprenorphine glucuronide and internal standards post extraction that 
represent 100% recovery. 
 
To evaluate the effect of endogenous matrix on the ionization of buprenorphine and three 
metabolites, responses of buprenorphine and three metabolites at the QC concentrations (0.1, 0.2, 
4, 40, 80 ng/mL for buprenorphine, 0.2, 4, 40, 80 ng/mL for norbuprenorphine; 0.4, 8, 80, 160 
ng/mL for buprenorphine glucuronide and norbuprenorphine glucuronide) in triplicate were 
evaluated. The effect of plasma matrix on analytes was defined by comparing the response 
obtained from extracted blank plasma samples spiked with buprenorphine, norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide post extraction with the absolute 
response of reconstitution solvent to which the same amount of analytes were added. 
Chemical Stability  
The freeze-thaw stability (subjected to three cycles at –80 °C and room temperature), 
bench-top stability (subjected to laboratory handling conditions up to 24 hours at room 
temperature), and storage at 4 °C for 3 days of buprenorphine and three metabolites were studies 
at QC concentrations (0.1, 0.2, 4, 40, 80 ng/mL for buprenorphine, 0.2, 4, 40, 80 ng/mL for 
norbuprenorphine; 0.4, 8, 80, 160 ng/mL for buprenorphine glucuronide and norbuprenorphine 
glucuronide) in plasma.  
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2.4 Results 
Following an injection of the reconstitution solution into UPLC-MS/MS system with 
positive ion electrospray ionization interface, the retention time of buprenorphine, 
norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide were 3.3, 1.64, 
1.35 and 0.84 min, respectively. The assay did not show any significant interference with plasma 
constituent at the retention times of analytes of each ion pair for MRM. Representative 
chromatogram of human blank plasma, blank plasma spiked with internal standards are shown in 
Figure 2-3. Typical chromatogram of plasma samples spiked with buprenorphine at 0.05 ng/mL; 
norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide at 0.2 ng/mL, 
and their respective internal standards are listed in Figure 2-4. The regression coefficient (r2) of all 
calibration curves was higher than 0.99 for buprenorphine, norbuprenorphine, buprenorphine 
glucuronide, and norbuprenorphine glucuronide.
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Figure 2-3. Representative chromatogram of pooled blank human plasm without spiked with internal standards. (A) 
buprenorphine-D4-3-β-D-glucuronide; (B) buprenorphine-3-β-D-glucuronide; (C) Norbuprenorphine glucuronide-D3; (D) 
Norbuprenorphine glucuronide (E) buprenorphine-D4; (F) buprenorphine; (G) Norbuprenorphine-D3; (H) Norbuprenorphine 
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Figure 2-4. Representative chromatogram of pooled blank human plasm spiked with internal standards. (A) buprenorphine-D4-
3-β-D-glucuronide; (B) buprenorphine-3-β-D-glucuronide; (C) Norbuprenorphine glucuronide-D3; (D) Norbuprenorphine 
glucuronide (E) buprenorphine-D4; (F) buprenorphine; (G) Norbuprenorphine-D3; (H) Norbuprenorphine 
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Figure 2-5. Representative chromatogram spiked with buprenorphine (0.05 ng/mL, 4A), 
norbuprenorphine (0.2 ng/mL, 4B), buprenorphine glucuronide (0.2 ng/mL, 4C), and 
norbuprenorphine glucuronide (0.2 ng/mL, 4D) with their respective deuterated internal 
standards. 
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2.4.1  Accuracy and precision 
The QC plasma samples at different concentrations were processed to examine the 
accuracy and precision of the assay. The intra-day and inter-day accuracies expressed as 
percentage of the nominal concentrations were within 98.2-108.0 %. The intra-day and inter-day 
precision determined by the coefficient of variations were within 9 %. Results of the assay 
precision and accuracy are presented in Table 2-3 and Table 2-4, respectively. 
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Table 2-3. Inter-day and Intra-day accuracy of buprenorphine and three metabolites (expressed as a percentage of the 
nominal concentration) 
 
 
 
 
 
 BUP NBUP  BUPG NBUPG 
       QC 
Concentration 
    (ng/mL) 
Intra-day accuracy (%, n=5) 
       QC 
Concentration 
    (ng/mL) 
Intra-day accuracy (%, n=5) 
0.1  106.1 NA 0.4 109.5 104.9 
0.2 98.7 99.9 8 108.5 108.0 
4 102.4 106.5 80 102.6 98.2 
40 100.5 103.7 160 108.4 103.0 
80 99.8 107.2  
       QC 
Concentration 
    (ng/mL) 
Inter-day accuracy (%, n=5) 
       QC 
Concentration 
    (ng/mL) 
Inter-day accuracy (%, n=5) 
0.1  108.8 NA 0.4 106.5 103.8 
0.2 98.7 102.9 8 105.0 107.5 
4 105.3 106.0 80 102.7 99.9 
40 98.4 102.9 160 105.2 104.0 
80 102.2 106.6  
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Table 2-4. Inter-day and Intra-day precision of buprenorphine and three metabolites 
(expressed as coefficient of variation) 
 
 
 
 BUP NBUP  BUPG NBUPG 
       QC 
Concentration 
    (ng/mL) 
Intra-day precision (%, n=5) 
       QC 
Concentration 
    (ng/mL) 
Intra-day precision (%, n=5) 
0.1  2.6 NA 0.4 2.7 3.7 
0.2 5.6 6.9 8 2.4 2.4 
4 5.9 3.5 80 1.3 3.7 
40 1.8 6.0 160 1.1 1.5 
80 3.5 2.2  
       QC 
Concentration 
    (ng/mL) 
Inter-day precision (%, n=5) 
       QC 
Concentration 
    (ng/mL) 
Inter-day precision (%, n=5) 
0.1  4.5 NA 0.4 4.1 2.1 
0.2 3.8 8.9 8 4.3 3.8 
4 1.4 2.4 80 0.8 6.0 
40 2.6 5.7 160 3.6 5.1 
80 2.5 3.0  
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2.4.2   Recovery and matrix effect 
The QC plasma samples at different concentrations were processed to examine the 
recovery of buprenorphine and three metabolites. The recoveries for all analytes were above 85% 
over the concentration range tested. No significant matrix effects were observed for buprenorphine 
and its three metabolites from extracted human plasma samples. Results are presented in Table 2-
5.
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Table 2-5. Recovery and matrix effect of buprenorphine and three metabolites in human 
plasma samples  
 
 BUP NBUP  BUPG NBUPG 
       QC 
Concentration 
    (ng/mL) 
Recovery (%, n=3) 
       QC Concentration 
    (ng/mL) 
Recovery (%, n=3) 
0.1  95.8 NA 0.4 91.1 90.8 
0.2 98.4 102.8 8 99.2 88.6 
4 93.2 99 80 94.6 85.6 
40 92.3 104.1 160 89.4 86.8 
80 86.8 97.9  
       QC 
Concentration 
    (ng/mL) 
Matrix effect (%, n=3) 
       QC Concentration 
    (ng/mL) 
Matrix effect (%, n=3) 
0.1  6.7 NA 0.4 -4.3 -13.7 
0.2 -2.2 -10.2 8 -1.0 5.3 
4 5.2 -12.2 80 1.8 3.5 
40 -0.6 -15.3 160 12.6 2.9 
80 13.6 -8.2  
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2.4.3  Stability 
After subjecting the samples to three freeze–thaw cycles, 24 hr bench - top storage at room 
temperature, and 4 °C storage for 72 hrs, changes in the concentrations for buprenorphine and 
three metabolites at four concentrations of all the QC samples were within 85-115% of nominal 
concentrations (Table 2-6). No significant degradation for buprenorphine and its three metabolites 
was observed in plasma samples under the condition tested.  
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Table 2-6. Stability of buprenorphine and three metabolites in human plasma samples 
(expressed as mean of nominal concentration ± SD %) 
 
 BUP NBUP  BUPG NBUPG 
       QC 
Concentration 
    (ng/mL) 
3 Freeze–thaw cycles (%, n=3) 
       QC 
Concentration 
    (ng/mL) 
3 Freeze–thaw cycles (%, n=3) 
0.1  105.8 ± 7.6 NA 0.4 105.4 ± 7.0 106.0 ± 1.9 
0.2 111.0 ± 1.3 99.5 ± 4.0 8 105.5 ± 1.2 105.4 ± 4.7 
4 112.0 ± 1.1 107.5 ± 2.5 80 102.3 ± 2.5 104.0± 3.8 
40 110.9 ± 0.9 106.9 ± 4.0 160 101.4 ± 4.7 106.6 ± 2.1 
80 108.0 ± 3.4 110.0 ± 3.1  
       QC 
Concentration 
    (ng/mL) 
24 h bench‐top (%, n=3)        QC Concentration 
    (ng/mL) 
24 h bench‐top (%, n=3) 
0.1  110.9 ± 2.0 NA 0.4 108.3 ± 7.2 101.7 ± 7.2 
0.2 111.6 ± 1.0 103.3 ± 2.9 8 104.2 ± 1.4 108.3 ± 3.1 
4 110.9 ± 0.7 110.0 ± 6.6 80 101.4 ± 2.5 101.0 ± 1.4 
40 109.0 ± 0.8 103.8 ± 1.5 160 100.8 ± 4.7 109.4 ± 0.2 
80 106.3 ± 0.9 104.3 ± 4.2  
       QC 
Concentration 
    (ng/mL) 
4 °C storage for 72 hrs (%, n=3) 
       QC 
Concentration 
    (ng/mL) 
4 °C storage for 72 hrs (%, n=3) 
0.1  112.2 ± 1.2 NA 0.4 110.0 ± 4.3 104.9 ± 4.4 
0.2 112.2 ± 0.8 95.0 ± 5.0 8 104.2 ± 0.7 107.5 ± 2.5 
4 112.4 ± 2.0 105.8 ± 1.4 80 100.3 ± 2.5 105.8 ± 0.7 
40 105.3 ±0.08 103.8 ±2.6 160 104.0 ± 0.8 100.3 ± 3.9 
80 105.3 ± 5.3 108.2 ± 4.0  
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2.4.4  Analysis of buprenorphine and three metabolites in pregnant women 
This validated UPLC-MS/MS was used to quantify buprenorphine, norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide in pregnant women following 
administration of a sublingual dose of buprenorphine at steady state.  The study was approved by 
the Institutional Review Board (IRB) at the University of Pittsburgh. Written informed consent 
was obtained from all patients prior to initiation of any study-related activities. In this 
pharmacokinetic study, blood samples were collected at steady state after patients were 
administrated several doses of sublingual buprenorphine. The time courses of buprenorphine, 
norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide after a dose in 
one patient at steady state are shown in Figure 2-6. The mean dose normalized concentration versus 
time plot of buprenorphine are presented in Figure 2-7. The summary of PK parameters of BUP 
following SL administration of BUP in the clinical study are listed in Table 2-7. The comparison 
of the PK parameters of BUP in postpartum period in our clinical study to the PK parameters in 
non-pregnant population are shown in Table 2-8. Buprenorphine PK parameters at postpartum 
period is comparable to the PK parameters in non-pregnant population in published reports as 
shown in Table 2-8. 
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Figure 2-6. Plasma concentration vs time profiles of buprenorphine, norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide following sublingual 
administration of buprenorphine in one pregnant women.
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Figure 2-7. Dose normalized buprenorphine mean concentration time profile (expressed as mean± SD) 
Red, green and blue curve represent study at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
N = 12 (2, 9 and 1patients completed study in 6, 8 and 12 hrs, respectively), 5 (4 and 1 patients completed study in 6 and 8 hrs, 
respectively), and 3 (All 3 patients completed study in 6 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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                          Table 2-7. Buprenorphine pharmacokinetic parameters during pregnancy and postpartum period 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: Tmax, time to maximum concentration, Cavg,ss, average concentration plasma concentration during a dose interval at steady state, AUCss, area under 
the plasma concentration-time curve over a dose interval at steady state, CLss, total body clearance at steady state.  
Parameter  
(Mean ± SD) 
1st- half 
(n=12) 
2nd-half 
(n=5) 
Postpartum 
(n=3) 
Dose (mg) 4.2 ± 1.3 4.8 ± 1.8 4 ± 0 
Tmax (hr) 1.1 ± 0.4 0.6 ± 0.2 1.2 ± 0.3 
Dose-normalized Cavg,ss 
(ng/mL/mg) 
0.4 ±0.2 0.5 ± 0.3 0.6 ± 0.4 
Dose-normalized AUCss 
(ng/mL/mg) 
2.9 ± 1.1 2.7 ± 1.2 3.7 ± 2.3 
Apparent CLss/F (L/h) 386.5 ± 138.7 420.6 ± 157.4 348.3 ± 190.9 
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Table 2-8. Comparisons of BUP PK from our in-house clinical PK studies at postpartum 
period and non-pregnant population from literatures following multiple doses of SL BUP 
administration (expressed as mean (SD)) 
 
                  Study Dose Normalized AUC0-t,ss          Tmax 
Compton et al. [236] 
(16 mg group, n = 16) 
3.42 (3.07) Not reported 
Compton et al. [236] 
(24mg group, n = 15) 
3.38 (2.73) Not reported 
Compton et al. [236] 
(32 mg group, n = 10) 
3.67 (3.83) 0.94 (0.5) 
Greenwald et al.a [237] 
(2 mg group, n = 5) 
3.25 0.9 
Greenwald et al. [237] 
(16 mg group, n = 16) 
3.04 1.2 
Greenwald et al. [237] 
(32 mg group, n= 32) 
3 1.2 
Our in-house data at postpartum (n 
= 14c) 
4.09 (2.34) 0.86 (0.33) 
 
a Standard deviation were not reported. 
b Values obtained from graph digitized data. 
c Pooled subjects from two BUP clinical studies of postpartum period.
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2.4.5  Alterations of buprenorphine metabolic pathway during pregnancy 
We analyzed the changes of CYP- and UGT- mediated metabolic pathways of 
buprenorphine using the concentrations of BUP and three metabolites from the current clinical 
study, as well as the data from our previous publication [201]. The mean concentration-time 
profiles of norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide are 
shown in Figure 2-8, 2-9, and 2-10. As defined below, the AUC ratios of CYP-mediated 
metabolites to parent, and the ratios of UGT-mediated metabolite to parent at 1st-and 2nd-trimester 
vs postpartum and 3rd-trimester vs postpartum were shown in Figure 2-11, 2-12, 2-13 and 2-14, 
respectively.  
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑃𝑃+𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑃𝑃𝑁𝑁
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑁𝑁𝑃𝑃
 = CYP-mediated metabolism of buprenorphine 
 𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑁𝑁𝑃𝑃𝑁𝑁
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑁𝑁𝑃𝑃
=  UGT-mediated metabolism of buprenorphine 
The area under the curves the plasma molar concentration of BUP, NBUP, BUPG, and 
NBUPG during a dose interval (AUC0-t) were calculated from time 0 to 12 hours or the end of a 
dosing interval using trapezoidal rule. Natural logarithmic transformation were applied to the AUC 
ratios of metabolite/parent to generate approximately normally distributed data for the purpose of 
statistical analysis. A univariate linear mixed effect model was used to compare the statistical 
difference in the AUCs ratios of metabolite/parent during pregnancy vs postpartum period. In the 
linear mixed effect model, time was treated as fixed effect, subject was treated as random effect. 
The linear mixed effect model was fitted through maximum likelihood estimation in Stata (Version 
14.0 SE). The results have shown that the AUC ratios of CYP- and UGT- mediated metabolic 
pathway were significantly higher during pregnancy compared to postpartum (Table 2-9). 
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Table 2-9. The AUC ratios of CYP- and UGT- mediated metabolism of buprenorphine 
during pregnancy compared to postpartum (expressed as mean (SD)) 
Parameter  
1st- and 2nd-
trimester 
(n=19) 
3rd-
trimester 
(n=18) 
Postpartum 
(n=14)  p Value 
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃+𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃𝑁𝑁
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝐴𝐴𝑃𝑃
 1.89 (0.56) 1.84 (0.59) 1.33 (0.60) 
0.004, 1st-and 2nd-trimester 
vs postpartum 
0.013, 3rd-trimester vs 
postpartum 
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝐴𝐴𝑃𝑃𝑁𝑁
𝐴𝐴𝐴𝐴𝐴𝐴𝑁𝑁𝐴𝐴𝑃𝑃
 0.71 (0.70) 2.07 (3.62) 0.30 (0.24) 
< 0.001, 1st-and 2nd-
trimester vs postpartum 
< 0.001, 3rd-trimester vs 
postpartum 
The AUC were calculated from molar concentrations of BUP and its three metabolites; 
A natural logarithmic transformation to ratios were used for the linear mixed effect model analysis. 
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Figure 2-8. Dose normalized norbuprenorphine mean concentration time profile (expressed 
as mean± SD) 
Red, green and blue curve represent study at the 1st- and 2nd-trimester, 3rd-trimester and 
postpartum, respectively. 
N = 19 (2, 9 and 8 patients completed study in 6, 8 and 12 hrs, respectively), 18 (4,1 and 13 patients 
completed study in 6, 8 and 12 hrs, respectively), and 14 (3 and 11 patients completed study in 6 
and 12 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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Figure 2-9. Dose normalized buprenorphine glucuronide mean concentration time profile 
(expressed as mean± SD) 
N = 19 (2, 9 and 8 patients completed study in 6, 8 and 12 hrs, respectively), 18 (4,1 and 13 patients 
completed study in 6, 8 and 12 hrs, respectively), and 14 (3 and 11 patients completed study in 6 
and 12 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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Figure 2-10. Dose normalized norbuprenorphine glucuronide mean concentration time 
profile (expressed as mean± SD) 
N = 19 (2, 9 and 8 patients completed study in 6, 8 and 12 hrs, respectively), 18 (4,1 and 13 patients 
completed study in 6, 8 and 12 hrs, respectively), and 14 (3 and 11 patients completed study in 6 
and 12 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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Figure 2-11. The ratios of AUC of norbuprenorphine and AUC of norbuprenorphine 
glucuronide to the AUC of buprenorphine at 1st-and 2nd-trimester vs postpartum.  
Dotted black line is the mean ratios. Each line represents a pair of ratios from one patient. ID is 
the patient identification number in the studies. 
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Figure 2-12. The ratios of AUC of norbuprenorphine and AUC of norbuprenorphine 
glucuronide to the AUC of buprenorphine at 3rd-trimester vs postpartum 
Dotted black line is the mean ratios. Each line represents a pair of ratios from one patient. ID is 
the patient identification number in the studies. 
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Figure 2-13. The ratios of AUC of buprenorphine glucuronide to the AUC of 
buprenorphine at 1st-and 2nd trimester vs postpartum 
Dotted black line is the mean ratios. Each line represents a pair of ratios from one patient. ID is 
the patient identification number in the studies. 
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Figure 2-14. The ratios of AUC of buprenorphine glucuronide to the AUC of 
buprenorphine at 3rd-trimester vs postpartum 
Dotted black line is the mean ratios. Each line represents a pair of ratios from one patient. ID is 
the patient identification number in the studies. 
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2.5 Discussion 
A rapid and sensitive UPLC-MS/MS assay to simultaneously quantify plasma 
concentrations of buprenorphine, norbuprenorphine, buprenorphine glucuronide and 
norbuprenorphine glucuronide using a small volume of human plasma was developed and 
validated. This method displayed linearity over a wide range of concentrations buprenorphine 
(0.05 - 100 ng/mL), norbuprenorphine (0.2 - 100 ng/mL), and buprenorphine glucuronide and 
norbuprenorphine glucuronide (0.2 - 200 ng/mL) with acceptable intra- and inter- day precision 
and accuracy. Following simple protein precipitation, buprenorphine and three metabolites have 
shown good extraction recovery with no significant matrix effects from human plasma 
constituents. This assay was successfully applied for the analysis of buprenorphine and its 
metabolites in a clinical pharmacokinetic study of buprenorphine in pregnant women. 
In this method, isotopically labelled molecules of buprenorphine-D4, norbuprenorphine-
D3, buprenorphine-D4-3-β-D-glucuronide and norbuprenorphine glucuronide-D3 were used as 
internal standards. This is the first time that deuterated labelled buprenorphine glucuronide and 
deuterated labelled norbuprenorphine glucuronide were used as internal standards to quantify the 
concentrations of buprenorphine glucuronide and nor buprenorphine glucuronide, respectively. In 
previously reported analytical method, norbuprenorphine-D3 was used as an internal standard to 
quantify the concentrations of norbuprenorphine, buprenorphine glucuronide and nor 
buprenorphine glucuronide. The deuterated labelled internal standards have similar 
physiochemical properties compared to the analytical compounds, therefore, normally they have 
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the same extraction efficiency, chromatographic retention time, matrix effect (if any), and 
ionization response in mass spectrometry to the analytes to be quantified. The use of deuterated 
internal standards is very specific for the analytical compounds, which improves the reliability and 
reproducibility of the assay that we have developed. We did observe signal for norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide but not buprenorphine when only 
deuterated internal standards, buprenorphine-D4, norbuprenorphine-D3, buprenorphine-D4-3-β-D-
glucuronide and norbuprenorphine glucuronide-D3 were injected with neat solution or plasma. We 
made corrections for the responses of norbuprenorphine, buprenorphine glucuronide and 
norbuprenorphine glucuronide by subtracting the product of the fraction of the signal of non-
deuterated compound from corresponding deuterated labelled compound (𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 non−deuterated compound
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑑𝑑𝑅𝑅𝑓𝑓𝑑𝑑𝑅𝑅𝑁𝑁𝑑𝑑𝑑𝑑𝑅𝑅𝑑𝑑 𝑐𝑐𝑁𝑁𝑐𝑐𝑅𝑅𝑁𝑁𝑓𝑓𝑅𝑅𝑑𝑑 ) in blank plasma spiked with internal standards and the 
response of corresponding deuterated labelled compound from the absolute response of non-
deuterated compound for each run. The equations are shown below. 
Corrected response NorBUP = Absolute response NorBUP – ( 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃−𝐷𝐷4) × response NorBUP-D4 in 
samples 
Corrected response BUPG = Absolute response BUPG – ( 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝐴𝐴𝑃𝑃𝑁𝑁
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝐴𝐴𝑃𝑃𝑁𝑁−𝐷𝐷3) × response BUPG-D3 in samples 
Corrected response NorBUPG = Absolute response NorBUPG – ( 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃𝑁𝑁
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑁𝑁𝑅𝑅𝑅𝑅𝑅𝑅 𝑁𝑁𝑓𝑓 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝐴𝐴𝑃𝑃−𝐷𝐷4) × response NorBUPG-D4 in 
samples 
Buprenorphine, three metabolites and their respective internal standards were eluted by 3.3 
min, so the total run time for one injection could be shortened to 5 mins. However, a few small 
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endogenous substances from extracted human plasma appeared after 5 min. Therefore, we set the 
run time to 7 min to obtain a stable baseline. Only 200 μL plasma was required for this assay, 
which favors a pharmacokinetic study by decreasing the total blood volume collected from a 
patient. Furthermore, out of a 100 μL of reconstitution volume, the injection volume was 2 μL, 
which makes it possible to re-inject samples, multiple times if necessay. 
Protein precipitation, liquid-liquid extraction and solid phase extraction are three common 
methods used to remove proteins or interfering compounds from plasma samples. Protein 
precipitation using miscible organic solvents, usually methanol or acetonitrile, is the simplest and 
most rapid approach of sample processing among the three methods. Liquid-liquid extraction 
method uses immiscible solvents to separate analytes and quantify from the matrix such as plasma. 
To simultaneously determine buprenorphine, norbuprenorphine and two conjugated glucuronide, 
liquid-liquid extraction is not suitable due to wide ranging polarity of the four analytes. Compared 
to protein precipitation and liquid-liquid extraction, solid phase extraction is more time consuming 
and expensive, but solid phase extraction can produce more purified extracts. Solid phase 
extraction employs the affinity of analytes to an elution solvent and to the packing material of the 
stationary phase to separate or purify analytes. The process of a solid phase extraction includes 
samples pretreatment (usually adding water to dilute plasma samples), cartridge conditioning, 
sample loading, sample washes, and analytes collection. During the development of the assay, we 
evaluated protein precipitation and solid phase extraction for the sample preparation. However, 
the recovery of the analytes were low, especially for buprenorphine glucuronide and 
norbuprenorphine glucuronide using the solid phase extraction. Buprenorphine has high affinity 
to mu-opioid receptor, so small concentrations are sufficient for its therapeutic effect in treating 
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opioid addiction. The low extraction efficiency using solid phase extraction makes it more 
challenging to accurately determine low concentrations of buprenorphine and all three metabolites.  
The plasma concentrations of buprenorphine and three metabolites were comparable to the 
reported data in other studies. For example, Concheiro et al. reported that the peak concentrations 
of buprenorphine, norbuprenorphine, buprenorphine glucuronide and norbuprenorphine 
glucuronide ranged 1.1 - 35.2, 0.8 – 27.5, 1.7 – 31.0, 8.3 – 81.2 ng/mL, respectively, in 3 pregnant 
women following 14 – 20 mg SL administration of BUP at steady state [238]. In the study 
conducted by Kuhlman et al., the Cmax of buprenorphine and norbuprenophine ranged 0.9 -2.1, 
1.26 - 2.25 ng/mL following 8 mg SL administration of BUP at steady state [239].  
The AUC ratios of metabolites to parents demonstrated that CYP- and UGT- mediated 
buprenorphine metabolism were altered during pregnancy compared to postpartum. These results 
were supported by the observations of increase in the activities of CYP3A4 and UGT1A4 in other 
studies [165, 168]. The increase in the activities of metabolic enzymes of BUP can partially explain 
the lower exposure of buprenorphine observed in pregnancy. 
2.6 Conclusions 
We successfully developed and validated a rapid, sensitive and robust UPLC-MS/MS assay 
with simple sample preparation to quantify the concentration of buprenorphine, norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide in human plasma. The advantages 
of this analytical method include simple sample processing, small plasma volume requirement, 
high recovery of BUP and three of its metabolites, and short sample run time. We applied the assay 
to evaluate the pharmacokinetics of buprenorphine and its three metabolites in pregnant women. 
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This assay enables us to quantify concentration time profiles of buprenorphine, norbuprenorphine, 
buprenorphine glucuronide and norbuprenorphine glucuronide after low dose of BUP using 
limited volume of blood samples. 
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 A Physiologically Based Pharmacokinetic Modeling Approach to Predict 
Buprenorphine Pharmacokinetics following Intravenous & Sublingual Administration 
 
 
(This chapter has been published in the British Journal Clinical Pharmacology (2017) 
83: 2458–2473)
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3.1 Abstract 
Introduction: Opioid dependence is associated with high morbidity and mortality. 
Buprenorphine (BUP) is approved by the FDA to treat opioid dependence. There is a lack of clear 
consensus on the appropriate dosing of BUP in the presence of inter-patient physiological 
differences in absorption/disposition, subjective response assessment and other patient 
comorbidities. The objective of this study is to build and validate robust physiologically-based-
pharmacokinetic (PBPK) models for intravenous (IV) and sublingual (SL) BUP in non-pregnant 
adults as a first step to optimize BUP pharmacotherapy. 
Methods: BUP-PBPK modeling and simulations were performed using Simcyp® by 
incorporating physiochemical properties of BUP, establishing Inter-System Extrapolation Factors 
(ISEF) based In-Vitro In-Vivo Extrapolation (IVIVE) methods to extrapolate in-vitro enzyme 
activity data, and using tissue specific Kp estimations. Published data on IV and SL BUP in opioid 
and non-opioid dependent patients was used to build the models. Fourteen model naïve BUP-PK 
datasets were used for inter-study and intra-study validations. 
Results: IV and SL BUP-PBPK models developed are robust in predicting multi-
compartment disposition of BUP over a dosing range of 0.3-32 mg. Predicted plasma 
concentration-time profiles in virtual patients are consistent with reported data across 5 IV-single 
dose studies, 5 SL-single dose studies and 4 SL-multiple dose studies. All PK parameter 
predictions were within 75%-137% of the corresponding observed data. The model developed 
predicted brain concentration of BUP to be about 4 times higher than that of BUP in plasma.  
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Conclusion: The validated PBPK models will be used in future studies to predict BUP 
plasma and brain concentrations based on varying demographic, physiological and pathological 
characteristics of the patients. 
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3.2 Introduction 
Drug overdose and associated deaths have become a nation-wide crisis in the United States 
[240]. Data from the Centers for Disease Control and Prevention (CDC) indicate that deaths 
associated with drug overdose are predominantly driven by an increase in opioid abuse [241-243]. 
Broadly speaking, the term opioid applies to any endogenous or exogenous substance that interacts 
with the opioid receptors present in the body [244]. Because of their efficacy in pain management, 
prescription opioids, such as morphine, hydromorphone, oxycodone, hydrocodone and fentanyl 
are routinely used in patients [245]. Besides blocking pain-signaling pathway, opiates also activate 
brain reward system and produce euphoric effects. This makes them highly addictive with 
prolonged exposure [246, 247]. 
Opioid dependence is associated with high morbidity and mortality [248, 249]. There is no 
cure for opioid dependence. Medication-assisted maintenance therapies can reduce complications 
of opioid dependence, as a consequence of decreased illicit drug use [250, 251]. Currently 
methadone, buprenorphine (BUP), and naltrexone are the three primary pharmacotherapies 
approved for treating opioid dependence. The effectiveness of methadone as a maintenance 
treatment for opioid dependence has been demonstrated in many clinical studies [252, 253]. As a 
full mu receptor agonist, methadone has abuse potential; consequently methadone maintenance 
treatment requires daily patient clinic visits. Naltrexone is a mu receptor antagonist; it can reduce 
illicit drug use by blocking euphoric effects and has no abuse potential, but poor patient retention 
hampers its routine clinical use [254, 255].  
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The Food and Drug Administration (FDA) approved BUP for treatment of opioid addiction 
in 2002. Compared to methadone, BUP is a relatively new drug that has several advantages in 
clinical practice. BUP exhibits mixed agonist-antagonist opioid effect [256, 257], is highly potent 
towards kappa (antagonist) and mu (partial agonist) opioid receptors; and it is roughly 50-100 
times more potent than morphine [258]. BUP has a ceiling dose-response profile, which limits the 
risk of major life-threatening adverse effects associated with mu receptor agonists such as 
respiratory depression [259]. Because of this profile, BUP can provide competitive antagonism to 
other illicit opioids. In recent times, a sublingual (SL) formulation of BUP (Subutex®) has been 
shown to be more favorable due to its safety profiles and ease of administration [260].  Suboxone®, 
a SL BUP formulation in combination with naloxone (full mu receptor antagonist), is another 
product which was developed and approved to avoid intravenous (IV) abuse. 
Despite the proven efficacy of BUP in treating opioid addiction, a meta-analysis showed 
that patients on BUP had 1.26 times relative risk of discontinuing the treatment compared to 
patients receiving methadone [261]. In addition, a randomized phase IV study found BUP to be  
associated with 54% of patient dropout compared to 26% in the methadone group [262]. Several 
factors such as lack of clear consensus on induction and a maintenance dosing regimen for BUP; 
subjectivity of the of the Clinical Opioid Withdrawal (COW) scale that is used to determine the 
dose [263]; confounding effects of factors such as mental health comorbidities, smoking, as well 
as concomitant medication use that can confound COW scoring and selection of improper BUP 
dosing would have an impact on the outcomes of BUP therapy and in turn affect compliance. In 
addition, there is a high inter-patient variability in the bioavailability of BUP due to differences in 
the extent of absorption with sublingual administration in different patients [264]. 
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A better understanding of the physiological and drug formulation parameters affecting 
BUP pharmacokinetic and pharmacodynamic profiles is needed to develop a more objective 
dosing regimen of BUP. Physiologically based pharmacokinetic (PBPK) modeling is a very 
comprehensive and relatively inexpensive strategy to address the impact of various clinical 
pharmacotherapeutic factors that impact drug dosing. PBPK modeling approach incorporates a 
drug’s physiochemical properties, human physiological variables and population variability 
estimates to predict drug exposure [265]. Because PBPK models incorporate anatomical, 
physiological, and metabolic attributes, any physiological alterations induced by disease, age, 
gender, genetic polymorphism, and other pathophysiologic conditions can be captured by such 
models. To the best of our knowledge, the use of PBPK modeling in predicting BUP exposure has 
not been explored in adult populations. The objective of this study is to predict the time courses of 
BUP following IV and SL administration of BUP in an attempt to optimize dosing of BUP in 
patients through the development of BUP PBPK models. 
3.3 Methods 
BUP PBPK modeling and simulations were conducted using SimCyp® population-based 
simulator v15.1 (Simcyp limited, Sheffield, UK). WinNonLin software (Phoenix WinNonLin®: 
version 6.4, Pharsight Corp, Mountainview, CA) was used to simulate steady-state exposure after 
administration of the SL formulation. Systematic and extensive literature search in MEDLINE 
through Pubmed was performed to identify published physicochemical properties, plasma protein 
binding, in-vitro disposition and metabolism profiles of BUP. Similar strategies were used to 
identify published clinical trials using IV and SL BUP. These data were tabulated and digitized 
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where necessary for PBPK model building or model validation. The bibliographies of selected 
articles were also reviewed to identify additional relevant information. GetData Graph Digitizer 
V.2.26 [266] was used to digitize published BUP clinical pharmacokinetic data.  
3.3.1  General workflow for model building and model validation   
A full PBPK model was initially developed for IV BUP formulation using physiochemical 
properties (Table 3-1) [70, 89, 267], in-vitro metabolic profiles [268-270] and published IV BUP 
clinical PK data in healthy subjects. In the IV model, BUP was modeled to enter the systemic 
circulation through venous blood (Figure 3-1). Several model naïve IV BUP clinical PK datasets 
were used to perform inter-study and intra-study validations by comparing mean AUC and Cmax 
values between the observed and predicted data. After establishing a validated IV BUP PBPK 
model, a SL BUP PBPK model was built by incorporating SL absorption component to the IV 
model. Sublingual route of administration involves drug being absorbed through reticulated vein 
underneath oral mucosa, and then entering  systemic circulation via facial vein in addition to a 
portion of the dose being swallowed orally [271].  In order to simulate this, we built a custom 
administration route that involves inhalation route to mimic the SL absorption, oral absorption to 
mimic the portion of the drug that is swallowed and a depot release component to mimic the slow 
release of the drug from the buccal tissue into the systemic circulation (Figure 3-1). Following 
model building for the SL route, we performed inter-study and intra-study validations similar to 
the IV model by comparing the mean AUC and Cmax values of the predicted model and observed 
data. Model performance was assessed by intra- and inter-study validations. For the intra-study 
validations, we used the clinical PK data from different dosing ranges from the same study that is 
used to build the PBPK profiles. For inter-study validations, we used data from several model 
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naïve clinical PK studies that were not used in model building. For the validations, we performed 
visual plots of fitted and the predicted against the observed mean concentration-time profiles. Fifth 
to 95th percentile intervals (PI) were calculated to show the overall inter-patient variability. The 
goal was to use IV and SL BUP PBPK models to predict area under the plasma drug concentration-
time curve (AUC), which represents the systemic exposure over time following a dose, and 
compare it to observed data. The criterion for model validation is that the difference of the mean 
predicted and observed AUC in 100 virtual subjects should fall ± 25% for IV model and should 
fall ± 50% for SL model. A wider criterion was chosen for SL model to account for the inherent 
interpatient variability in dose administered and variable drug absorption by this route. 
We were also interested in predicting other BUP PK parameters such as total clearance 
(CLtotal) and maximum concentration (Cmax) as well as their corresponding population variability 
limits. AUC0-t is the drug exposure between time zero and t hours (the last blood collection time 
point) and this was estimated using trapezoidal method. AUC0-∞  is the drug exposure between 
zero hours and infinity and this was estimated by the summation of AUC0-t and extrapolated 
exposure from Clast to infinity (AUClast-∞= Clast/k), where k is the terminal disposition rate 
constant. CLtotal was calculated per the following equation: CL = dose/AUC0–∞. Cmax is the 
observed maximus concentration after administration of a dose.
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 Table 3-1. Summary of BUP physiochemical parameters 
 
Parameter Value Source/Reference 
MW (g/mol) 467.64 Pubchem/ DrugBank 
Log Po:w 4.98 Avdeef et al. [70] 
Compound type Diprotic Base  
pKa1, pKa2  9.62, 8.31 Avdeef et al. [70] 
B/P 0.55 Mistry et al. [89] 
fua 0.03* Walter et al. [267] 
Abbreviations: MW: molecular weight; logP: logarithm of the octanol to water partition 
coefficient, pKa: negative logarithm of the acid dissociation constant, B/P: blood to plasma 
partition coefficient; fu: Plasma fraction unbound; a fu was fitted by non-linear mixed effect 
modeling strategy using parameter estimation module of Simcyp. Nelder-Mead method was used 
for the minimization. fu, 0.04, published by Walter et al [267]. was used as the initial estimate.  
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Figure 3-1.  Compartmental structure of the full BUP IV and SL PBPK models. The 
schematic shows how SL and IV administration was modeled. 
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3.3.2  IV Buprenorphine - PBPK model development  
Distribution Profile: 
The volume of distribution at steady state (Vss), 2.77 L/kg, reported by Bullingham et al 
[272] was used as a reference to build the PBPK distribution component. A predicted Vss of 2.48 
L/kg was estimated using reported BUP physicochemical properties as well as estimated tissue to 
plasma partition coefficients (Kp) for all major tissue specific physiological compartments (Table 
3-2). Vss (equation 1) is estimated by serial addition of plasma volume (Vp), erythrocyte volume 
(Ve) and volumes associated with each major tissue (Vt) [273].  
Vss = Vp + Ve × (E: P) + ∑ Vt × Kp      ………………. Equation 1 
Where E:P represents erythrocyte to plasma partitioning. The E:P is estimated using the 
SimCyp® parameter estimation modules based on the information of blood to plasma ratio and 
hematocrit. 
Tissue specific Kp values of BUP for the full-PBPK model were estimated using the 
corrected Poulin and Theil method [274-276]. Furthermore, sequential sensitivity analysis was 
performed to further identify and optimize tissue Kp values utilizing non-linear mixed effects 
modeling methods. In the final model Kp estimates for just the bone/additional compartment had 
to be optimized and Kp values for all other organ and tissues remained as the predicted values. 
Table 11 summarizes distribution parameters used in the BUP simulations. A hypothetical 
additional compartment was incorporated along with the bone and the Kp value for this combined 
compartment was predicted and optimized using non-linear mixed effects modeling methods using 
the parameter estimator module of Simcyp®. 
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Table 3-2. Distribution parameters for BUP drug profile 
 
Parameter Value 
Model Full PBPK 
Vss (L/kg)-predicteda 2.48 
Vss (L/kg)-observedb 2.77 
Tissue Partition Coefficients (Kp) 
Adipose 0.0044 
Bone/Additionalc 35 
Brain 3.41 
Gut 2.69 
Heart 0.83 
Kidney 1.29 
Liver 2.13 
Lung 0.29 
Pancreas 2.20 
Muscle 1.31 
Skin 1.60 
Spleen 1.31 
Kp scalard 0.225 
 
Abbreviation: Vss: Volume of distribution at steady state; a Bullingham et al. [272]; b Vss predicted 
and Kp values for all tissue were predicted by corrected Poulin and Theil method [274-276]; c 
Bone/Additional compartment Kp value was optimized using the Simcyp® parameter estimation 
module, Nelder-Mead method was used for the minimization. The predicted Kp value, 3.73, by 
Poulin and Theil method was used as the initial value, and (0.001, 100) used as the boundaries; d 
Kp scalar was optimized using the Simcyp® parameter estimation module, Nelder-Mead method 
was used for the minimization. The default Kp scalar, 1, was used as the initial value, and (0.01, 
100) used as the boundaries. 
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Clearance Profile: 
BUP is extensively metabolized to nor-BUP by N-dealkylation, and then both BUP and 
nor-BUP are further conjugated to BUP glucuronide and nor-BUP glucuronide respectively [277]. 
The N-dealkylation is primarily mediated by CYP3A4 and CYP2C8, and the glucuronidation is 
mainly mediated by UGT1A1, 1A3, and 2B7 [268, 277-279]. Together these enzymes are 
responsible for majority of BUP metabolism with minor contribution from other CYP450 and UGT 
enzymes. Established in vitro-in vivo extrapolation (IVIVE) methods using enzyme specific 
microsomal BUP metabolism parameters and inter-system extrapolation factors (ISEF) based 
estimates were used to extrapolate recombinant in-vitro enzyme activities to in vivo intrinsic 
clearances (equation 2) [280].  
CLint = [∑ (𝑅𝑅𝑗𝑗=1  ∑  𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑗𝑗𝑗𝑗× 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝑗𝑗 �𝑁𝑁ℎ𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗�×𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗 𝑑𝑑𝑎𝑎𝑓𝑓𝑅𝑅𝑑𝑑𝑑𝑑𝑅𝑅𝑐𝑐𝑅𝑅 𝐾𝐾𝑚𝑚𝑗𝑗 (𝑁𝑁ℎ𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗)𝑅𝑅𝑖𝑖=1 )]  × MPPGL  × liver weight 
………………Equation 2 
Where CLint is the sum of Vmax/Km of metabolic pathways (i) for each of the involved 
enzyme (j), Vmax is the maximum rate of metabolism, Km is the BUP Michaelis-Menten constant 
for each individual enzyme, rhCYPs are the recombinantly expressed human cytochrome P450s, 
MPPGL is the amount of microsomal protein per gram of human liver, CYPj abundance is the 
amount of jth enzyme in pmol for every mg microsomal protein of the human liver. The CYPj 
abundance, MPPGL, and liver weight are assigned by SimCyp® V.15 for each individual virtual 
population, which are parts of predicted population variability (Table 3-3). 
ISEF is used to scale activity of a unit amount of each enzyme in the recombinant 
microsomal system to human liver microsomal, and scaling of rhCYPs data to the entire human 
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body is accomplished through equation 2. ISEF values for each drug metabolizing enzyme can be 
calculated with either Vmax and Km or CLint as given by the following equations: 
ISEF (Vmax) = 
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝑗𝑗𝑗𝑗(𝐻𝐻𝐻𝐻𝐻𝐻)
𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝑗𝑗 (𝑁𝑁ℎ𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗)×𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗 𝑑𝑑𝑎𝑎𝑓𝑓𝑅𝑅𝑑𝑑𝑑𝑑𝑅𝑅𝑐𝑐𝑅𝑅(𝐻𝐻𝐻𝐻𝐻𝐻)     ………………..Equation 3 
ISEF (CLint) = 
𝐴𝐴𝐻𝐻𝑗𝑗𝑖𝑖𝑖𝑖𝑗𝑗𝑗𝑗(𝐻𝐻𝐻𝐻𝐻𝐻)
𝐴𝐴𝐻𝐻𝑗𝑗𝑖𝑖𝑖𝑖𝑗𝑗 (𝑁𝑁ℎ𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗)×𝐴𝐴𝐶𝐶𝑃𝑃𝑗𝑗 𝑑𝑑𝑎𝑎𝑓𝑓𝑅𝑅𝑑𝑑𝑑𝑑𝑅𝑅𝑐𝑐𝑅𝑅(𝐻𝐻𝐻𝐻𝐻𝐻)    ………………...Equation 4 
CYPj abundance (HLM) is the estimated abundance of jth CYP enzyme in a human liver. 
The intrinsic clearance of BUP and ISEF values associated with enzymes primarily involved in 
BUP metabolism were listed in Table 3-4.
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Table 3-3. Values used in equation 2 to scale rhCYPs data to the entire human body 
(Adapted from healthy population in SimCyp®) 
Drug Metabolizing Enzyme Abundance (pmol/mg protein) CV% 
CYP2C8 24 81 
CYP3A4 137 41 
UGT1A3 23 36 
UGT2B7 71 30.4 
 
          UGT1A1 
EM 48 24 
PM 0.42 50.8 
IM 0.72 39.9 
UM 1.46 30 
Mean population liver volume (L) 1.65056 
Mean population liver density (g/L) 1080 
Mean population MPPGL (mg/g) 39.79066 
 
Abbreviations: EM: Extensive metabolizer; PM: Poor metabolizer; IM: Intermediate 
metabolizer, UM: Ultra-rapid metabolizer. Except UGT1A1, only EM were included for CYP2C8, 
CYP3A4, UGT1A3, and UGT2B7 in SimCyp healthy population. CV: Coefficient of variation
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Table 3-4. Intrinsic clearance and ISEF values associated with enzymes primarily involved 
in buprenorphine metabolism 
 
Enzyme Value Source/Reference 
CYP3A4   
    Vmax (pmol/min/pmol of isoform) 10.4 Picard et al. [268] 
    Km (µM) 13.6 Picard et al. [268] 
    fumic 0.1 Cubitt et al. [269] 
    ISEF 2.355 Calculated from equation 3 
CYP2C8   
    Vmax (pmol/min/pmol of isoform) 1.4 Picard et al. [268] 
    Km (µM) 12.4 Picard et al. [268] 
    fumic 0.1 Cubitt et al. [269] 
    ISEF 8.33 Calculated from equation 3 
UGT1A1   
    Clint (µL/min/pmol of isoform) 0.0162 Oechsler et al. [281] 
    fumic 0.1 Cubitt et al. [269] 
    ISEF 0.636 Calculated from equation 3 
UGT1A3   
    Clint (µL/min/pmol of isoform) 0.0155 Oechsler et al. [281] 
    fumic 0.1 Cubitt et al. [269] 
    ISEF 6.65 Calculated from equation 3 
UGT2B7   
    Clint (µL/min/pmol of isoform) 0.0116 Oechsler et al. [281] 
    fumic 0.1 Cubitt et al. [269] 
    ISEF 5.19 Calculated from equation 3 
Abbreviation: fumic: Fraction of unbound drug in the in vitro microsomal incubation 
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3.3.3  IV BUP Clinical Pharmacokinetic Studies: Model validation 
BUP clinical pharmacokinetic studies in healthy opioid dependent and opioid non-
dependent subjects listed in Table 3-5 were considered for the study. The 72 hr pharmacokinetic 
profile from Huestis et al [87] was used for model development (8 mg) and intra-study validation 
(2,4,12 and 16 mg).One hundred virtual healthy subjects spread over 10 trials were used for each 
of the PBPK simulation. Data from Bai et al [74], Harris et al [88], and Mendelson et al [78] were 
used for inter-study validation. As mentioned above mean AUC was primarily compared between 
observed datasets and predicted simulations. The population variability from the virtual population 
is presented in the concentration-time plots as 5th and 95th percentile plots. Due to lack of individual 
concentration-time profiles reported for each observed study and limitations involved in digitizing 
observed variability data we were not able to compare predicted population variability with 
observed population variability. The basic demographic information such as age and sex were 
matched when performing the simulations.
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Table 3-5. Intravenous buprenorphine clinical pharmacokinetic studies 
 
Abbreviations: Cmax: maximum plasma concentration; AUC0-∞: area under plasma concentration-time curve from time 0 to infinite after a dose; t1/2: half-life; CLtotal: 
total clearance; a n: Subject numbers; b The AUC from Harris et al [88] was reported as 0-24 hrs. 
 
No. 
 N 
   Subject 
Age range  Dosage Cmax  AUC0-∞  t1/2  CLtotal  
Reference (male 
/female) yrs mg ng/mL ng•h/mL h L/h 
1 25 (19/6) 
Healthy 
female and 
male non-
opioid 
dependent  
20-53 0.3 2.3 5.2 8.6 58 Bai et al. [74]  
2 
  
  
  
  
6 (6/0)  
Healthy male 
non-
dependent 
opioid user 
32-39 
2  21.6 41.4 21.8 49.8 
Huestis et al. 
[87]  
4  56.3 75.9 27.5 53.2 
8  110.8 153.3 28 52.4 
12  164.5 245.1 22.3 54.7 
16  174.8 269.1 25.6 60 
3 9 (8/1) Opioid dependent 21-42 4  69.7 
 70.4
b 32.1  NA Harris et al. [88]  
4 6 (5/1) 
Healthy 
female and 
male non-
dependent 
opioid user 
21-38 1  14.3 18.4 16.2 62.5 Mendelson et al. [78]  
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3.3.4  SL BUP - PBPK model development 
Absorption Profile: 
Modeling and simulation of SL administration is not available in the current version of 
Simcyp®. A custom depot and non-depot combination approach was used to simulate SL 
administration. The non-depot component included an inhalation part to mimic SL arterial 
absorption of BUP and an oral part to represent the portion of the SL formulation that is swallowed 
and subjected to absorption and metabolism in the GI tract. Despite drug is supposed to diffuse 
into blood through vessels in the mouth to avoid first-pass metabolism in the gut and liver 
following SL administration, there is a large portion of the dose is swallowed. This is supported 
by the results of a clinical study that voriconazole increased the exposure (as measured by AUC) 
of SL BUP 1.8-fold after pretreatment of voriconazole for 5 days in healthy subjects [282]. The 
depot route of drug absorption was used to mimic the slow release of BUP from surrounding buccal 
tissue following SL absorption. BUP is a multi-phasic drug, SL and oral components explained 
two disposition phases and the depot component explained the disposition during the terminal 
elimination phase.  The percent contribution of each route is listed in Table 3-6. A first-order 
absorption model was used for prediction of oral absorption profile (Table 3-7).
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Table 3-6. Sublingual buprenorphine dosing allocation between depot and non-depot 
components 
Total SL 
Dose 
Depot          Non-Depot            Non- Depot Breakdown 
(37.5% of Total Dose)  (62.5% of total dose) SL Oral 
4 mg 1.5 mg 2.5 mg 10% 90% 
8 mg 3 mg 5 mg 10% 90% 
12 mg 4.5 mg 7.5 mg 10% 90% 
16 mg 6 mg 10 mg 7% 93% 
24 mg 9 mg 15 mg 7% 93% 
32 mg 12 mg 20 mg 7% 93% 
 
 
Table 3-7. First-order absorption model parameter values 
Parameter Value Reference/Source 
fa 0.80 Parameter estimation module 
Ka (1/h) 2.34 Parameter estimation module 
Qgut (L/h) 8.12 Predicted 
fuGut 1 User input 
Abbreviations: fa: Fraction of absorption; Ka: Absorption rate constant; Qgut: nominal flow from 
gut model; fuGut: unbound fraction within enterocyte 
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3.3.5  SL BUP Clinical Pharmacokinetic Studies: Model validation 
BUP clinical pharmacokinetic studies in healthy non-opioid dependents and opioid 
dependents listed in Table 3-8 were used for this study. The 72 hr pharmacokinetic data from 
Ciraulo et al [66] was used for model building (8 mg) and intra-study validation (4, 8, 16 and 24 
mg). Data from Harris et al [69] and McAlear et al [283] was used for inter-study validation. Data 
from Compton et al [284] and Greenwald et al [237] were used for the validation of multiple-dose 
simulations (Table 3-9). One hundred virtual healthy subjects spread over 10 trials were used for 
each of the PBPK simulations. 
 BUP exposure in plasma and the corresponding mu receptor availability was predicted 
along with predicted BUP brain concentrations using the validated SL BUP PBPK model (16 mg 
dose) and plasma concentration to mu receptor availability relationship reported by Greenwald et 
al [60]. BUP brain Kp value (Table 3-2) estimated using the corrected Poulin and Theil method 
[274-276] was used to simulate BUP exposure profile in brain compartment. 
Similar to the IV BUP model validation, mean AUC and Cmax was primarily compared 
between observed datasets and predicted simulations. The population variability from the virtual 
population is presented in the concentration-time plots as 5th and 95th percentile plots. Due to lack 
of individual concentration-time profiles reported for each observed study and limitations involved 
in digitizing observed variability data in the literature we were not able to compare predicted 
population variability with observed population variability. The basic demographic information 
such as age and sex were matched in the simulations.
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Table 3-8. SL BUP clinical PK single dose studies considered for modeling 
Abbreviations: Cmax: maximum plasma concentration; AUC0-t: area under plasma concentration-time curve from time 0 to time t after a 
dose; t1/2: half-life; tmax: time to maximum concentration. NAL: Naloxone; 1AUC0-t is AUC0-72h in Harris et al [69], Ciraulo et al [66] 
study, and AUC0-12h in McAleer et al [283] study. 
Ref. Subject N 
 
Age range BUP/NAL Cmax AUC0-t1 t1/2 Tmax 
(male /female)     yrs mg ng/mL ng•h/mL h h 
Harris et al. 
[69] 
  
Healthy female and male 
non-dependent opioid 
user 
8 
(7/1) 
22-42 
 
4/1 1.8 12.5 NA 1.1 
8/2 3.0 20.2 NA 1.0 
16/4 5.9 34.9 NA 0.8 
16/0 5.5 32.6 NA 1.0 
McAleer et 
al. [283] 
 
 
 
Opioid naïve healthy 
male subjects 
 
27 (27/0) 19-42 
2/0 1.6 NA NA 1.5 
8/0 4.0 31.8 30.0 1.0 
12/0 5.4 41.6 25.6 1.0 
16/0 6.4 52.0 23.9 0.8 
8/2 3.2 24.5 25.5 1.0 
8/2 3.2 24.6 26.8 1.0 
Ciraulo et al. 
[66] 
 
Healthy non-dependent 
opioid user  
23 (16/7) 21-45 
4/0 2 9.4 NA 1.1 
8/0 2.6 19.9 NA 1.2 
16/0 4.4 34.9 NA 0.9 
24/0 5.4 48.8 NA 0.9 
15 (14/1) 21-55 
4/1 2.3 13.1 NA 1.0 
8/2 3.5 23.2 NA 1.0 
16/4 5.8 39.4 NA 1.1 
24/6 6.4 47.5 NA 1.0 
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Table 3-9. SL BUP clinical PK multiple dose studies considered for modeling 
 
Abbreviation: Cmax: maximum plasma concentration; AUC0-24: area under plasma concentration-time curve from time 0 to 24 hours after 
a dose; t1/2: half-life; CLtotal: total clearance; NP, not provided. a Values calculated from graph digitized data.
Ref. Subject 
N 
(male/female) 
Age range BUP/NAL Cmax AUC0-24 t1/2 Tmax 
yrs mg ng/mL ng•h/mL h h 
Compton et al. 
[236] 
 
Healthy 
female and 
male 
dependent 
opioid 
user 
16 
(NP) 
18-65 
16/0 6.88a 54.7 NA NA 
15 
(NP) 
24/0 9.1a 81.1 NA NA 
10 
(NP) 
32/0 13.93a 103.0 NA 0.94 
Greenwald et al. 
[237] 
Healthy 
female and 
male 
dependent 
opioid 
user 
5 
(3/2) 
34-45 2/0 0.85a 6.5 NA 0.9 
16/0 6.3 48.6 NA 1.2 
32/0 13.2 96.0 
NA 
1.2 
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3.3.6  Virtual Patient Population 
Simcyp® virtual healthy volunteer patient population was used to simulate single dose IV 
and SL BUP exposure. During model building and validation steps for both models, demographic 
details of the reported patient populations in considered PK studies (Tables 3-5, 3-8, 3-9) were 
matched with virtual healthy patient population to avoid altered physiology-based differences. No 
changes were made to the Simcyp® healthy volunteer patient population file.  
Since virtual patient population was used for all PBPK simulations and published clinical 
PK data was used to build and validate our PBPK models, this work was not submitted for approval 
to an ethics committee for approval. 
3.3.7  SL BUP Steady State Exposure Simulations 
Since SimCyp® does not have the ability to perform virtual multiple dosing and drug-drug-
interaction simulations for custom defined formulations, we used SimCyp® to predict single dose 
SL BUP concentration-time profiles for 100 virtual subjects and following this Phoenix® 
WinNonlin® was used to characterize single dose PK parameters and simulate SL BUP steady 
state PK. A two compartment, 1st order absorption with a lag time PK model within WNL5 classic 
modeling module was used to predicted concentration-time profile after a single dose. Gauss-
Newton (Levenberg and Hartley) was selected as the minimization method, and the convergence 
criterion was set as 0.0001. The generated micro rate constants were used as the user supplied 
initial parameter values for the multiple dose simulation through the same PK model. 
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3.4 Results 
3.4.1  BUP Exposure Prediction following a single IV BUP dose in healthy subjects: 
Predicted concentration-time profile of the final BUP PBPK model following 8 mg IV BUP 
dose was within the range of the observed data published by Huestis et al [87]. The predicted 
means of concentration-time profiles and 90% PI overlaid with the observed data for the first 24 
hrs of the 72 hr data set are shown in Figure 3-2. As shown in the figure 3-2 A the observed data 
was within the 90% PI of the variability observed around the predicted mean exposure. The 
predicted and observed mean concentration-time profiles were visually similar. This was true for 
the inter and intra study validation plots as shown in Figures 3-2 B and 3-2 C, D, E, F respectively. 
The accuracy of the predicted means of AUC0-∞ and CLTotal were within 85-115% of the observed 
means (Table 3-10). These limits hold true for all doses (2, 4, 12 and 16 mg) tested for intra-study 
validation. 
The model was further validated by two model-naïve clinical PK datasets (Bai et al [74], 
Harris et al [88], and Mendelson et al [78]) for inter-study validations and the comparisons are listed 
in Table 19. The accuracy of the predicted means of AUC and CL were within 85-115% of the 
observed means. These limits held true for all doses (0.3, 1, 4 mg) tested for inter-study validation.
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Figure 3-2. Predicted and observed concentration-time profiles following a single IV push 
doses of BUP. 
 “A” represents plot of the final model built with and 8 mg IV BUP single dose comparing observed 
data from Huestis et al. [87]; “B” represents inter-study validation plot with 0.3 mg IV BUP single 
dose as observed by Bai et al. [74]; C, D, E, and F represents intra-study validation plots with 2, 
4, 12 and 16 mg IV BUP single doses respectively as observed by Huestis et al. [87]; 0-24 hrs PK 
simulations shown here
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Table 3-10. Goodness of fit for IV BUP model in healthy subjects 
Process Data source 
Dose 
(mg) 
                       AUC0-∞        CLTotal 
Observed 
Predicted 
(90% PI) 
Diff. Observed 
Predicted 
(90% PI) 
Diff. 
mg•h/L mg•h/L % L/h L/h % 
Final 
model 
Huestis et 
al [87] 
8 0.153 0.151 
(0.0821 – 0.2688) 
1.3 52.4 53.1 
(29.8-97.4) 
1.3 
Intra-study 
validation 
2 0.0414 0.0379        
(0.0209 -0.0665) 
-8.5 49.8 52.8 
(30.1-95.7) 
6.0 
4 0.0759 0.0756 
(0.0419 -0.1314) 
0.4 53.2 52.9           
(30.4-95.5) 
0.6 
12 0.245 0.226            
(0.123 -0.402) 
7.7 54.7 53.1           
(29.8-97.6) 
2.9 
16 0.2691 0.2886 
(0.1561 – 0.5125) 
7.2 60.0 55.4  
(31.2-102.5) 
-7.6 
Inter-study 
validation  
Bai et al 
[74] 
0.3 0.0052 
 
0.0049 
(0.0025-0.0087) 
9.1 57.7a 61.2            
(34.5-120) 
13 
Harris et al 
[88] 
4 0.0704b 0.0727       
(0.0534-0.0958) 
3.3 NP NP NP 
Mendelson 
et al [78] 
1 0.0184 0.0181 
(0.00993-0.0313) 
-1.6 62.5 55.2   
(31.9-100.7) 
-11.7 
Abbreviations: AUC0-∞: area under plasma concentration-time curve from time 0 to infinite after a dose; CLtotal: total body clearance. NP: not 
provided; PI: percentile interval. aBai et al [74] didn’t report CL, so the observed CL was calculated by using Dose/ the reported AUC0-∞;b Harris 
et al [88] only reported AUC0-24. And CL was not available. Difference (%) = ((predicted– observed mean value)/ observed mean value)*100
115 
3.4.2  Modeling prediction following a SL of BUP in healthy volunteers 
The predicted means of concentration-time profiles and 90% PI overlaid with the observed 
data are shown in Figure 3-3. As shown in the figure 3-3 A the observed data was within the 90% 
PI of the variability observed around the predicted mean exposure. Moreover, the predicted and 
observed mean concentration-time profiles were visually similar. This was true for the intra and 
inter study validation plots as shown in Figures 3-3 B and 3-3 C, D respectively. The accuracy of 
the predicted means of AUC were within 75-125% of the observed means for all inter and intra-
study validations with the exception of a 24 mg single dose study where the accuracy was +137%. 
The accuracy of the predicted means of Cmax were within 80-125% for all the studies (Table 3-11).  
The model was further validated by two model-naïve clinical PK datasets published by 
Harris et al [69] and McAleer et al [283] (Table 3-11) as a measure of inter-study validation. The 
accuracy of the predicted means of AUC were within 85-115% of the observed means, and the 
accuracy of the predicted means of Cmax were within 80-125% of the observed means. Sixteen, 24, 
and 32 mg doses of SL BUP at steady state was also validated against studies published by 
Compton et al [284] (Figure 3-4) and Greenwald et al [237]. Accuracy of AUC and Cmax are 
tabulated in Table 3-12. The accuracy limits for these comparisons were between 85 and 115%. 
We were able to predict the brain concentrations of BUP using the model that was 
developed. BUP brain exposure was predicted to be about 4 times higher than that of plasma 
(Brain-AUC0-72h: 0.195 mg•h/L; Plasma-AUC0-72h: 0.0536 mg•h/L). We were able to use the mu 
receptor availability data from Greenwald et al [206] to illustrate the relationship between 
brain/plasma concentration of BUP and mu receptor occupancy (Figure 3-5). 
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Figure 3-3. Predicted and observed concentration-time profiles following a single SL doses 
of BUP in 100 virtual healthy subjects. 
 
 “A” represents plot of the final model built with an 8 SL BUP single dose comparing observed 
data from Ciraulo et al. [66]; “B” represents intra-study validation plot with 4 mg SL BUP single 
dose as observed by Ciraulo et al. [66]; C and D represent inter-study validation plots with 8 and 
16 mg SL BUP single dose respectively as observed by Harris et al. [69]; 0-24 hrs of 48 and 72 
hrs simulations shown here. 
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Table 3-11. Goodness of fit for SL BUP model in healthy subjects 
Process Data source 
Dose 
(mg) 
       AUC0-∞        CLTotal 
Observed 
Predicted 
(90% PI) 
Diff. Observed 
Predicted 
(90% PI) 
Diff. 
mg•h/L mg•h/L % L/h L/h % 
Final 
model 
Ciraulo 
et al 
[66] 
8 0.0199 0.0221 
(0.0100-0.0423) 
11.0 0.00265 0.00329 
(0.0016-0.0057) 
24.2 
Intra-study 
validation 
4 0.0094 0.0110 
(0.0050-0.0211) 
18.1 0.002 0.00164 
(0.0008-0.02518) 
18 
16 0.0349 0.0395 
(0.0175-0.0764) 
13.2 0.00442 0.00547          
(0.0025-0.0095) 
23.8 
24 0.04881 0.0606 
(0.0258-0.114) 
24.1 0.00541 0.00738 
(0.00372-0.0139) 
36.4 
Inter-study 
validation 
Harris 
et al 
[69] 
4 0.01252 0.00938 
(0.00408-0.0174) 
-25.1 0.00184 0.00155 
(0.0008-0.0029) 
-15.8 
8 0.0202 0.0184 
(0.0825-0.0355) 
8.9 0.003 0.00326 
(0.00162-0.00596) 
8.7 
16 0.03489 
 
0.0317 
(0.014-0.0631) 
9.1 0.00595 0.00547 
(0.00246-0.0100) 
8.1 
McAlee
r et al 
[283] 
8 0.02689 0.0227 
(0.00967-0.0423) 
-15.6 0.004 0.0031 
(0.0016-0.0059) 
22.5 
12 0.03652 0.034 
(0.0145-0.0635) 
-6.9 0.0054 0.00466 
(0.00241-0.0806) 
-13.7 
16 0.04619 0.0404 
(0.0171-0.0760) 
-12.5 0.0064 0.0049 
(0.0025-0.0092) 
-23.4 
Abbreviations: AUC0-∞: area under plasma concentration-time curve from time 0 to infinite after a dose; Cmax: maximum plasma concentration; PI: 
percentile interval. aAUC0-t were 0 to 72 hours for Ciraulo et al [66] and McAleer et al [283] study, and was 0-48 hours for Harris et al 
[69] study. Difference (%) = ((predicted– observed mean value)/ observed mean value) *100 
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Table 3-12. Goodness of fit for sublingual buprenorphine models in healthy volunteers at 
steady state 
Process Data source 
Dose 
(mg) 
AUCss, 0-24 Cmax,ss 
Observed 
Predicted 
(90% PI) 
Diff. Observed 
Predicted 
(90% PI) 
Diff. 
mg•h/L mg•h/L % mg/L mg/L % 
Inter-study 
validation 
Compton et 
al [236] 
16 0.05472 
0.05508 
(0.00255-0.139) 
0.7 0.0068 
0.0065 
(0.0032-0.0142) 
4.4 
24 0.08112 
0.08252 
(0.0379-0.1767) 
1.7 0.0091 0.0099         (0.0487-0.0191) 8.8 
32 0.10301 
0.1099 
(0.0504-0.2670) 
6.7 0.0139 0.0133         (0.0065-0.0288) 4.3 
Greenwald 
et al [237] 
16 0.0486 
0.05508 
(0.00255-0.139) 
13.3 0.0063 0.0065         (0.0032-0.0142) 3.2 
32 0.096 
0.1099 
(0.0504-0.2670) 
14.5 0.0132 0.0133         (0.0065-0.0288) 0.8 
Abbreviations: AUCss, 0-24: area under plasma concentration-time curve from time 0 to infinite after a dose 
at steady state; Cmax,ss: maximum plasma concentration at steady state; PI: percentile interval. 
Difference (%) = ((predicted– observed mean value)/ observed mean value)*100 
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Figure 3-4. Steady state predicted and observed concentration-time profiles following daily 
SL doses of BUP in healthy subjects. 
A, B, and C represent inter-study validation plots with 16 mg, 24 mg, and 32 mg SL BUP 
respectively as observed by Compton et al. [236]. 
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Figure 3-5. Predicted plasma and brain concentration-time profiles following a 16 mg SL 
doses of BUP in healthy subjects. 
mu receptor availability is simulated on the secondary axis. 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.00E+0
5.00E-3
1.00E-2
1.50E-2
2.00E-2
2.50E-2
3.00E-2
3.50E-2
4.00E-2
4.50E-2
0.00 4.00 8.00 12.00 16.00 20.00 24.00
m
u 
R
ec
ep
to
r 
av
ai
la
bi
lit
y 
in
 B
ra
in
 
(B
m
ax
/K
d)
 
B
U
P 
Co
nc
en
tr
at
io
n 
(m
g/
L)
Time (h)
Simulation of mu Receptor Availability & BUP Exposure
in Brain & Plasma following a single 16 mg SL BUP Dose
Brain Conc. (Mean)95th Percentile (Brain)5th Percentile (Brain)Plasma Conc. (Mean)95th Percentile (Plasma)5th Percentile (Plasma)Mu Receptor Availability
121 
3.5 Discussion 
In this study, we built and validated full-PBPK models of IV and SL BUP in healthy non-
opioid dependent and opioid dependent patient populations across a wide range of BUP doses. The 
full-PBPK models incorporate enzymatic metabolism of BUP, its disposition into 13 major tissues 
in the body and three modes of absorption following the SL dosage forms. The models are robust 
in representing the multi-compartment first order disposition of BUP. The predicted concentration-
time profiles in the study-matched virtual patient population are consistent with observed data 
across 14 independent studies (5 intravenous single dose, 5 SL single dose, and 4 SL multiple 
dose) among healthy non-opioid dependent and opioid dependent patient populations. The 
predicted IV BUP PK parameters fell within 85%-115% range of the corresponding PK parameters 
calculated from the IV BUP observed studies. The predicted SL BUP PK parameters fell within 
75% to 137% range of corresponding PK parameters calculated from single dose SL BUP observed 
studies. This range was 100% to 115% when comparing steady state SL BUP PK parameters. Both 
models were robust in predicting BUP exposure after IV and SL administration in healthy 
population in the dose ranges of 4 to 32 mg. 
BUP is a lipophilic drug with a large volume distribution (200-400 L) [67]. The semi-log 
concentration-time profile after IV administration shows a rapid drop in systemic concentration 
followed by a slower terminal phase indicating that BUP is a multi-compartmental drug with three 
distinct phases of disposition.  It undergoes metabolism by various hepatic and gut CYP450 and 
UGT enzymes making it susceptible to extensive first-pass metabolism [89, 285, 286]. A mass 
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balance study following radiolabeled IV BUP administration reported 30% of the dose recovered 
in urine and 69% of the dose recovered in feces. The breakdown of BUP free drug, parent drug 
and its metabolites with sources of metabolism from this mass balance study is shown in Table 3-
13 [287]. The relative contribution of CYP450 enzymes (71.8%) appears to be much higher than 
UGT enzymes (28.2%) when comparing the known major metabolites of BUP. We would 
speculate that the relative contribution of CYP450 enzymes following SL administration would be 
much higher than 71.8% as there is a higher abundance of CYP3A4 and CYP2C8 enzymes in the 
gut compared to UGT1A1, 1A3, and 2B7 enzymes. In the proposed SL BUP PBPK model, the 
modeled relative contributions of CYP450 and UGT enzymes are 95.46% and 4.54%. These 
relative contributions were estimated from recombinant CYP and UGT activities reported in 
referenced in-vitro study and ISEF based extrapolations [268-270]. Currently we are not able to 
validate the exact relative contribution of these enzymes as there is no published SL BUP mass 
balance study and we acknowledge this as a limitation of the PBPK models. Currently SimCyp® 
does not allow us to perform steady state simulations for the purposes of evaluating the effect of 
drug-drug interactions with known CYP3A4 inhibitors such as ketoconazole to verify the 
magnitude of CYP3A4 involvement. A limitation of this study is not having the ability to perform 
steady-state drug-drug interaction simulations. 
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Table 3-13. Results from mass balance study following administration of radiolabeled IV 
BUP  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviation: BUP-Glu, buprenorphine glucuronide; CYP, cytochrome; N-BUP, 
norbuprenorphine; N-BUP-Glu, norbuprenorphine glucuronide; UGT, UDP-
glucuronosyltransferase
Drug/Metabolite Enzyme Urine (%) Feces (%) 
Free BUP - 1.0 33 
BUP-Glu UGTs 9.4 5 
N-BUP CYP450s 2.7 21 
N-BUP-Glu CYP450s > UGTs 11 2 
Other CYP450s or UGTs 5.9 8 
 Total 30.0 69.0 
Relative contribution of CYP450 and UGT enzymes (%) 
When considering 
N-BUP, BUP-Glu 
and N-BUP-Glu 
CYP450s 71.82  
UGTs 28.18   
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Based on various in-vitro transporter studies, there is no conclusive evidence for the 
involvement of ABC (ATP binding cassette) and SLC (solute carrier) drug transporters in BUP 
disposition [176]. Due to its poor oral bioavailability (F=10-15%) [288, 289],  SL route of 
administration is the preferred route and is currently approved by the FDA. The half-life of BUP 
after SL administration is longer compared to IV administration suggesting a slow release of the 
drug from a depot to the systemic circulation after SL administration, in addition to the rapid initial 
absorption [67]. 
Physiologically, drug absorption following SL administration involves a combination of 
rapid passive absorption across the SL mucosal membrane, a slow depot release from the buccal 
tissue depot space, as well as gut absorption from the portion of the formulation that is swallowed. 
To mimic the three distinct phases, our SL PBPK model incorporates SL, oral and buccal depot 
release of the drug. Based on the drug absorption and disposition profiles reported in studies 
considered for building the model, we divided dose into the following routes: 62.5 % non-depot 
which comprises of 7-10% SL passive absorption into the circulation and 90-93% swallowing in 
the GI tract; the remaining 37.5% of the dose was attributed to the depot release from the buccal 
tissue.  The percent distribution of the dose among these routes were optimized and validated with 
model naïve clinical PK datasets of SL BUP. Due to the multi-compartment disposition profile of 
BUP, the half-life reported for BUP in the literature after SL BUP administration could be different 
based on how long the PK study is conducted; prospective single dose PK studies that are 12 hrs, 
48 hrs and 72 hrs long would yield sequentially increasing calculated half-lives for BUP after SL 
administration [74, 87, 88].  
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BUP exposure (Cmax and AUC) increases in a linear dose-proportional manner after IV 
administration. BUP exposure vs dose relationship after SL administration is linear only between 
the dose ranges of 4 to 12 mg; beyond 16 mg the exposure increase is not dose-proportional. This 
is consistent with published data [61].  This behavior does not suggest saturation of hepatic 
metabolism or gut metabolism. We believe this nonlinearity is due to differences in absorption 
profile and the differences in the percent dose absorbed for orally doses beyond 16 mg (Table 15). 
BUP PK profiles after SL administration exhibits a large inter-study variability, especially 
for the Cmax and Tmax in single dose administration studies. The large inter-study variability is 
probably due to the variability in SL administration technique i.e., there could be difference in the 
proportion of the formulation that is swallowed vs absorbed after SL administration; some patients 
may not follow directions and may chew the formulation; some patients may retain the SL 
formulation for varied residence time in the mouth, and some may take whole tablets, while the 
others may cut or crush and use the product. 
In order to treat opioid substance dependence, BUP has to cross the brain-blood barrier and 
bind to mu opioid receptors. However, currently there are no studies reporting BUP concentrations 
in the cerebrospinal fluid (CSF). Greenwald et al [206] studied the mu receptor occupancy in the 
brains of heroin dependent patients and reported a logarithmic relationship between BUP plasma 
concentrations and mu receptor binding potential or mu receptor availability in brain (Bmax/Kd). 
They also reported that plasma concentration of at least 1 ng/mL is needed for 50% mu-opioid 
receptor occupancy, in order to depress drug withdrawal syndrome and show efficacy [206]. 
We were able to illustrate the applicability of the developed model and brain concentration 
time profiles to the mu receptor occupancy data published by Greenwald et al [206]. Given the 
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lipophilic properties of BUP, its brain exposure was about 4 times higher than that of plasma 
(Brain-AUC0-72h: 0.195 mg•h/L; Plasma-AUC0-72h: 0.0536 mg•h/L). The mean plasma BUP 
concentrations in healthy subjects fall below 1 ng/mL threshold about 9 hours following a 16 mg 
dose, suggesting loss of efficacy beyond this time range (Figure 9). 
Some studies have reported that BUP metabolites such as nor-BUP, BUP-3-glucuronide, 
and nor-BUP-3-glucuronide may also be biologically active[290, 291]. However, the exposure of 
BUP-3-glucuronide, and nor-BUP-3-glucuronide in brain should be minimal due to high 
hydrophilic properties of the glucuronides. The exposure of norbuprenorphine in the brain is also 
limited based on the reported data from postmortem brain samples. From 6 overdose death cases, 
the concentrations of norbuprenorphine was 5.8 ng/g (BUP concentration was 151 ng/g) in one 
postmortem brain sample, and not detectable in the other 5 postmortem brain samples (BUP 
concentration ranged 7.1 – 76.1 ng/g) [292]. Taken together, the contribution towards anti-
nociceptive effect by the metabolites should be very limited. For these reasons, we did not 
incorporate metabolite profiles of BUP in this study. 
Using the PBPK model developed, we will be able to predict plasma and brain 
concentrations of BUP in patients to optimize BUP dosing in patients. These PBPK models could 
also be potentially extrapolated to special patient populations such as pregnant women.
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  Gestational Changes in Buprenorphine Exposure: A Physiologically Based 
Pharmacokinetic Analysis 
(This chapter has been published at British Journal Clinical Pharmacology (2018) 84: 2075 
–2087)
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4.1 Abstract 
Introduction: Buprenorphine (BUP) is approved by the FDA for the treatment of opioid addiction. 
The current dosing regimen of BUP in pregnant women is based on recommendations designed 
for non-pregnant adults. However, physiological changes during pregnancy may alter BUP 
exposure and efficacy. The objectives of this study were to develop a physiologically-based-
pharmacokinetic (PBPK) model for BUP in pregnant women, to predict changes in BUP exposure 
at different stages of pregnancy, and to demonstrate the utility of PBPK modelling in optimising 
BUP pharmacotherapy during pregnancy. 
Methods: A full PBPK model for BUP was initially built and validated in healthy subjects. A feto-
placental compartment was included as a combined compartment in this model to simulate 
pregnancy induced anatomical and physiological changes. Further, gestational changes in 
physiological parameters were incorporated in this model. The PBPK model-predictions of BUP 
exposure in pregnancy, and during the postpartum period were compared to published data from a 
prospective clinical study. 
Results: The predicted BUP plasma concentration-time profiles in the virtual pregnant populations 
are consistent with the observed data in the 1st, 2nd and 3rd trimesters, and the postpartum period. 
The differences in the predicted means of dose normalized AUC0-t, and Cmax were within 2-fold of 
the corresponding observed means.  
Conclusion: PBPK model-based simulation may be a useful tool to optimise BUP 
pharmacotherapy during pregnancy, obviating the need to perform pharmacokinetic studies in each 
trimester and the postpartum period that normally require intensive blood sampling. 
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4.2 Introduction 
Drug addiction has become a nationwide health crisis in the United States [293-295]. From 
2013 to 2014, the death rate from an overdose of opioids has increased by 14% [296]. Currently, 
death due to drug overdose has surpassed that of motor vehicle accidents as the leading cause of 
unintentional deaths in the US [296].  Concurrently, the rate of opiate use in pregnant women has 
increased nearly 5 fold between 2000 and 2009 [297]. Maternal opioid use is associated with an 
increase in obstetrical complications, such as maternal death, cardiac arrest, intrauterine growth 
restriction and placental abruption [180]. Antepartum use of opioids commonly results in neonatal 
abstinence syndrome (NAS), and is associated with an increased risk of birth defects, stillbirth, 
and preterm labor [298, 299]. Buprenorphine (BUP) is approved by FDA for treatment of opioid 
addiction, but it is not approved for use in pregnancy. The efficacy of BUP in suppressing 
symptoms of withdrawal appears to be comparable to methadone [194, 195, 300]; but treatment 
with BUP is more convenient to patients and BUP exposed neonates appear to have less severe 
and less frequent Neonatal Abstinence Syndrome (NAS) [182, 301, 302]. 
 
The current dosing of BUP in pregnant women is based on recommendations designed for 
non-pregnant subjects since limited information is available to optimize BUP dosing in pregnant 
women. Pregnancy induces many physiological changes including the development of the foetal- 
placental compartment, an increase in renal filtration, body fluid volume and hepatic portal blood 
flow, as well as changes in the expression and activity of drug metabolizing enzymes and drug 
transporters [125, 145, 147]. These pregnancy-induced changes can impact absorption, 
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distribution, metabolism, and elimination of drugs which may ultimately alter efficacy and safety 
of medications used in pregnant women.  
Response to BUP appears to be related to the plasma concentration of BUP. Greenwald et 
al. reported that a plasma BUP concentration of 1 ng/mL, is required for prevention of withdrawal 
symptoms in opioid exposed subjects. This concentration is associated with 50%-60% occupancy 
of the mu-opioid receptors in the brain [206].  We have demonstrated in a small cohort of pregnant 
women that plasma concentrations of BUP and the corresponding BUP exposure is significantly 
reduced during pregnancy compared to the postpartum state [201]. We have suggested that more 
frequent dosing of buprenorphine will reduce the time that treated women are likely to be sub-
therapeutic during pregnancy [201, 303]. Our observations may at least in part explain the report 
of Jones et al., who in a large clinical trial reported higher study withdrawal rates in subjects 
assigned to BUP compared with methadone. Apparently, 71% of the dropouts were due to 
dissatisfaction of the subjects with the dosage of BUP used in that study [202].  
 
A better understanding of BUP exposure in pregnancy is required in order to optimise 
treatment outcomes in pregnant women with opiate addiction. In our published pilot study, we did 
not enroll subjects prior to 20 weeks and therefore we were not able to evaluate the changes in 
BUP pharmacokinetics during the first half of pregnancy [201].   
 
A variety of physiologically based pharmacokinetic (PBPK) modelling approaches have 
been used in drug development. PBPK modelling is a useful tool for predicting pharmacokinetic 
changes of a drug during pregnancy. Beside the differences in anatomy and physiology, the PBPK 
model can incorporate known pregnancy-related alterations in the activities of CYPs, UGTs, and 
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drug transporters, that can contribute to altered drug metabolism and clearance [304-309]. The 
objectives of this study were to predict the changes in BUP exposure at different stages of 
pregnancy through developing a PBPK model of BUP in pregnant women in order to optimizing 
BUP pharmacotherapy in this understudied population. 
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4.3 Methods 
PBPK modelling and simulations for BUP were conducted using SimCyp® population-
based simulator v15.1 (SimCyp limited, Sheffield, UK). WinNonlin software (Phoenix 
WinNonlin®: version 6.4, Pharsight Corp, Mountainview, CA) was used to simulate steady-state 
exposure of BUP after administration of the sublingual (SL) formulation. A systematic literature 
search to identify physiological changes throughout pregnancy, and to identify published clinical 
trials of BUP was conducted using the Medline database from the National Library Medicine 
through the PubMed interface. We used the search terms “buprenorphine”, or “subutex”, plus 
“opioid”, “pharmacokinetic”, “concentration”, and “ng/mL”. The inclusion criteria used were 
clinical studies that reported PK data on intravenous (IV), and / or SL BUP. We excluded studies 
that evaluated the PK of BUP in solution or in film formulations or continuous intravenous 
infusion; were performed in patients with severe disease (compromised liver or renal function); 
were published prior to BUP availability for sublingual administration (1990 or earlier); utilized 
a non-specific radioimmunoassay method to quantify BUP concentrations; or used a washout 
period between the IV and SL study of less than 5 half-lives of BUP. The bibliographies of the 
selected articles were also reviewed to identify additional relevant information. For PBPK model 
building and model validation, we used published data reporting the mean plasma concentrations 
of BUP following IV or SL administration. These mean plasma concentrations of BUP were 
digitized using GetData Graph Digitizer V.2.26 from the plasma concentration-time profiles of 
reported BUP clinical studies.  
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4.3.1  A PBPK model for BUP in non-pregnant subjects 
The details of building and validating the IV and SL BUP PBPK models in healthy non-
pregnant opioid non-dependent or dependent subjects have been previously published by our group 
[310]. In that study, we have outlined how a mechanistic BUP PBPK model was established by 
employing the physiochemical properties of BUP including tissue to plasma partition coefficient 
(Kp), the first-order absorption (for SL administration), and the kinetic parameters for metabolism 
and elimination (CYPs and UGTs).  The tissue specific Kp values of BUP for the full-PBPK model 
were estimated using the corrected Poulin and Theil method [274-276]. The inter-system 
extrapolation factors (ISEF) based in vitro-in vivo extrapolation (IVIVE) methods were used to 
extrapolate in-vitro enzyme kinetic data. Published data on BUP plasma concentration vs time 
profile after IV and SL administration in opioid non-dependent and dependent patients were 
employed to build the models. Sensitivity analysis was performed for parameters (plasma unbound 
drug fraction (fu), and all tissue specific Kp values) with no or poor initial estimates. The parameters 
that were not sensitive were defaulted to the initial prediction estimates; when the parameters were 
sensitive to the analysis, a systematic optimization on a one-by-one basis using the built-in 
parameter estimation module was performed. After individual optimization, all the sensitive 
parameters were re-optimized together in order to get the best fit with the observed data. The SL 
BUP model was built by adapting the IV PBPK model and adding a BUP absorption component. 
Similar parameter optimization methods were used to optimize absorption characteristics of BUP 
after SL administration. Fourteen model naïve BUP-PK datasets were used for inter-study and 
intra-study validations [310]. Introducing a Tlag parameter (lag time between dose administration 
and the appearance of BUP in the systemic circulation) better explained the SL BUP PBPK model 
in non-pregnant subjects. The parameter estimation module was used to fit the Tlag value and this 
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fit was verified by visual predictive check. It reduced the prediction error, when comparing the 
observed and predicted Tmax, Cmax and AUC estimates. The physicochemical properties and PK 
parameters that were used to develop a BUP profile; the key PK parameters of BUP in the non-
pregnant subjects are provided in the appendix (Appendix A.1 and Appendix A.2).  
  
4.3.2  A PBPK model for BUP in pregnant subjects 
The perfusion limited BUP SL full PBPK model developed in healthy non-pregnant 
subjects was modified to create the BUP PBPK model in pregnant women [310]. The foetal-
placental compartment characteristics in the custom virtual pregnancy population were adapted 
from the default SimCyp pregnancy population file. As with other compartments, the foetal-
placental compartment is also a perfusion-limited compartment and its Kp value was estimated 
using the corrected Poulin and Theil method [274-276] (Table 4-1). The foetal-placental 
compartment combines the fetus, placenta, amniotic fluid, uterus and umbilical cord. The foetal-
placental compartment is assumed to have the same characteristics as the muscle tissue (SimCyp® 
assumption). Given the lack of reports on BUP concentrations in the foetus or placenta it was not 
possible to validate model predictions in the foetal-placental compartment at this point. In this 
BUP PBPK model in pregnant women, all of the drug components including physiochemical 
properties of BUP, Kp values, and initial enzyme kinetics that were used were the same as in the 
BUP PBPK model developed in healthy non-pregnant subjects. The changes applied to the 
pregnancy BUP PBPK model were selected based on the changes that were expected to impact 
BUP PK. These include changes in hepatic blood flow, plasma protein level, drug metabolizing 
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enzyme activities, and the partition between plasma and red blood cells (Table 4-2) [165, 205, 
311].
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Table 4-1. Distribution parameters for BUP PBPK model in pregnant women 
 
 
Parameter Value 
Model Full PBPK 
Vss (L/kg)-predicteda 2.48 
Vss (L/kg)-observedb 2.77 
Tissue Partition Coefficients (Kp) 
Adipose 0.0044 
Bone/Additionalc 35 
Brain 3.41 
Gut 2.69 
Feto-Placenta 1.31 
Heart 0.83 
Kidney 1.29 
Liver 2.13 
Lung 0.29 
Pancreas 2.20 
Muscle 1.31 
Skin 1.60 
Spleen 1.31 
Kp scalard 0.225 
 
Abbreviation: Vss: Volume of distribution at steady state  
a Bullingham et al. [272]; 
b Vss predicted and Kp values for all tissue were predicted by corrected Poulin and Theil 
method [274-276];  
c Bone/Additional compartment Kp value was optimized using the Simcyp® parameter 
estimation module, Nelder-Mead method was used for the minimization. The predicted Kp value, 
3.73, by Poulin and Theil method was used as the initial value, and (0.001, 100) used as the 
boundaries;  
d Kp scalar was optimized using the Simcyp® parameter estimation module, Nelder-Mead 
method was used for the minimization. The default Kp scalar, 1, was used as the initial value, and 
(0.01, 100) used as the boundaries. 
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Table 4-2. Summary of gestational age associated physiologic parameters incorporated into SimCyp® healthy population 
 
 Non-
Pregnant 
Female 
1st trimester  
(≤12 gestation 
weeks) 
2nd trimester  
(13-28 gestation 
weeks) 
3rd trimester                 
(≥ 29 gestation 
weeks) 
Physiological and metabolic change 
Cardiac output [312] 100% Increased 35% Increased 40% Increased 50% 
Plasma volume [312] 100% Increased 12.5% Increased 32.5% Increased 50% 
Red cell volume [312] 100% Remain same Remain same Increased 30% 
Hematocrit [313] 100% Decreased 3% Decreased 4% Decreased 5% 
Albumin [313] 100% Decrease 27% Decrease 27% Decrease 27% 
Activity of CYP3A4 [165] 100%  Increased 35% Increased 35% Increased 38% 
 
Parameter used in model 
Cardiac output scalar 1 1.35 1.4 1.5 
Plasma Volume scalar 1 1.125 1.325 1.50 
Red blood cell volume 
scalar 
1 1 1 1.3 
Hematocrit (%) 38 35 34 33 
Albumin (g/L) 49 36 36 36 
CYP3A4 
(pmol/mg protein) 
137  185 185 189 
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BUP is primarily metabolized by N-dealkylation [277]. This N-dealkylation of BUP is 
primarily mediated by CYP3A4 in the liver [90, 91]. Although CYP2C8, UGT1A1, UGT1A3, and 
UG2B7 are also involved in the metabolism of BUP, their contributions are relatively minor. A 
quantitative mass-balance diagram describing the absorption, distribution, metabolism and 
excretion of BUP after sublingual and intravenous (IV) administration as implemented in the 
PBPK model is shown in Figure 4-1. The mass balance study following IV dosing of BUP showed 
that a total of 69% and 30% of the radioactivity is recovered in the faeces and urine, respectively 
[96]. The unconjugated BUP and norbuprenorphine in feces probably comes from the hydrolysis 
of the conjugates of BUP and norbuprenorphine via biliary excretion [96]. As BUP is primarily 
eliminated by the liver, the changes in renal function during pregnancy should have minor impact 
on BUP elimination. This assumption was affirmed by performing a sensitivity analysis (Figure 
4-2). Identical BUP concentration-time profiles were observed in all trimesters in the virtual 
pregnant women with and without an increase (50%) in GFR [311]. 
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Figure 4-1. Quantitative mass balance diagram describing buprenorphine (BUP) 
absorption, distribution, metabolism and excretion after sublingual and intravenous (IV) 
administration. BUPG, Buprenorphine glucuronide; NBUP, Nor-buprenorphine; NBUPG, 
Nor-buprenorphine glucuronide
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Figure 4-2. Sensitivity analysis to simulate the impact of the abundance of CYPs, UGTs 
and renal function on buprenorphine total clearance 
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4.3.3  Comparison during pregnancy and the post-partum (non-pregnant period) 
BUP exposure during the postpartum period was simulated in virtual female healthy 
subjects using SimCyp® population simulator. The simulated BUP exposure during 2nd and 3rd 
trimesters and the postpartum period were validated using the observed plasma concentrations of 
BUP from a prospective clinical BUP PK study conducted by our group in pregnant women during 
pregnancy (2nd and 3rd trimesters) and the postpartum state [201]. In this clinical study, pregnant, 
women with a singleton gestation who were on a stable twice-daily dose of SL BUP for opioid 
maintenance therapy for at least 7 days in the second and third trimesters and the postpartum period 
were evaluated. Participants were recruited through Magee-Womens Hospital of University of 
Pittsburgh Medical Center (UPMC) and written informed consents were obtained from all 
participants. Each woman participated at least in two PK studies; once during the postpartum 
period and once during the second or third trimesters of pregnancy or in both trimesters.  At each 
study visit, a total of 10 blood samples were collected from 0 hours (prior to the morning dose) up 
to 12 hours after the dose and BUP plasma concentrations in these blood samples were measured 
using high-performance liquid chromatography with tandem mass spectrometric detection [201]. 
Our goal was to use the SL BUP pregnancy PBPK model to predict the area under the plasma drug 
concentration-time curve (AUC) during pregnancy, and to compare it to the observed data. A ± 
50% difference between mean observed AUC in the prospective PK study and mean predicted 
AUC in 100 virtual pregnant subjects using BUP PBPK model was used as the model validation 
criteria. 
4.3.4  Nomenclature of targets and ligands 
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Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide 
to PHARMACOLOGY [314], and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2017/18 [315, 316].  
4.4 Results 
4.4.1  Steady state BUP systemic exposure prediction  
The disposition profiles of SL BUP following an 8 mg SL BID dose was predicted in 100 
virtual pregnant female subjects spread over 10 trials during each trimester, and during the 
postpartum period. The predicted mean concentration-time profiles are shown in Figure 4-3. After 
SL BUP administration, plasma concentrations of BUP reached peak levels in approximately 1 
hour followed by a rapid decline and a subsequent slow disposition. Lower trough BUP 
concentrations, peak concentrations, average concentrations, and systemic exposure (AUCs) were 
observed throughout pregnancy compared to the postpartum period, and the difference was 
pronounced in the 3rd trimester (AUC0-12,ss was approximately 50% lower in the 3rd trimester vs the 
postpartum period and 40% lower in 1st and 2nd trimester vs postpartum). Systemic exposure of 
BUP was similar in the 1st and 2nd trimesters. 
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Figure 4-3.  Predicted mean concentration–time profiles at steady-state following 
administration of 8 mg sublingual twice daily buprenorphine during 1st trimester, 2nd 
trimester, 3rd trimester, and postpartum in 100 virtual female subjects spread across10 
trials
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4.4.2  Evaluation of the predictive performance of the BUP PBPK model in pregnant 
women 
Figure 4-4 shows the predicted mean concentration-time profiles (with 5 and 95% 
confidence intervals) from 100 virtual pregnant women overlaid with the observed clinical data 
over a 12-hour PK study. As shown in the figure 4-4 A, B and C, the observed dose normalized 
mean concentration-time profiles were within 90% predicted percentile. The model did not 
adequately capture the Tmax. The prediction of Tmax is not clinically important since withdrawal 
symptoms are prevented not by the Tmax of BUP, but rather by the maintenance of BUP plasma 
concentration above a threshold of 1 ng/mL. The predicted mean dose normalized concentration-
time profiles fell within the 5th to 95th percentiles of the observed data. The difference in the 
predicted means of dose normalized AUC0-12, Cav, and Cmax were within ± 25% of the observed 
means during different trimesters of pregnancy and the postpartum period, with the exception of 
the dose normalized Cave in the 3rd trimester (-26.3%) (Table 4-3).  
Figure 4-5 compares the model predictions against individual observed BUP concentrations 
in women on a dose of 8 mg bid, the most common dosage used. The observed individual plasma 
concentrations of BUP were within the 5th -95th percentile of model predicted concentrations. PK 
parameters for of BUP during pregnancy and postpartum following 8 mg BID SL administration 
are provided in Table 4-4. The simulations demonstrated that at steady state, with 8 mg BID SL 
BUP dose, trough plasma concentrations of BUP (at 12 hrs) remained above 1 ng/mL in 88%, 58%, 
39%, and 12% of the subjects in the postpartum period, 1st, 2nd, and 3rd trimester. Figure 4-6 depicts 
the percentage of subjects who are below the BUP concentration required to prevent the appearance 
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of withdrawal symptoms in pregnant subjects, on an 8 mg BID dose of SL BUP based on the 
simulations of our PBPK model in pregnant and postpartum women. It demonstrates that in all three 
trimesters, predicted concentrations are sub-therapeutic in a substantial number of subjects long 
before the next scheduled dose. Seventy percent of women in the 3rd trimester is subtherapeutic by 
the 6th hour after a dose. 
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Table 4-3. Goodness of fit of BUP SL model in pregnancy and postpartum (PK parameters were expressed as mean (SD)) 
 
 
Inter-study 
validation Period Study 
AUC0-12/D Diffd 
 
CL/F Diff
d Cmax/D 
 
Diffd  
Cav/D Diffd Tmax 
 
Diffd  
ng•h/mL % L/h % ng/ml % ng/ml % h % 
Bastian et al 
[19] 
T2a 
Observed (n=7) 2.3  (1.8)  
607.8 
(270.8)  
0.5 
(0.2) 
 0.2  
(0.2) 
 0.4 
(0.2) 
 
Simulations 
(n=100) 
2.2 
(1.2) -6.4 
523.2 
(174.3) -13.9 
0.4  
(0.2) -15.4 
0.2 
(0.10) -5.3 
1.1 
(0.2) 
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T3b 
Observed 
(n=13) 
2.3  
(1.3)  
568.1 
(282.8)  
0.50  
(0.2) 
 0.19 
(0.11) 
 0.9 
(1.1) 
 
Simulations 
(n=100) 
1.7  
(0.8) 
-
23.4 
647.7 
(204.4) 14.0 
0.39 
(0.1) -22.0 
0.14 
(0.06) -26.3 
1.1 
(0.2) 
 
19.6 
PPc 
Observed 
(n=11) 
4.2  
(2.3)  
301.3 
(137)  
0.8  
(0.3) 
 0.4  
(0.2) 
 0.8 
(0.3) 
 
Simulations 
(n=100) 
3.8 
(1.1) -7.7 
280.2 
(77.7) -7.0 
0.7 
(0.2) -10.4 
0.3 
(0.1) -8.5 
1.1 
(0.3) 
 
46.7 
Abbreviations: AUC0-12/D: Dose normalized area under plasma concentration-time curve from time 0 to 12 hours, CL/F: Oral clearance, Cmax/D: Dose 
normalized maximum concentration, Cav/D: Dose normalized average concentration, Tmax: Time to reach maximum concentration. 
aT2: 2nd trimester; bT3: 3rd trimester; cPP: postpartum 
dDiff (difference)% = (predicted - observed mean value)/observed mean value*100 
Cav/D=AUC0-12/12 
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Table 4-4. Pharmacokinetic parameters of buprenorphine during pregnancy and postpartum following 8 mg BID BUP SL 
administration (geometric mean ± SD) 
 
 
PK parameters 
Our in-house clinical study Model Prediction 
2nd trimester 3rd trimester postpartum 2nd trimester 3rd trimester postpartum 
No. of subjects 4 4 10 100 100 100 
Dose regimen 8 mg bid 
AUC0-12 
(ng*h/mL) 
15.4 ± 14.8 12.4 ± 6.5 27.9 ± 20.2 16.2 ± 9.5 13.0 ± 6.2 29.6 ± 8.7 
CL/F (L/h) 520 ± 288.8 644.8 ± 362.3 286.4 ± 145.7 523.2 ± 174.3 647.7 ± 204.4 280.2 ± 77.7 
Cmax (ng/mL) 3.8 ± 1.4 2.6 ±0 .6 5.4 ± 2.5 3.4 ± 1.2 3.0 ± 1.0 5.4 ± 1.3 
Tmax (h) 1.0 ± 3.8 0.5 ± 0.6 0.9 ± 3.6 1.1 ± 0.2 1.1 ± 0.3 1.04 ± 0.27 
 
Abbreviations: Tmax: Time to reach maximum concentration, Cmax: Maximum concentration, AUC0-12: Area under plasma concentration-time curve 
from time 0 to 12 hours; CL/F: Oral clearance 
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Figure 4-4. Predicted and observed dose normalized concentration–time profiles at steady-
state following administration sublingual twice daily buprenorphine 
4-4 A, B, and C represent interstudy validation by plotting mean predictions, 5th–95th
percentiles of predictions against clinical observed mean concentrations during 2nd
trimester, 3rd trimester, and postpartum respectively as observed by Bastian et al.
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Figure 4-5. Predicted and observed concentration–time profiles at steady-state following 
administration of 8 mg sublingual twice daily buprenorphine 
4-5 A, B, and C represent interstudy validation by plotting mean predictions, 5th -95th
percentiles of predictions against clinical observed mean concentrations, and observed
individual concentrations during 2nd trimester (Figure 14A), 3rd trimester (Figure1 4B), 
and postpartum (Figure 14C) as reported by Bastian et al.
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Figure 4-6. Percent of 100 virtual subjects with buprenorphine plasma concentration above 
1 ng/ml in one dosing interval at steady-state following administration of 8 mg sublingual 
twice daily during postpartum, 1st, 2nd, 3rd trimester 
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4.5 Discussion 
In the current study, we developed and validated a SL BUP PBPK model in pregnant 
women utilizing published data in non-pregnant women and adjusting for recognized anatomical 
and physiological changes associated with pregnancy that may impact BUP pharmacokinetics 
during gestation.  The performance of our pregnancy model was evaluated by comparing it to the 
observed plasma concentrations of BUP in pregnant women during the 2nd and 3rd trimester, and 
after delivery. The predicted plasma concentration-time profiles in the virtual pregnant populations 
were consistent with the observed data. The model demonstrates that pregnancy is associated with 
a decrease in BUP systemic exposure, which is more pronounced in the 3rd trimester.  
 
One of the limitations of PBPK modelling in special patient populations is the inability to 
assess the model predictive performance due to limited availability of drug concentration vs time 
data. In the current study, the SL BUP PBPK model in pregnant women was systematically 
developed using a stepwise strategy, where the base model was extensively validated using 
multitude of studies in non-pregnant populations over a wide range of doses [310]. First, a BUP 
IV PBPK model was developed for non-pregnant healthy volunteers and then the absorption 
component was added to the BUP IV PBPK model to describe SL administration of BUP. After 
validation of the predicted plasma concentrations of BUP for both a single and multiple dose at 
steady state in a non-pregnant population, we developed the full BUP SL PBPK pregnancy model 
to predict BUP disposition in pregnant women.  
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In this study, we built a customized pregnancy PBPK model rather than using the SimCyp® 
default parameters used for pregnancy, given the differences in certain parameters in the SimCyp® 
default option and our clinical observations. For example, in SimCyp® the pregnant default 
parameter describes changes of CYP3A4 activity during the entirety of pregnancy as a bell-shaped 
variable, increasing gradually at the beginning of pregnancy to a maximum level around 20 weeks 
of gestation, and then falling to normal level just prior to delivery. However, our in-house data 
showed that CYP3A4 activity is consistently, and significantly increased throughout pregnancy 
[165]. The increased CYP3A4 activity in the late stage of pregnancy has also been reported by 
other groups for as determined by the altered metabolism of midazolam, 4β-hydroxycholesterol/ 
cholesterol [157, 317]. The physiological changes incorporated into the custom pregnancy 
population model are provided in Table 24. As there is currently no conclusive data on the 
involvement of ABC (ATP binding cassette) and SLC (solute carrier) drug transporters in the 
disposition of BUP [176], we assumed that BUP only passively diffuses across the placenta and is 
not metabolized by the placenta. Several groups have developed maternal-fetal PBPK models and 
various compartment structures have been used to model the fetal-placental unit [305, 309]. Still, 
the primary challenge in building a comprehensive fetal compartment is the limited information 
on the fetal physiological development and drug exposure in the fetus during pregnancy. In 
SimCyp®, the fetal-placental unit is considered as a combined compartment in the pregnant 
women. The fetal-placental unit is simplified as a homogenous organ with the assumption that the 
components of the unit have similar characteristics of blood perfusion and drug partitioning [140].  
 
In the BUP PBPK model developed, we used the corrected Poulin and Thiel method to 
estimate BUP distribution between blood and tissue. Both corrected Poulin and Thiel method and 
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Rodgers and Rowland method utilize drug specific properties such as lipophilicity, pKa and 
plasma protein binding to estimate drug partitioning among the components of tissue and plasma 
including water, neutral lipid and phospholipids. The main difference between the two methods is 
that the approach of Rodgers and Rowland divides tissue water into extracellular and intracellular 
parts and contains an added acidic phospholipid component for basic drugs. Rodgers and Rowland 
method also incorporates differences in pH of biological fluids and tissues and helps in modelling 
of active transporter uptake and efflux activity, whereas this ability is not present in Paulin and 
Theil method. In general Rodgers and Rowland method has a better predictive performance, but 
the prediction by this method is not optimal for highly lipophilic and/or highly protein bound drugs 
with minimal to no transporter involvement [318]. During base model building phase, Rodgers 
and Rowland method was tested to predict BUP Vss, but due to poor prediction results, corrected 
Paulin and Theil method was used from that point forward. Buprenorphine is a highly lipophilic 
drug and is extensively bound to plasma proteins with no transporter mediated disposition 
characteristics, and the corrected Paulin and Theil method is the preferred method for modelling 
this particular drug.  
 
In general, the model performed well in predicting BUP exposures within 25% of the 
observed mean values. Currently there is no guidance on the appropriate variance for goodness of 
fit or validation criteria for model predictions. We considered a 50% deviation as reasonable, 
considering the variability in the physiological parameters and disposition of BUP in this 
population. Although our model predicted the plasma concentration versus time profiles fairly 
well, the model underestimated the time to maximal concentration (tmax); the predicted tmax values 
lagged the actual values by about half an hour. This might be attributable to the fact that patients 
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in the published clinical study broke the SL tablet into small pieces to reduce the nausea and 
discomfort of holding the medication under the tongue [201]. Published studies in non-pregnant 
populations did not control for this variable. Breaking up a tablet decreases the disintegration and 
dissolution time, and leads to a faster drug absorption, which likely reduced the time to the peak 
concentrations in the clinical study. The assumption was affirmed by model simulations, as 
increases of Ka or decrease of lag time shortened the tmax without affecting AUC, and Cmax.  
 
BUP plasma clearance is around 50 L/h after an intravenous injection in healthy volunteers 
[74, 78, 87, 88]. The blood clearance of buprenorphine is approximate 80 L/hr (the blood to plasma 
ratio of buprenorphine is 0.6 [89]). Comparing BUP blood clearance with 1.5 L/min (the hepatic 
blood blow in healthy subjects), the estimated BUP hepatic extraction ratio is approximate 0.9, 
which indicates BUP is a high hepatic clearance drug. For a drug given by extravascular, the 
intrinsic clearance, hepatic blood flow and unbound fraction of a drug in blood affect drug 
clearance. Cardiac output increases from 35% to 50%, and the activity of CYP3A4 increases from 
35% to 38% during pregnancy. Therefore, the higher clearance of BUP during after SL 
administration pregnancy is likely due to higher intrinsic clearance and the increased hepatic blood 
flow. The increased BUP clearance during gestation leads to a lower systemic exposure in pregnant 
women.  
 
In clinical practice, most drug dosing regimens are prescribed based on drug specific half-
life.  In non-pregnant patients, BUP is recommended to be administered as a single daily dose due 
to its long half-life (31-35 hours) after SL administration [319]. Using positron emission 
tomography scan, Greenwald et al have reported that the occupancy of mu-opioid receptors in the 
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brain is correlated with plasma concentrations of BUP [206].  A plasma concentration of BUP of 
1 ng/mL is associated to 50% mu-opioid receptor occupancy, a minimum requirement to inhibit 
drug withdrawal. The recommended plasma concentration of BUP of 1 ng/mL as a threshold for 
withdrawal suppression is based on a study in non-pregnant subjects [206], and no similar 
pharmacokinetic-pharmacodynamics studies have been conducted in pregnant women. If we use 
plasma concentration of 1ng/mL of BUP as a threshold for 50% of mu-opioid receptor occupation 
[206], among 100 virtual subjects, 40 subjects would be sub-therapeutic in the 1st trimester in about 
10 hours after dosing, 47 subjects would be sub-therapeutic in the 2nd trimester in about 6 hours 
after dosing and 37 subjects would be sub-therapeutic in the 3rd trimester in about 4 hours following 
administration of 8 mg SL BUP. The model predictions demonstrate the need for an increase in 
dose or dosing frequency to maintain efficacy of BUP for opioid addiction in pregnancy. The 
model predictions are in agreement with the current clinical practice in pregnant women. At the 
Pregnancy Recovery Center at Magee-Womens Hospital, among 62 pregnant women followed up 
in an opioid agonist treatment program, 68% of the patients chose a three or four times dosing per 
day to maximally suppress craving/withdrawal symptoms [303]. 
Recruitment of pregnant women on opioid maintenance therapy during the first trimester 
of pregnancy is difficult and as such data on BUP PK profiles in the 1st trimester is lacking.  The 
PBPK modelling study provided us additional information during 1st trimester that we were unable 
to obtain from our clinical study. We have also used the PBPK model to simulate the duration over 
which the plasma concentration of BUP will be above 1 ng/mL (the threshold to suppress drug 
withdrawal) with various dosing regimens across three trimesters. Such information enables 
optimization of BUP dosing during pregnancy. 
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We verified our SL BUP PBPK pregnancy model by using data from our clinical study 
data as there are no other published data on BUP PK in pregnancy. We are currently recruiting for 
a larger prospective BUP clinical study in pregnant women (NCT02863601), and we will be able 
to further validate this PBPK model upon study completion. In addition, we have collected cord 
blood samples at delivery in the prior study as well in the on-going BUP study to further optimise 
and validate the estimates of BUP fetal exposure.  
 
As discussed above, we developed a BUP PBPK model to predict BUP exposure in three 
trimesters to improve BUP pharmacotherapy in pregnant women. However, previously we were 
not able to verify the model prediction in 1st trimester of gestation due to lack of observed clinical 
data.  
Recently we performed another BUP PK/PD study in pregnant women to assess the 
association between BUP plasma concentrations and PD effects. Pregnant, singleton gestation 
women who were stabilized on sublingual BUP opioid substitution therapy for at least 7 days were 
recruited in this prospective, open-label, non-randomized longitudinal BUP PK study. Up to 3 
studies were performed in each participant including 1st-half pregnancy (gestational week < 20 
weeks), 2nd-half pregnancy (gestational week ≥ 20 weeks), and postpartum (at least 4 weeks after 
delivery). The study was approved by the University of Pittsburgh Institutional Review Board. All 
patients were recruited through Magee-Womens Hospital, and written informed consent was 
obtained from all participants. At each study visit, a total of 10-13 blood samples were collected 
from 0 hours up to 12 hours after the dose. Several physiological measurements including craving 
score, clinical opioid withdrawal (COW) score, pupillary diameter size, galvanic response, 
respiration rate, blood pressure, as well as body temperature were also collected. Plasma 
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concentrations of BUP were quantified using a validated HPLC-MS/MS assay (shown in Chapter 
II). By utilizing the observed BUP plasma concentrations in this study, we further modified the 
previous BUP PBPK model and verified the predictions of the BUP PBPK model. The summary 
of the characteristics of study participants and gestational age associated physiological parameters 
incorporated into the modified model (Model 12) are listed in Table 4-5 and Table 4-6.
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Table 4-5. Characteristics of study participants 
Characteristic 1st trimester 
(<13 gestation 
weeks, n=4) 
2nd trimester 
(13 -28 
gestation weeks, 
n=8) 
3rd trimester 
(≥ 29 gestation 
weeks, n=5) 
Postpartum1 
(> 4 weeks of 
delivery, n=3) 
Age (year) 28 ± 4 31 ± 5 31 ± 4 31 ± 6 
Gestational age (weeks) 11±1 17 ± 2 30 ± 1 NA 
Postpartum (weeks) NA NA NA 5 ± 1 
Body weight (kg) 76.2 ± 14.7 71.6 ± 12.8 78.0 ± 10.8 68.8 ± 0.6 
Albumin (g/dL) 4.1 ± 0.2 3.9 ± 0.3 3.4 ± 0.2 4.1 ± 0.3 
Total protein (g/dL) 7.1 ± 0.4 6.9 ± 0.4 6.5 ± 0.6 7 ± 0.3 
1 Albumin and total protein level were missing for one study participant. 
 
Table 4-6.  Summary of gestational age associated physiologic parameters incorporated 
into SimCyp® healthy population model_2 
 
 
 
Parameter 1st trimester  
(≤12 gestation weeks) 
2nd trimester  
(13-28 gestation weeks) 
3rd trimester                 (≥ 29 
gestation weeks) 
Cardiac output [137] Increased 13.2% Increased 26.2% Increased 36.5% 
Plasma volume [137] Increased 9.5% Increased 20.6% Increased 31.4% 
Red cell volume [137] Increased 3.9% Increased 10.3% Increased 18.5% 
Hematocrit [138] Decreased 2% 
 
Decreased 8% 
 
Decreased 15% 
 
Albumin [139] Decrease 13% 
 
Decrease 23% 
 
Decrease 30% 
 
α1-AGP [140] Decrease 1% Decrease 22% Decrease 19% 
Activity of CYP3A4 [165] Increased 35% 
 
Increased 35% 
 
Increased 38% 
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Using the modified BUP PBPK model in pregnancy, we simulated BUP concentration-
time profile following BUP SL 8 mg twice daily dosing in pregnant women at three trimesters as 
shown in Figure 4-7.  
 
Figure 4-7. Buprenorphine mean concentration-time profiles in 100 virtual pregnant women 
at 1st, 2nd, 3rd trimesters following 8 mg sublingual twice daily dosing. 
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The prediction from both of the models were compared with our observed data as shown 
in Table 4-7. The differences in the predicted means of dose normalized AUC0-t,ss and Cmax, ss were 
within 2-fold of the corresponding observed means at 1st, 2nd, 3rd trimesters and postpartum. The 
predictions from the two models were similar with a higher predicted BUP exposure from model 
2 at three trimesters in pregnancy. The observation from the clinical studies showed that BUP 
exposure were lower at 1st, 2nd, 3rd trimesters compared to postpartum. Also, the decreased BUP 
exposure were more profound at 2nd, 3rd trimesters. 
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Table 4-7. The goodness of fit of model predictions with the observed clinical data 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Study Dose (mg) Tmax(h) 
Cmax,SS/D  
(ng/ml) 
Ratio 
(pred/obs) 
AUC0-t/D 
(ng*h/mL) 
Ratio  
(pred/obs) 
T1 
Observed (n=4) 4 (4) 
1.3  
(1 – 1.5) 
0.83  
(0.53 -1.5) NA 
3.46  
(2.11 – 5.57) 
 
Model_1 
(n=100) 8 1.1 
0.45 
(0.28 - 0.75) 0.54 
2.61 
(1.61 – 3.88) 0.75 
Model_2 
(n=100) 8  1.1 
0.53 
(0.30 - 0.89)  0.64 
3.29 
(1.74 -5.07)  0.95 
T2 
Observed (n=15) 5.7 (2 - 12) 
0.5 
(0 – 2) 
0.60 
(0.25-1.03) 
  
NA 
2.33 
(1.22 – 5.47) 
  
NA 
Model_1 
(n=100)  8 1.1 
0.45 
(0.22 – 0.75) 0.75 
2.54 
(1.26 – 3.93) 1.09 
Model_2 
(n=100) 8 
  
1.1 
0.48 
(0.27 - 0.81) 
  
0.8 
2.83 
(1.49 - 3.90)  1.21 
T3 
Observed (n=18) 8.3 (2 –16) 
0.8 
(0 - 4) 
0.62  
(0.25 – 1.75) 
  
NA 
2.39 
(0.83 – 5.40) 
  
NA 
Model_1 
(n=100) 8 1.1 
0.38 
(0.23 – 0.53) 0.61 
1.99  
(1.09 – 2.87) 0.83 
Model_2 
(n=100) 8 1.1 
0.42 
(0.24 - 0.70) 0.68 
2.28 
(1.1 5- 3.54) 
  
0.95 
PP 
Observed (n=14) 7.4 (4 - 8) 
1  
(0.3 – 1.5) 
0.80  
(0.51 – 1.62) NA 
4.05  
(1.57 – 10.45) NA 
Simulations 
(n=100) 8 1.1 
0.69  
(0.40 – 1.12) 0.86 
4.19 
(2.54 – 6.0) 1.03 
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4.6 Conclusions 
In conclusion, using the SL BUP PBPK model, we are able to predict maternal plasma 
concentrations of BUP in pregnant women across various gestational ages. The PBPK model 
predicted a decrease in BUP exposure during pregnancy and these results are aligned with 
published clinical study. We have also demonstrated the clinical implication of the SL BUP PBPK 
model in optimisation of BUP dosing in pregnant women by predicting the duration over which 
the plasma concentrations will be below the threshold for inhibiting drug withdrawal over a dosing 
interval. The model predictions demonstrate the need for an increase in dose or dosing frequency 
to maintain efficacy for opioid addiction during pregnancy.   
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 Model-based analysis to evaluate alterations in buprenorphine pharmacokinetics 
during pregnancy
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5.1 Abstract 
Introduction: Opioid addiction has become a nationwide health crisis in the United States. 
Buprenorphine (BUP) is an FDA-approved therapy for opioid addiction. The efficacy of BUP in 
suppressing symptoms of withdrawal appears to be comparable to methadone, but treatment with 
BUP is more convenient to patients, and BUP exposed neonates appear to have less severe and 
less frequent Neonatal Abstinence Syndrome (NAS). The current BUP dosing regimen is based on 
the recommendations designed for non-pregnant subjects. However, pregnancy-induced 
physiological changes may impact buprenorphine absorption, distribution, metabolism and 
elimination. Altered pharmacokinetic (PK) profiles have been reported for various therapeutic 
agents in pregnant women. Our aims were to use a population PK modeling approach to 
characterize BUP PK during pregnancy and to test potential covariates that may influence BUP 
PK during pregnancy in an attempt to optimize dosing of BUP in pregnant women. 
Methods: Two clinical studies were used for the present modeling analysis. In study 1, 
pregnant, singleton gestation women who were stabilized on twice-daily sublingual BUP opioid 
substitution therapy (2- 16 mg) for at least 7 days participated in a prospective, open-label, non-
randomized longitudinal BUP PK study. Up to 3 studies (2nd, 3rd trimester, and postpartum) were 
performed in each participant. The design of the pharmacokinetic study 2 was similar to Study 1, 
but patient recruitment was classified by the 1st, 2nd – half of pregnancy and postpartum period. 
The dosing frequency in the participants was not restricted to twice daily dosing regimen. Both of 
these studies were approved by the University of Pittsburgh Institutional Review Board. Patients 
were recruited through Magee-Womens Hospital, and written informed consent was obtained 
from all participants. At each study visit, a total of 10 blood samples were collected from 0 hours 
up to 12 hours after SL dose of BUP. Plasma concentrations of BUP were quantified using LC-
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MS/MS. A total of 527 concentration time points from 51 PK study occasions in 26 patients from 
study 1 and study 2 were used for this population PK analysis. Non-linear mixed effects modeling 
using the first-order conditional estimation with interaction (FOCE-I) was conducted in 
NONMEM. Because BUP was administered sublingually, the structural model evaluation included 
extensive exploration of different absorption models to optimize model fit during the absorption 
phase. The effects of demographic and other patient covariates (age, pregnancy, body weight and 
gestational weeks, albumin, and total protein) were investigated via parameters vs. covariates plots 
and bootstrap stepwise covariate evaluation.  
Results: BUP PK data were well-characterized by a two-compartment model with first-
order absorption incorporating enterohepatic recirculation and first-order elimination. Pregnancy 
was associated with significant differences in BUP PK, with apparent clearance of BUP being 
increased approximately 1.64 times during pregnancy compared to the postpartum period (p < 
0.001). A visual predictive check stratified by pregnancy status showed the 5th, 50th, and 95th 
percentiles of observed BUP plasma concentrations to be within 95% confidence intervals (CI) of 
1000 simulated replicate datasets. The model estimated population CL/F for a typical non-pregnant 
and pregnant woman, were 286 and 469 L/h, respectively. 
Conclusions: Pregnancy is the only covariate that is associated with significant changes in 
the PK of sublingual BUP. The currently recommended dose of BUP may need to be increased or 
the dosing frequency to be increased in pregnant women in order to achieve comparable systemic 
exposures in non-pregnant women. 
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5.2 Introduction 
Illicit maternal drug use and subsequent prenatal drug exposure in pregnant women has 
significantly increased since 2000. The 2010 National Survey on Drug Use and Health conducted 
by the National Institute on Drug Abuse reports a 47% increase of illicit drug use during pregnancy 
since 2002 (4.4% in 2010 versus 3% in 2002 between the ages of 15 and 44 of pregnant 
women)[177]. The term "illicit" refers to the use of illegal drugs, including marijuana, and misuse 
of prescription medications, such as cocaine, benzodiazepines, and opiates. The use of opioids 
during pregnancy can result in drug withdrawal syndrome in newborns called neonatal abstinence 
syndrome (NAS). Since 2000, the incidence of NAS has increased 5 folds [179]. Antepartum use 
of opioids can also result in intrauterine growth restriction, birth defect, stillbirth, and preterm 
labor [181, 182]. In addition, maternal opioid use is associated with increased obstetrical 
complications, such as maternal death, cardiac arrest, and placental abruption [180].  
 
There is no cure for opioid dependence, but medication-assisted maintenance therapies can 
reduce the overdose death and complications of opioid dependence such as HIV and hepatitis 
infections, as a consequence of decreased illicit drug use. Currently, methadone, buprenorphine, 
and naltrexone are the three primary pharmacotherapies for treating opioid dependence. The 
effectiveness of methadone as a maintenance treatment for opioid dependence has been 
demonstrated in many clinical studies. As a full agonist of μ-opioid receptor, methadone has abuse 
potential; therefore, methadone maintenance treatment requires daily patient visits for drug 
dispensing. Naltrexone is an antagonist of μ-opioid receptor. Naltrexone can root out illicit drug 
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use by blocking the euphoric effects and has no abuse potential, but poor patient retention hampers 
its routine clinical use. Many studies have reported that buprenorphine has comparable efficacy to 
methadone in treating opioid addiction [194-196]. As a partial μ-opioid receptor agonist, 
buprenorphine has less abuse potential compared to methadone. Therefore, patients usually get 
one or two weeks supply of buprenorphine during one clinic visit. Recently, several studies have 
reported that BUP exposed neonates have less severe and lower incidence of NAS [136, 182, 197]. 
On an average, there were less morphine required, shorter hospital stay, and shorter duration of 
medical treatment to treat neonatal abstinence syndrome in buprenorphine-exposed neonates 
[198]. These results support the use of buprenorphine as a potential first-line medication for 
pregnant opioid-dependent women. 
 
However, there are a few unresolved issues in regards to dosing of buprenorphine in 
pregnant women. The current dosing regimen of buprenorphine is based on the recommendations 
in non-pregnant women or men. Clinical observations in Magee-Womens Hospital indicate an 
increase in buprenorphine dose requirement during pregnancy [201]. Another clinical study that 
compared the efficacy of buprenorphine and methadone in pregnant women showed that 30% of 
patients converted to buprenorphine failed at start, and 71% of dropped out because of patient 
dissatisfaction with buprenorphine [202]. Pregnancy induces a variety of physiological changes 
including the development of placental-fetal compartment, an increase in renal filtration, body 
volume and hepatic portal blood flow, as well as changes in the activities of drug metabolizing 
enzymes and transporters [125, 145, 147]. These pregnancy-induced physiological changes can 
impact drug absorption, distribution, metabolism, and elimination [148]. Many clinical studies 
have reported significant changes in the systemic exposure of drugs used during pregnancy. 
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Specifically, pregnancy results in a decreased rate of absorption due to decreased gastric emptying 
and decreased intestinal motility. The bioavailability of a drug used during pregnancy may be 
decreased or increased depending on how the activity of drug metabolic enzymes and transporters 
are altered in the gut during pregnancy. Pregnancy leads to an increased volume of distribution 
because of the increased body fat, total body water, plasma volume, and blood volume. Pregnancy 
effect on drug metabolism is drug specific. For example, the metabolism of drugs mediated by 
cytochrome P-450 (CYP) 2C9, CYP2D6, CYP3A4, uridine 5'-diphospho-glucuronosyltransferase 
(UGT) 1A4, and UGT2B7 are enhanced, whereas the metabolism of substrates of CYP1A2 and 
CYP2C19 are decreased [158]. We hypothesized that buprenorphine clearance will be increased 
during pregnancy resulting in decreased BUP exposure and this may be responsible for the poor 
adherence to buprenorphine in pregnancy. The aims of the present study were to characterize BUP 
PK during pregnancy and to evaluate potential patient demographics that may influence BUP PK 
during pregnancy through a population PK modeling approach. 
5.3 Method 
5.3.1  Study Design 
Data from two BUP clinical pharmacokinetic studies were included in this population PK 
analysis. 
Study 1 was a prospective, open-label, non-randomized and longitudinal pharmacokinetic 
study of buprenorphine in pregnant and postpartum subjects. The study was approved by the 
University of Pittsburgh Institutional Review Board. Patients were recruited through Magee-
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Womens Hospital, and written informed consent was obtained from all participants prior to the 
initiation of any study-related activities. Pregnant, singleton gestation women who were stabilized 
on twice-daily sublingual BUP opioid substitution therapy (2 - 16 mg) for at least 7 days 
participated in this study. Up to 3 PK studies were performed in each participant during the 2nd (14 
weeks, 0 days through 28 weeks, 0 days), and 3rd trimester (28 weeks, 1 day through term), and 
postpartum period (after 4 weeks of delivery). At each PK study visit, a total of 10 blood samples 
were collected in heparinized tubes from each subject at 0 (trough), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8 
and 12 hours after a dose. After centrifugation of blood, the plasma samples were frozen at -80°C 
until analyzed.  
Study 2 was a prospective, open-label, non-randomized and longitudinal PK/PD study in 
pregnant women to assess the association between BUP plasma concentrations and PD effects. 
Pregnant, singleton gestation women who were stabilized on sublingual BUP opioid substitution 
therapy for at least 7 days were recruited. Up to 3 studies were performed in each participant 
including 1st-half of pregnancy (gestational week < 20 weeks), 2nd-half of pregnancy (gestational 
week ≥ 20 weeks), and postpartum (at least 4 weeks after delivery). The study was approved by 
the University of Pittsburgh Institutional Review Board. All patients were recruited 
through Magee-Womens Hospital, and written informed consent was obtained from all 
participants. At each study visit, a total of 10-13 blood samples were collected from 0 hours up to 
12 hours after the dose or till the end of a dosing interval. Several PD effects and physiological 
measurements including craving score, clinical opioid withdrawal (COW) score, pupillary 
diameter size, galvanic response, respiration rate, blood pressure, as well as body temperature were 
collected. 
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5.3.2  Determination of plasma concentration of buprenorphine  
The concentrations of BUP in plasma samples from study 1 were quantified using a 
validated ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-
MS/MS). Briefly, 500 μL of plasma samples containing buprenorphine and the deuterated internal 
standard (buprenorphine-d4) were extracted using pre-conditioned Strata X-C cartridges. The 
cartridge was washed with 1 mL of 2% formic acid in water twice, followed by 1 mL of 2% formic 
acid in methanol once. Buprenorphine and the internal standards were eluted from the cartridge 
and collected in a tube. The eluent was evaporated, reconstituted and an aliquot was injected in an 
Acquity UPLC Ethylene Bridged Hybrid (BEH) C18 1.7 µm column (2.1x100 mm) equipped with 
Waters ACQUITY UPLC system tandem Thermo TQS Quantum Ultra™ Triple Quadrupole Mass 
Spectrometer. Calibration curves were linear in the range of 0.05–50 ng/mL.  Both the intraday 
and interday precisions assessed by coefficient of variation values and the accuracy assessed by 
bias were within 15% of the nominal concentrations. 
The concentrations of BUP in plasma samples from study 2 were quantified using a 
validated assay of ultra-performance liquid with tandem mass spectrometry (UPLC-MS/MS). Two 
hundred μL of plasma sample containing deuterated labelled BUP (buprenorphine-D4) 
chromatography were processed by protein precipitation prior to chromatography. 
Chromatographic separation was performed using Acquity UPLC Ethylene Bridged Hybrid (BEH) 
C18 1.7 µm column (2.1x100 mm) with a mobile phase consisting of [A] 5% Acetonitrile in water 
containing ammonium acetate (2 mM) and formic acid (0.1%), and [B] Acetonitrile containing 
ammonium acetate (2 mM) and formic acid (0.1%) delivered at a flow rate of 0.3 mL/min in a 
gradient elution. The analytes were detected by a XEVO TQS mass spectrometer in positive 
electron spray ionization (ESI) mode using multiple reaction monitoring (MRM). The assay was 
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linear over the range of 0.05–100 ng/mL for buprenorphine. Both the intraday and interday 
precisions assessed by coefficient of variation values and the accuracy assessed by bias were within 
15% of the nominal concentrations. 
 
5.3.3  Population Pharmacokinetic Analysis 
Non-linear mixed effects model (NONMEM) using first-order conditional estimation with 
interaction (FOCE-I) was applied to develop a population PK model of buprenorphine. In this 
population PK model, fixed and random effects were estimated to describe the time course of 
buprenorphine plasma concentration after sublingual administration. The parameter estimation of 
a model was a process of minimizing the objective function value (OFV, approximately equal to -
2 ×log of the likelihood) using maximum likelihood estimation.  
 
For discrimination between different models, Akaike information criterion (AIC) was used 
to compare non-nested models. As OFV approximately follows χ2 distribution, and a likelihood 
ratio test was employed to compare the difference between two nested models. For adding one 
additional parameter to a model, a decrease of 3.84, 6.63, or 7.88 in the OFV was used as a cutoff 
for significant improvement in model fit at respectively 5%, 1% and 0.5% levels of rejecting the 
null hypothesis (there are no significant difference in the two models) due to type I error.  In 
addition, certain diagnostic plots, such as goodness-of-fit plot, plot of individual observed 
concentration time profile overlaid with population prediction and individual prediction, plot of 
conditional weighted residual against time, and plot of individual weighted residual against time 
were also employed during the model selection. 
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This population PK model of buprenorphine was developed in two steps. First, the 
structural model was explored and selected to describe the absorption and disposition of 
buprenorphine. Because BUP was administered sublingually, structural model evaluation included 
extensive exploration of different absorption models to optimize modeling fitting in the absorption 
phase. After optimization of the structure model, the effects of demographic and other patient 
covariates (age, pregnancy, body weight and gestational weeks, albumin, and total protein) were 
evaluated through PK parameter vs covariate plots. The covariates that are potentially associated 
with PK parameters from visual check was further investigated via bootstrap stepwise forward/ 
backward covariate evaluation (SCM, forward addition, p < 0.05; backward elimination p < 0.01).  
The magnitude of the differences between subjects and between occasions within a subject 
at model parameter level were estimated by the between subject variability (BSV) and between 
occasions variability (BOV). As a log-normal distribution across the population for each parameter 
was assumed, exponential models were used to estimate BSV and BOV. The residuals, the 
difference between observed and predicted concentration of buprenorphine, were assumed to have 
a normal distribution and centered around zero. Additive only, proportional only, and the 
combined additive and proportional error models were tested during the selection of the error 
model. 
The performance of the final model fit was evaluated by the goodness-of-fit plot, visual 
predictive check (VPC), and non-parametric bootstrap. In the VPC procedure, 1000 replicate 
datasets were simulated with the original dataset design. Variability was introduced into the 
replicate datasets by random sampling from matrices of random effects in the final model. The 
VPC plot constructed the 95% prediction intervals of the 5th, 50th and 95th percentiles from the 
1000 replicate datasets against the 5th, 50th and 95th percentiles of the observed concentration-time 
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profiles, which was used to graphically assess whether the simulations from the final model was 
able to reproduce the central tendency and the variability in the observed dataset. Using sampling 
with replacement of random subject in the original dataset, 500 of bootstrap datasets were 
generated containing the same subject numbers as the original dataset. The 90% of the prediction 
interval of the bootstrap datasets were compared with the parameter estimates from the final model. 
5.3.4  Software 
The population PK analysis was performed in NONMEM, version 7.3.0. Graphical 
diagnostics and exploratory analysis were conducted using R (Version 3.4.4) and Xpose version 
4. Pirana® was used as an interface to integrate these software. 
5.4 Results 
A total of 527 concentration time points from 51 PK study occasions in 26 patients from 
study 1 and study 2 were used for the population PK analysis. The characteristics of study subjects 
are summarized in Table 5-1.
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Table 5-1. Characteristics of study participants 
     
 
 
 
 
 
 
 
 
  
 
 
Note: 1. Albumin and total protein level were missing from one study participant.  
Study 2 
Characteristic  1st-half pregnancy 
(<20 gestation weeks, n=12) 
2nd-half pregnancy 
(≥ 20 gestation weeks, n=5) 
Postpartum1 
(n=3) 
Age (year) 30 ± 5 31 ± 4 31 ± 6 
Gestational age (weeks) 15 ± 3 30 ± 1 NA 
Postpartum (weeks) NA NA 5 ± 1 
Body weight (kg) 73.1 ± 13.0 78.0 ± 10.8 68.8 ± 0.6 
Albumin (g/dL) 3.9 ± 0.3 3.4 ± 0.2 4.1 ± 0.3 
Total protein (g/dL) 7.0 ± 0.4 6.5 ± 0.6 7 ± 0.3 
Study 1 
Characteristic  2nd trimester 
(13 -28 gestation weeks, n=7) 
3rd trimester 
(≥ 29 gestation weeks, n=13) 
Postpartum 
(n=11) 
Age (year) 26 ± 5 29 ± 5 29 ± 5 
Gestational age (weeks) 22 ± 2 34 ± 2 NA 
Postpartum (weeks) NA NA 6 ± 3 
Body weight (kg) 71.4 ± 8.1 74.5 ± 7.7 66.9 ± 8.7 
Albumin (g/dL) 3.4 ± 0.2 3.2 ± 0.3 4.1 ± 0.2 
Total protein (g/dL) 6.1 ± 0.6 6.0 ± 0.4 6.7 ± 0.6 
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5.4.1  Structural model of the population pharmacokinetic model following sublingual 
administration of buprenorphine 
One and two compartment models with first order elimination incorporating several types 
of absorption profiles were compared. The two-compartment structure model was chosen over the 
one-compartment model due to a higher AIC value and a U-shaped pattern in the scatterplot of 
weighted residuals versus population predictions in the one-compartment model. To represent 
buprenorphine absorption following sublingual administration, 1st-order absorption, zero-order 
absorption, different combinations of 1st-order and zero-order absorption with or without latency, 
transit model and enterohepatic circulation (EHC) absorption models were tested. A two-
compartment model with 1st-order absorption and enterohepatic circulation, followed by 1st-order 
elimination were identified as the best structure model to describe buprenorphine absorption and 
disposition after sublingual administration as illustrated in Figure 5-1. The model assumed that 
elimination of buprenorphine was only through the central compartment. In order to model the 
EHC process, a gall bladder compartment was included into the structural model in addition to a 
central and peripheral compartment. A percentage of the administered buprenorphine dose 
estimated by the model was transferred to the gall bladder through 1st-order rate constant (EHCP 
=  𝑘𝑘24
𝑘𝑘20+𝑘𝑘24
 × 100% ), where k24 is the rate constant of the transfer of BUP from central 
compartment to gall bladder, k20 is the rate constant of the elimination of BUP in central 
compartment. 
 
In addition to the percentage of administered dose of BUP undergoing enterohepatic 
recirculation (EHCP), the other typical values of the PK parameters estimated by the model 
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included apparent clearance of buprenorphine (CL/F), the apparent volume of distribution of 
buprenorphine central compartment (V2/F), the apparent volume of distribution of buprenorphine 
peripheral compartment (V3/F), absorption rate constant k12, the apparent intercompartment 
clearance of buprenorphine (Q/F). Due to insufficient blood sampling during the EHC process, 
several assumptions were made to the model according to a reported EHC model [320]. (1) The 
process of emptying of BUP from gall bladder was assumed to be similar to a bolus injection 
following 1st-order rate constant, so the duration of the gall bladder emptying and rate constant of 
buprenorphine from gall bladder to dose compartment was fixed as 0.01hr and 70 hr-1, respectively 
based on a reported EHC model. Also, the rate constant of slow gall bladder emptying did not 
significantly impact OFV values and the estimates of other parameters at the range of 10 to 70 hr-
1 based on our sensitivity analysis. (2) The emptying of gall bladder occurred at mealtime, 10 hrs 
after a dose. (3) Any BUP glucuronide excreted into the bile is immediately converted to BUP in 
the gut. The biotransformation of BUP glucuronide to BUP is not a rate-limiting step. 
After entering the gall bladder, BUP was retained and accumulated in the gall bladder 
compartment until the gall bladder was emptied. During the emptying of the gall bladder, 
buprenorphine was reintroduced into the dose compartment and was reabsorbed into the central 
compartment. Two dummy compartments (Compartment 5 and Compartment 6) were used to start 
and end the emptying of the gall bladder. The differential equations to describe the changes in the 
mass of buprenorphine in each of the compartment are listed below. 
    𝑑𝑑𝑑𝑑1
𝑑𝑑𝑑𝑑
 = k12 × X1 + k41×X4×FLAG 
    𝑑𝑑𝑑𝑑2
𝑑𝑑𝑑𝑑
 = k12 × X1 - k20 × X2 - k23 × X2 + k32 × X3 - k24 × X2 × Z 
    𝑑𝑑𝑑𝑑3
𝑑𝑑𝑑𝑑
 = k23 × X2 - k32 × X3 
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     𝑑𝑑𝑑𝑑4
𝑑𝑑𝑑𝑑
 = k24 × X2 - k41×X4 × FLAG 
     𝑑𝑑𝑑𝑑5
𝑑𝑑𝑑𝑑
 = 0 
     𝑑𝑑𝑑𝑑6
𝑑𝑑𝑑𝑑
 = 0 
Xn represented BUP amount in the nth compartment. The compartment 1, 2, 3, 4, 5, 6 were defined 
as dose compartment, central compartment, peripheral compartment, gall bladder compartment, 
dummy compartment to start the emptying of the gall bladder, dummy compartment to end the 
emptying of the gall bladder. The t represented time, kij represented the rate constant of the transfer 
of BUP among the compartments. FLAG is on (FLAG = 1) and off (FLAG = 0) indicator variables 
to turn on and turn off the empting of gall bladder.  Z was an indicator variable to turn off the 
buprenorphine entering gall bladder after the emptying of gall bladder before the next dose to 
prevent buprenorphine reaccumulating in the gall bladder. Due to the high variability of between 
subjects and insufficient samples collection around the EHC process, the interindividual variance 
of EHC were fixed at 0.5 based on sensitivity analysis as shown in Figure 5-2. 
178 
 
 
 
 
                                          
                                                                           
                                
                                                                                                                                 
 
 
 
 
 
Figure 5-1. Schematic diagram of buprenorphine structure model following sublingual administration  
k12, first-order absorption rate constant; k23 and k32, rate constants for distribution of buprenorphine between central and peripheral 
compartment; k20, first-order elimination rate constant of buprenorphine; k24, rate constant for the distribution of buprenorphine from 
central compartment to gall bladder; k41, rate constant for the distribution of buprenorphine from gall bladder to dose compartment. GB, 
gall bladder 
 
K12 
k23 
k32 
    Dose Central CMT   Peripheral CMT 
k20 
  Gall Bladder 
k24 
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Figure 5-2. Sensitivity analysis of the interindividual variability of the percentage of 
enterohepatic recirculation (EHCP). (A)  The impact of fixed values of variance of EHCP 
vs. OFV (B) The impact of fixed values of variance of EHCP vs. relative standard error of 
model parameters 
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5.4.2  Covariate identification 
In 100 simulated bootstrap datasets, the median of the density plot of the distribution of 
covariate model size was identified as one. Pregnancy was identified as a significant covariate on 
the apparent clearance of buprenorphine in 60% of the 100 bootstrap datasets. None of the other 
characteristics including body weight, gestational weeks, serum creatinine, albumin, alanine 
aminotransferase, and aspartate aminotransferase level in the subjects were identified as important 
variables to explain BSV of PK parameters in this patient population. There was a statistically 
significant drop in OFV ( OFV=12) after adding pregnancy in the model (p<0.005). As a result, 
the final model only included pregnancy as a covariate on the apparent clearance of buprenorphine. 
 
The parameter estimates from the final model are shown in Table 5-2. The final model 
estimated the apparent clearance of buprenorphine to be 469 L/h during pregnancy with 24.4% 
inter-individual variability. In comparison with pregnancy, the fraction changes on CL/F in the 
postpartum was -0.391. The median values of the PK parameters from the bootstrap datasets were 
similar to the parameter estimates from the original dataset.
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Table 5-2. Parameter estimates of final population pharmacokinetic model for 
buprenorphine following sublingual administration in pregnant women 
Parameter Final model estimate (RSE %) Bootstrap (n=500) 
Median (95% CI) 
Population typical value 
CL/F (L/hr) 469 (6) 465 (392 - 547) 
V2/F (L) 751 (19) 761 (481 - 1160) 
Q/F (L/hr) 730 (36) 709 (480 - 1100) 
V3/F (L) 7790 (22) 8166 (5307 - 13559) 
ka (hr-1) 1.05 (19) 1.07 (0.72 – 1.55) 
EHC % 1.79 (41) 1.75 (0.34 – 3.58) 
K41 (hr-1) 70 fixed  
ALAG5 (hr) 10 fixed  
ALAG6 (hr) 0.01 fixed  
CLPG -0.391 (36) -0.382 (-0.55 - -0.15) 
Interindividual variability (expressed as % CV) 
CL/F 24.4 (27.9) 24.8 (0.6 – 37.2) 
Q/F 89.6 (12.5) 87.3 (60 – 116.4) 
ka 40.2 (16.9) 39.6 (13.2 – 61.7) 
EHC% 70.7 (fixed)  
Interoccasion variability (expressed as % CV) 
CL/F 37.8 (14.2) 36.7 (22.3 – 47.5) 
Residual variability (expressed as % CV) 
Proportional error 6.94 (14.6) 6.84 (5 – 8.89) 
RSE: relative standard error; CI: confidence interval; CL/F: apparent clearance during pregnancy; 
V2/F: apparent volume of distribution of central compartment, Q/F: apparent intercompartment 
clearance; V3/F: apparent volume distribution of peripheral compartment; ka: absorption rate 
constant; EHC%: The percentage of administered dose of buprenorphine undergoing enterohepatic 
recirculation; k41: rate constant of buprenorphine transferring from gall bladder to dose 
compartment; ALAG5: a lag time for starting of emptying of gall bladder; ALAG6: duration of 
the emptying of gall bladder; CLPG: fraction changes in the clearance of buprenorphine in 
postpartum. 
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5.4.3  Model evaluation 
In the goodness-of-fit plots, the observed concentration against population predicted 
concentration or individual predicted concentrations were clustered towards the lines of identity. 
The conditional weighted residuals data were symmetrically distributed around the line of zero 
and majority of the residuals were within the range of 2 times of the standard deviations (Figure 
5-3).
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Figure 5-3. Goodness of fit diagnostic plots for buprenorphine concentrations fitted of final 
model.  
(A) Individual predicted buprenorphine concentration vs. observed buprenorphine concentration.
(B) Population predicted buprenorphine concentration vs. observed buprenorphine concentration.
(C) Conditional weighted residuals vs. population predictions (D) Conditional weighted residuals
vs. sample collection time after a dose. The solid black lines in (a) and (b) represent the line of
identity and those in (c) and (d) represent the line y = 0. The solid red lines in each panel represent
loess smooth of the data.
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The VPC plot stratified by pregnancy status displayed that the 5th, 50th, and 95th percentiles 
of the observed BUP plasma concentration were within 95% predicted interval from 1000 
simulated replicate datasets. Also, most of the observed concentrations were within the predicted 
95% intervals as shown in Figure 5-4.  
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Figure 5-4. Predictive performance of the final model using visual predictive check plots.  
 
The model predicted concentrations of buprenorphine at postpartum (left, PG =0) and at postpartum (right, PG=1) were plotted against 
observed concentrations at each time point after a dose. Y-axis, Dependent variable represented buprenorphine plasma concentration; 
x-axis, Independent variable represented time after a dose. Open dots represented observed concentrations, solid blue lines represented 
the 5th, and 95th percentiles of observed buprenorphine plasma concentrations; the solid red lines represented the 50th percentiles of the 
observed buprenorphine concentrations; shaded area represented the model predicted 95% confident intervals surrounding the 5th, 50th, 
and 95th percentiles from 1000 simulated datasets.
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5.5 Discussion 
In the present study, we developed a population pharmacokinetic model of buprenorphine 
in women during pregnancy and postpartum period. A two-compartment model with 1st-order 
absorption with EHC and 1st-order elimination best described the absorption and the disposition 
of buprenorphine following sublingual administration. Simulation based diagnostic methods, 
including VPC and non-parametric bootstrap resampling, were applied to evaluate the 
performance of the final model. Pregnancy was identified as a significant covariate with the 
apparent clearance of buprenorphine being increased 1.64-fold during pregnancy compared to the 
postpartum period.  
 
Buprenorphine plasma clearance is around 50 L/h after an intravenous injection in healthy 
volunteers [74, 78, 87, 88]. The blood clearance of buprenorphine is approximately 80 L/hr (the 
blood to plasma ratio of buprenorphine is 0.6 [89]). Comparing BUP blood clearance with the 
hepatic blood blow in healthy subjects (1.5 L/min), the estimated BUP hepatic extraction ratio is 
approximate 0.9, which indicates BUP is a high hepatic clearance drug. For a drug given by 
extravascular route, the intrinsic clearance, hepatic blood flow and unbound fraction of a drug in 
blood can affect clearance of such a drug.  After IV administration, BUP is completely metabolized 
in the liver through N-dealkylation to norbuprenorphine, primarily mediated by CYP3A4. 
Norbuprenorphine is further converted to norbuprenorphine glucuronide [90, 91]. A portion of 
buprenorphine directly goes through phase II metabolism mediated by UGT1A1, UGT1A3, and 
UG2B7 to buprenorphine glucuronide. Pregnancy is associated with enhanced cardiac output, 
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hepatic blood flow, and increased expression and activities of CYP3A4, UGT1A1, and UGT1A3 
[165, 204, 205]. Also, pregnancy leads to a decrease in plasma protein concentration, which may 
result in an increase in unbound fraction of buprenorphine in blood [321]. Taken together, the 
increase in hepatic blood flow and activities of CYP3A4, UGT1A1, 1A3, as well as increase in 
unbound fraction of buprenorphine in blood may explain the increased apparent clearance of 
buprenorphine as identified in the model. 
 
In the clinical study, we observed complex absorption profiles in the buprenorphine 
concentration - time profiles in some subjects. Physiologically, drug absorption following SL 
administration may involve a rapid passive absorption across the SL mucosal membrane, a slow 
depot release from the buccal tissue depot space, as well as gut absorption from the portion of the 
drug dose that is swallowed. During model development, we tested two dose compartments to 
mimic the complex absorption profiles of sublingual administration of buprenorphine. The process 
of buprenorphine transferring to the central compartment through the two dose compartments were 
investigated using 1st-order absorption or zero order absorption kinetic property with or without 
lag time. However, the fraction of administered dose through each of the dose compartment was 
unable to be precisely estimated by these models. Also, we tried to fix the fraction of administered 
dose within each dose compartment, but none of these models fitted the data well. As of now, only 
two population modeling studies have been conducted with buprenorphine following sublingual 
administration in humans [322, 323]. The two modeling studies used 1st-order absorption model 
to describe their data. One of the two studies was conducted in 24 infants. Only one or two plasma 
samples were collected from each participant at one hour before or after a dose. The time course 
of buprenorphine after a single SL dose in 5 adult subjects were added in the modeling analysis 
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[323]. In the second study, the blood samples were collected at 0.5, 1, 2, 4, 6, 8, 12, and 24 after a 
dose. Both of the clinical studies have sparse blood sampling time points, so the second peak from 
EHC may have not been observed in the two studies. In our study, we observed a second peak in 
more than 50% of the plasma concentration-time profiles. We speculate that enterohepatic 
circulation may be involved in buprenorphine disposition. In an animal study, paired rats, donor 
and recipient were used to assess EHC of BUP [324]. A cannula was inserted into the bile duct of 
the donor rat and connected to the duodenum of the recipient rat. Buprenorphine was administered 
to the donor rats intravenously. In this study, BUP was detected in the plasma of recipient rats. 
The peak BUP concentration in the recipient rats was observed at 8 hrs after dosing in the donor 
rats. A second peak of buprenorphine has been also observed in some clinical PK studies. 
Concheiro et al conducted a PK study of buprenorphine following SL administration at late stage 
of pregnancy and postpartum in 3 women. The PK profiles at different study occasion in all of the 
subjects showed a secondary peak after 8 hrs following a SL administration of BUP [238]. 
McAleer et al. reported the observation of a secondary peak of buprenorphine around 10 hr after 
administration of 16 mg SL BUP in many participants in a PK study [283]. A total of 105 healthy 
male subjects with no history of opioid abuse participated in the study. Each participants received 
two doses of buprenorphine on two study occasions. At each study occasion, a single dose of 
sublingual BUP was given to the subjects [283]. The observed second peak around 10 hrs after a 
dose in the clinical study in pregnant women was in agreement with the observations in the studies 
reported by Concheiro et al. and McAleer et al [225, 283]. The second peaks and elevated 
concentration of buprenorphine at a later time period after administration of SL buprenorphine 
may be due to the variability in the absorption introduced by SL administration or the reabsorption 
of from buprenorphine that is secreted in the bile. However, without administering intravenous 
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formulation of buprenorphine, the cause of the complex absorption is not identifiable at this point. 
The presence of a second peak in BUP plasma concentration-time profile might be a result of BUP 
glucuronide being converted to BUP and being reabsorbed in the gut. However, the model was 
unable to identify the proportion of metabolism of BUP through N-demethylation and 
glucuronidation pathways due to relative small patient sample size.  
Including EHC in buprenorphine disposition in the current population PK modeling 
resulted in a decrease of AIC by 33. The model estimated that a typical percentage of EHC of 
buprenorphine was 1.79% of the administered dose with large intersubject variability. The relative 
low biliary excretion of buprenorphine was also reported in a rat study [324]. The reason for the 
large variance in the percentage of BUP undergoing EHC may be the difference in the time of 
meals and content of the meal which were not strictly controlled in the clinical studies. Due to 
inadequate blood samples collected around EHC process, it was not possible to precisely estimate 
the parameter describing the rate and duration of the emptying of the gall bladder, and the 
interindividual variability of the percentage of BUP undergoing EHC. We have tested the rate 
constant of emptying of gall bladder from 10 to 70 hr-1. The changes of OFVs were not greater 
than 3 and there was minimal changes to the estimates of other model parameters, so we fixed the 
model based on the estimate from the report of other publications on EHC model [320]. Fixing 
such parameters has also been used in other population PK model with EHC reabsorption [320, 
325]. 
Buprenorphine is a lipophilic drug (LogP = 4.98) with large volume of distribution, and 
usually two- or three-compartment models are used to describe buprenorphine disposition [70]. In 
the clinical study, patients were prescribed to take sublingual buprenorphine twice daily. 
Therefore, the blood samples were collected from time 0 up to 12 hours after a dose. Due to the 
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clinical study design and patient sample size, two-compartment structural model was selected over 
three-compartment model to ensure the adequacy of the data for the parameter estimation. 
Although several characteristics of the patients were tested including age, body weight, BMI, 
gestational weeks, etc., pregnancy was identified as the only significant covariate to predict 
buprenorphine apparent clearance in this patient population.  
 
The ability to predict drug exposure during pregnancy is critical to the success of drug 
therapy in pregnant women. Currently there is an opioid crisis in several countries. Optimizing 
treatment of opioid addiction is important to address this crisis. While buprenorphine is considered 
to be a better treatment option compared to methadone in treating substance abuse disorder in 
pregnant women, there is increased dropout of pregnant patients on buprenorphine therapy. This 
modeling study provides us a better understanding of the changes in buprenorphine 
pharmacokinetics during pregnancy. With the modeling result we will be able to tailor BUP dosing 
during pregnancy, which could potentially improve patient retention in BUP maintenance therapy 
and improve outcome of NAS in the newborns. A new clinical BUP PK/PD study in pregnant 
women is ongoing. More patients will be added to the modeling study to enrich the dataset to 
further improve model development and validation. Genotypes of CYPs and UGTs in study 
participants will be also included in further analysis. Developing a buprenorphine population PK-
PD model to evaluate the exposure and response relationship in pregnant women in order to 
optimize buprenorphine dosing in pregnant women is our final goal. 
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5.6 Conclusions 
The population pharmacokinetic model-based analysis demonstrated that pregnancy is 
associated with significant increase in the apparent clearance of BUP following SL administration. 
The currently recommended doses of BUP may need to be increased or the dosing frequency to be 
increased from BID to TID in pregnant women in order to achieve exposures comparable to those 
in non-pregnant women. The pharmacokinetic model-based analysis is a useful tool to evaluate 
changes in pharmacokinetics of drugs used during pregnancy in an attempt to optimize 
pharmacotherapy in pregnant women, obviating the need to perform pharmacokinetic studies in 
each trimester and the postpartum period that normally require intensive blood sampling.
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6.1 Abstract 
Introduction: Drug addiction has become a nationwide health crisis in the United States. 
Recently there has been a significant increase in opioid use during pregnancy. Correspondingly, 
the number of newborns exhibiting opioid withdrawal after birth has increased by 5 times from 
2000 to 2012. Several studies have reported that the use of buprenorphine (BUP) results in a lower 
incidence and less severe neonatal abstinence syndromes (NAS). Our aims were to evaluate the 
effect of buprenorphine on various psychological and physiological parameters such as Clinical 
Opioid Withdrawal Scale (COWS) score, and pupillary diameters in order to understand the 
pharmacodynamics of BUP in pregnancy women. 
Methods: Data from two clinical studies were used in the present modeling analysis. Study 
1 involved pregnant, singleton gestation women who were stabilized on twice-daily sublingual 
BUP opioid substitution therapy (2- 16 mg) for at least 7 days prior to the study day. This was a 
prospective, open-label, non-randomized longitudinal BUP PK study. Up to 3 studies (the 2nd, 3rd 
trimester, and postpartum) were performed in each participant. The COWS scores and pupillary 
diameter sizes were collected at trough (before a dose), 4, 8, and 12 hrs after a dose of 
buprenorphine. For the second study, the design of the pharmacokinetic portion was similar to 
study 1, but patient recruitment was classified as 1st, 2nd – half of pregnancy and postpartum period. 
The dosing frequency of BUP in participants was not restricted to twice daily dose regimen only. 
The COWS scores and pupillary diameters were collected at trough (before a dose), 0.5, 1, 2, 4, 6, 
8, 10, 12 hrs or the end of a dose interval based on the dosing frequency in each patient. Both of 
these studies were approved by the University of Pittsburgh Institutional Review Board. All 
patients were recruited through Magee-Womens Hospital, and written informed consent was 
obtained from all participants. At each study visit, a total of 10 blood samples were collected from 
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0 hours up to 12 hours after a dose or the end of a dosing interval based on the dosing frequency 
in each patient. Plasma concentrations of BUP were quantified using UPLC-MS/MS. A total of 
527 concentration time points, 303 COWS scores, and 303 pupillary diameters from 51 PK study 
occasions in 26 patients were used for the population PK analysis and PD analysis. Non-linear 
mixed effects modeling using the first-order conditional estimation with interaction (FOCE-I) 
method was conducted in NONMEM to analyze the time course of the effect of BUP on pupillary 
diameter.  
Results: Our analysis showed that the average Clinical Opioid Withdrawal Scale (COWS) 
scores were generally higher during pregnancy than postpartum period following administration 
of buprenorphine, which is in agreement with the observed lower buprenorphine exposure during 
pregnancy. A population PK /PD modeling analysis demonstrated that pupillary constriction was 
induced after administration of buprenorphine. The relationship between pupillary diameter and 
buprenorphine concentration was described by a sigmoidal Emax model with a hypothetical effect 
compartment. The model revealed that buprenorphine was transferred from central compartment 
to a biophase compartment with a 1st-order transfer kinetics with a rate constant of 0.723 hr-1 (27.2, 
CV%). The estimated maximal effect (Emax), buprenorphine concentration at effect site exerting a 
half-maximal effect (IC50) and the shape of the sigmoidal factor were 82.9% (4.2 CV%), 0.63 
ng/mL (16.3, CV%), and 82.9 % (4.2, CV%), respectively. 
Conclusions: Clinical Opioid withdrawal Scale scores were significantly higher during 
pregnancy compared to postpartum under the current dose regimen, which suggested a need to 
increase the dose of BUP in pregnant women to reach similar exposure and therapeutic effect in 
non-pregnant subject . The IC50 of BUP was not significantly different during pregnancy and 
postpartum in the PK/PD model analysis of buprenorphine concentration and pupillary diameter, 
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which suggest that there might be no significant changes in the sensitivity or number of µ-opioid 
receptors during pregnancy compared to non-pregnant women. Clinical studies in a larger number 
of patients are needed to validate the findings from the present study. 
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6.2 Introduction 
Opioid addiction has become a crisis in the United States.  From 1999 to 2017 age-adjusted 
drug overdose death rate has increased from 6.1 to 21.7 per 100,000 population [326]. In 2017, 
68% of the drug overdose deaths involved an opioid [327]. There has been a significant increase 
in opioid use during pregnancy during this time period. The 2010 national survey on drug use and 
health conducted by the National Institute on Drug Abuse reported a 47% increase in illicit drug 
use during pregnancy since 2002 (4.4% in 2010 versus 3% in 2002 between the ages of 15 and 44 
of pregnant women) [11]. Another survey conducted between 2005 to 2011showed that among the 
500,000 interviewees, 14% of women received at least one dose of a prescription opioid during 
gestation [328]. Maternal opioid use leads to increased obstetrical complications, including higher 
risks of maternal infections, preterm labor, malnutrition, and fetal death [329]. Prenatal opioid 
exposure can also result in drug withdrawal syndrome in the newborns. The number of newborns 
with neonatal abstinence syndrome (NAS) has increased from 2.8 per 1,000 births in the year 2004 
to 14.4 per 1,000 births in the year 2014 [330]. Despite the barrier function of placenta, many 
substances are able to cross the placenta and reach the fetus by diffusion, carrier-mediated transport 
or transcytosis [129]. After birth, infants experience drug withdrawal symptoms due to the sudden 
cessation of opioids. Infants with NAS may experience sleeping and feeding problems, increased 
muscle tone, increased crying, irritability, seizures, tremors, diarrhea and fever, etc. [331]. The 
types and severity of NAS may differ among infants who experience opioid withdrawal. Neonatal 
abstinence syndrome needs medical interventions. The treatment of NAS requires hospitalization 
as the dosing and frequency of the pharmacotherapy interventions are tailored based on NAS 
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scores of newborns throughout the treatment period. Also, since most of the mediations used for 
treating NAS, such as morphine can cause respiratory depression, infants receiving NAS treatment 
need to be closely monitored. The delay in identifying NAS in newborns may result in infant 
morbidity and mortality [331]. Due to lengthy hospital stays and intensive medical care, the 
average cost of healthcare for newborns with NAS is 10 times higher than newborns without NAS 
[332]. 
Currently, there is no cure for opioid use disorder. However, medication-assisted treatment 
that combines the use of medications with behavioral therapies and counselling can effectively 
improve quality of life, suppress opioid withdrawal symptoms, prevent opioid overdose death, and 
decrease infections (hepatitis B, C and human immunodeficiency virus) in patients [32, 333]. 
Methadone has been approved by the FDA for the treatment of opioid use disorder since 1960s’. 
As a full agonist of µ-opioid receptor, methadone also has abuse potential. Therefore, patients are 
required to visit the clinic daily in order to get a dose of methadone. Buprenorphine was approved 
by the FDA as a maintenance therapy for opioid addiction in 2003. Many clinical studies have 
demonstrated that BUP has comparable efficacy to methadone [16-18]. As a partial agonist of µ-
opioid receptor, buprenorphine has less abuse potential. Buprenorphine is regulated as an office-
based pharmacotherapy for opioid use disorder. During one clinic visit, patients can be prescribed 
buprenorphine supply for one or two weeks. In addition, recently a subcutaneous formulation of 
buprenorphine implanted under skin has been approved by the FDA, which is able to sustain the 
release of buprenorphine for up to 6 months. Due to better accessibility, buprenorphine may 
increase patient compliance to mediation-assisted treatment compared to methadone.  
Neonates with prenatal exposure to methadone or buprenorphine also experience NAS after 
birth as both of the drugs can pass through the placenta barrier. However, recently several studies 
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have reported that BUP exposure may result in less severe and lower incidence of NAS in the 
neonates [15, 19, 20]. On an average, there is a 89% lower morphine requirement, a 43% shorter 
hospital stay, and a 58% shorter duration of medical treatment in neonates with prenatal exposure 
to buprenorphine compared to the neonates who have prenatal exposure to methadone [21]. These 
results support the use of buprenorphine as a potential first-line medication for pregnant opioid-
dependent women.  
However, there is no clear consensus on how to dose buprenorphine in pregnant women. 
Due to the lack clinical pharmacokinetic and pharmacodynamic studies of buprenorphine in 
pregnant women, the current BUP dosing regimen in pregnancy is based on the recommendation 
for non-pregnant females and males. Pregnancy induces many anatomical and physiological 
changes that can impact absorption, distribution, metabolism and elimination (ADME) of drugs. 
The lack of a clear consensus may result in dosing bias by individual physician and in turn may 
affect retention of a pregnant patient in BUP therapy. Recent observation in a small cohort of 
pregnant women by our group has shown that BUP exposure is reduced approximately by half 
during pregnancy compared to the non-pregnant state, but nothing is known about the 
pharmacodynamics of buprenorphine in pregnant women. One of the challenges in dosing BUP in 
pregnant women is the need for balance between the exposure of BUP in the mother and in the 
fetus. In pregnant women, the treatment goal is to maximally inhibit drug withdrawal, craving and 
illicit opioid use of by the mother with a minimum drug exposure to the fetus. It is desirable to 
have a better understanding of BUP PK/PD relationship in pregnant women in order to accomplish 
this.  
The Clinical Opioid Withdrawal Scale (COWS) is commonly used in practice to assess 
opioid withdrawal due to its ease of administration by the clinicians. The dose of medications used 
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to suppress drug withdrawal is tailored to individuals based on the COWS score. The COWS score 
has subjective and objective components. The subjective components include restlessness, bone 
or joint aches, runny nose or tearing, gastrointestinal upset, tremor, yawning, anxiety or irritability. 
These subjective components can be manipulated by the patients. As a result, COWS score can be 
impacted by patients’ responses to certain questions. The reliability of COWS for detecting 
withdrawal needs to be validated by additional studies. 
There is a need to identify a reliable and readily measurable objective marker to assess 
opioid withdrawal in pregnant women. As a maintenance therapy to treat opioid substance 
dependence, BUP crosses brain–blood barrier (BBB) and binds to mu-opioid receptors. The ideal 
marker to assess opioid withdrawal would be to get an estimate of BUP concentration in the brain 
and the mu-opioid receptor occupancy. Utilizing positron emission tomography (PET) scan, 
Greenwald et al. have studied the association of mu-opioid receptor occupancy and opioid 
withdrawal in heroin-dependent patients. The results of the study showed that 50% of mu-opioid 
receptor occupancy is a minimal requirement to suppress drug withdrawal symptoms in heroin-
dependent patients [24]. However, it is not feasible to routinely measure the mu-opioid receptor 
occupancy in patients using PET study in the clinic, especially in pregnant women. Therefore, we 
would like to explore a physiological measurement, mediated by mu-opioid receptor occupancy in 
the brain, as an objective measurement to facilitate optimal dosing of BUP in pregnant women. 
Regulation of pupillary diameter is one of the opioid induced effects in the central nervous system. 
A few clinical studies and our preliminary data in pregnant women have found that BUP can induce 
pupillary constriction [31, 32]. There might be a potential to use pupillometry as an index to 
objectively evaluate opioid withdrawal in patients who use BUP to treat opioid addiction.    
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The objectives of the present study were to evaluate the time courses of the effect of 
buprenorphine on COWS score and pupillary diameters, and to characterize the pharmacodynamic 
properties of buprenorphine during pregnancy. 
6.3 Method 
6.3.1  Clinical study design 
Data from two BUP clinical pharmacokinetic and pharmacodynamic studies were included 
in this pharmacodynamic analysis. 
Study 1 was a prospective, open-label, non-randomized and longitudinal pharmacokinetic 
study of buprenorphine in pregnant and postpartum subjects. This study was approved by the 
University of Pittsburgh Institutional Review Board. Patients were recruited through Magee-
Womens Hospital. Written informed consent was obtained from all participants prior to initiation 
of any study-related activities. Pregnant, singleton gestation women who were stabilized on twice-
daily sublingual BUP opioid substitution therapy (2 - 16 mg) for at least 7 days were participated 
in this study. Up to 3 PK studies were performed in each participant including 2nd (14 weeks, 0 
days through 28 weeks, 0 days), 3rd trimester (28 weeks, 1 day through term), and postpartum 
period (after 4 weeks of delivery). At each PK study visit, a total of 10 blood samples were 
collected in heparinized tubes from each subject at 0 (trough), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 8 and 
12 hours after the dose. After centrifugation of blood, plasma samples were frozen at -80°C until 
analyzed. Several pharmacological effects and physiological measurements including craving 
score, clinical opioid withdrawal (COW) score, pupillary diameter size, respiration rate, blood 
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pressure, as well as body temperature were collected at 0 (trough), 4, 8 and 12 hours after 
buprenorphine dose. 
Study 2 was a BUP PK/PD study in pregnant women to assess the association between 
BUP plasma concentrations and PD effects. Pregnant, singleton gestation women who were 
stabilized on sublingual BUP opioid substitution therapy for at least 7 days were recruited in this 
prospective, open-label, non-randomized longitudinal BUP PK study. Up to 3 studies were 
performed in each participant including 1st-half of pregnancy (gestational week < 20 weeks), 2nd-
half of pregnancy (gestational week ≥ 20 weeks), and postpartum (at least 4 weeks after delivery). 
The study was approved by the University of Pittsburgh Institutional Review Board. All patients 
were recruited through Magee-Womens Hospital, and written informed consent was obtained 
from all participants. At each study visit, a total of 10-13 blood samples were collected from 0 
hours up to 12 hours after the dose or till the end of a dose interval. Several pharmacological effects 
and physiological measurements including craving score, clinical opioid withdrawal (COW) score, 
pupillary diameter size, galvanic response, respiration rate, blood pressure, as well as body 
temperature were collected at 0, 0.5, 1, 1.5, 2, and every two hours afterwards until the end of the 
dosing interval.  
6.3.2   Determination of buprenorphine concentration in plasma 
The concentrations of BUP in plasma samples from study 1 were quantified using a 
validated ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-
MS/MS). Briefly, 500 μL of plasma samples containing buprenorphine and the deuterated internal 
standard (buprenorphine-d4) were extracted using pre-conditioned Strata X-C cartridges. The 
cartridge was washed with 1 mL of 2% formic acid in water for two times, followed with 1 mL of 
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2% formic acid in methanol for one time. Buprenorphine and the internal standard were eluted and 
collected. The eluent was evaporated, reconstituted and an aliquot was injected in an Acquity 
UPLC Ethylene Bridged Hybrid (BEH) C18 1.7 µm column (2.1x100 mm) equipped with Waters 
ACQUITY UPLC system tandem Thermo TQS Quantum Ultra™ Triple Quadrupole Mass 
Spectrometer. Calibration curves were linear in the range 0.05–50 ng/mL.  Both the intraday and 
interday precisions assessed by coefficient of variation values and the accuracy assessed by bias 
were within 15% of the nominal concentrations. 
The concentrations of BUP in plasma samples from Study 2 were quantified using a 
validated ultra-performance liquid with tandem mass spectrometric assay (UPLC-MS/MS). Two 
hundred of plasma sample containing deuterated compound of buprenorphine-D4 chromatography 
were processed with protein precipitation prior to chromatography. Chromatographic separation 
was performed using Acquity UPLC Ethylene Bridged Hybrid (BEH) C18 1.7 µm column (2.1x100 
mm) with a mobile phase consisting of [A] 5% Acetonitrile in water containing ammonium acetate 
(2 mM) and formic acid (0.1%), and [B] Acetonitrile containing ammonium acetate (2 mM) and 
formic acid (0.1%) delivered at a flow rate of 0.3 mL/min in a gradient elution. The analytes were 
detected by a XEVO TQS mass spectrometer in positive electron spray ionization (ESI) mode 
using multiple reaction monitoring (MRM). The assay was linear over the range of 0.05–100 
ng/mL for buprenorphine. Both the intraday and interday precisions assessed by coefficient of 
variation values and the accuracy assessed by bias were within 15% of the nominal concentrations. 
6.3.3   Measurement of pupillary diameter 
Pupillary diameter was measured by trained study nurses using an infrared portable 
pupillometer (VIP®-300, Neuroptics®, San Clemente, CA). Before the measurement of pupil 
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diameter, patients were required to sit in a low light room for at least 3 minutes in order to avoid 
any impact of environmental factors on pupill size. Three repetitive measurements were made 
(within 30 second) at each time point and the mean value was used in the analysis. 
6.3.4   Assessment of craving score and COWS score 
The COWS scores were collected by trained study nurses. The area under the curves of 
COWS scores during a dosing interval (AUC0-t) was calculated from time 0 to 12 hours or the end 
of a dosing interval using trapezoidal rule. Box-Cox transformation were applied to the AUCs of 
COWS scores to generate approximately normally distributed data for the purpose of statistical 
analysis. A univariate linear mixed effect model was used to compare the statistical difference in 
the AUCs of COWS scores during pregnancy vs postpartum period. In the linear mixed effect 
model, time was treated as fixed effect, subject was treated as random effect. The linear mixed 
effect model was fitted through maximum likelihood estimation in Stata (Version 14.0 SE). 
6.3.5  Population pharmacokinetic /pharmacodynamic Analysis 
Non-linear mixed effects model (NONMEM) using the first-order conditional estimation 
with interaction (FOCE-I) was applied to develop a buprenorphine population PK/PD model to 
describe the relationship between plasma concentration of BUP and pupillary diameter. 
Stepwise model development approach was applied to develop a PK/PD model. (1). In the 
PK model, fixed and random effects were estimated to describe the time course of buprenorphine 
plasma concentration after sublingual administration. (2) The pupillary diameter size was 
modelled as a function of BUP plasma concentration (Cp) or as a function of predicted BUP 
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concentration (Ce) in a theoretic effect compartment. In the PD modeling, the PK parameters for 
each individual estimated by the PK model were incorporated. Fixed and random effects were 
estimated to describe the time course of pupil diameter driven by Ce or Cp of buprenorphine after 
a dose. 
The buprenorphine population PK model was developed in two steps. First, the structural 
model was explored and selected to describe the absorption and disposition of buprenorphine. 
Because BUP was administered sublingually, structural model evaluation included extensive 
exploration of different absorption models to optimize model fitting in the absorption phase. After 
optimization of the structural model, the effects of demographic and other patient covariates (age, 
pregnancy, body weight and gestational weeks, etc.) were evaluated through PK parameter vs 
covariate plots. The covariates that are potentially associated with PK parameters from visual 
check was further investigated via bootstrap stepwise forward/ backward covariate evaluation 
(SCM, forward addition, p < 0.05; backward elimination p < 0.01).  
Based on prior information and plots such as mean pupillary diameter vs time and quartiles 
of BUP concentration vs pupillary diameter, a sigmoid Emax function was assumed for the 
relationship between pupillary diameter and buprenorphine concentration in plasma (Cp) or in the 
effect compartment (Ce). The miotic effect of buprenorphine on pupil diameter is evaluated by the 
following equation, 
Pupil size = 𝐸𝐸0 - 
1
100
 × 𝐸𝐸0 × (𝐼𝐼𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐴𝐴𝑝𝑝𝛾𝛾𝐼𝐼𝐴𝐴50𝛾𝛾 + 𝐴𝐴𝑝𝑝𝛾𝛾 )                           (as a function of CP) 
Pupil size = 𝐸𝐸0 - 
1
100
 × 𝐸𝐸0 × (𝐼𝐼𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐴𝐴𝑒𝑒𝛾𝛾𝐼𝐼𝐴𝐴50𝛾𝛾 + 𝐴𝐴𝑒𝑒𝛾𝛾 )                           (as a function of Ce) 
Where E0 is the baseline pupil diameter, Emax is the percentage of maximum changes of 
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buprenorphine induced miotic effect compared to baseline value. EC50 is the concentration of 
buprenorphine at 50% of maximum effect, 𝛾𝛾 is the shape factor of the sigmoidal Emax function. 
The parameter estimation of a model was a process of minimization of the objective 
function value (OFV, approximately equal to -2 ×log of the likelihood) using maximum likelihood 
estimation.  
For the discrimination between different models, Akaike information criterion (AIC) was 
used to compare non-nested models. As OFV approximately follows χ2 distribution and a 
likelihood ratio test was employed to compare the difference of two nested models. For adding 
one additional parameter to a model, a decrease of 3.84, 6.63, or 7.88 in OFV was used as a cutoff 
for significant improvement in model fit at respectively 5%, 1% and 0.5% levels of rejecting the 
null hypothesis (there are no significant difference in the two models) due to type I error.  In 
addition, certain diagnostic plots, such as goodness-of-fit plot, plot of individual observed 
concentration time profile overlaid with population prediction and individual prediction, 
conditional weighted residual against time plot, and individual weighted residual against time plot 
were also employed during model selection. 
The magnitude of the differences between subjects and between occasions within a subject 
at model parameter level were estimated by the between subject variability (BSV) and between 
occasions variability (BOV). As a log-normal distribution across the population for each parameter 
was assumed, the exponential models were used to estimate BSV and BOV. The residuals, (the 
difference between observed and predicted concentration of buprenorphine), were assumed to have 
a normal distribution and centered on zero. Additive only, proportional only, and the combined 
additive and proportional error models were tested during the selection of the error model. 
206 
The performance of the final model fitting was evaluated by the goodness-of-fit plot, 
prediction-corrected visual predictive check (pcVPC), and non-parametric bootstrap. In the VPC 
procedure, 1000 replicate datasets were simulated with the original dataset design. Variability was 
introduced into the replicate datasets by random sampling from matrices of random effects in the 
final model. The VPC plot constructed the 95% prediction interval of the 5th, 50th and 95th 
percentiles from the 1000 replicate datasets against the 5th, 50th and 95th percentiles of the observed 
concentration-time profiles, which was used to graphically assess whether the simulations from 
the final model was able to reproduce the central trend and variability in the observed dataset. 
Using sampling with replacement of random subject in the original dataset, 200 of bootstrap 
datasets were generated containing the same subject numbers as the original dataset. The 90% of 
prediction intervals of the bootstrap datasets were compared with the parameter estimates from the 
final model. 
6.3.6   Software 
The population PK /PD analysis was performed in NONMEM, version 7.3.0. Graphical 
diagnostics and exploratory analysis were conducted using R (Version 3.4.4) and Xpose (Version 
4). Pirana® was used as an interface to integrate these software. 
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6.4   Results 
6.4.1  Clinical data 
A total of 527 buprenorphine plasma concentrations, 303 COWS scores, and 303 pupillary 
diameters from 51 PK/PD study occasions in 26 patients from the two clinical studies were used 
for the PK /PD analysis. The characteristics of study subjects are summarized in Table 28.  
6.4.2   COWS scores and BUP exposure during pregnancy and postpartum 
The time course of mean COWS score following administration of BUP in the two clinical 
studies are shown in Figure 6-1. The plots showed that COWS scores were higher during 
pregnancy than the values during postpartum period. The linear mixed effect model analysis found 
that the AUCs of COWS scores in a dose interval were significantly higher during pregnancy 
compared to the values at postpartum period, whereas, the exposure of BUP were significantly 
lower during pregnancy compared to the values at postpartum period (Table 6-1). We also explored 
the relationship between BUP exposure and COWS score as shown in Figure 6-2, 6-3.
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Figure 6-1. Mean COWS score time profiles following administration of a SL BUP dose.  
Red, green and blue curves represent study at the 1st- and 2nd-trimester, 3rd-trimester and 
postpartum, respectively. 
N = 19 (2, 9 and 8 patients completed study in 6, 8 and 12 hrs, respectively), 18 (4,1 and 13 patients 
completed study in 6, 8 and 12 hrs, respectively), and 14 (3 and 11 patients completed study in 6 
and 12 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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Table 6-1.  The AUCs of Clinical Opioid Withdrawal Scale score and BUP exposure within 
a dose interval during pregnancy and postpartum (expressed as mean (SD)) 
 
Parameter 
(Mean (SD)) 
1st- and 2nd-
trimester 
(n = 19) 
3rd-trimester 
(n = 18) 
Postpartum 
(n = 12)*              P Value 
AUC_COWS 16.79 (17.02) 16.50 (12.45) 
9.14  
(12.61) 
0.001, 1st- and 2nd-trimester vs 
postpartum 
< 0.001, 3rd- trimester vs postpartum 
AUC_BUP 12.36  (5.79) 18.97 (13.09) 
28.76  
(20.49) 
< 0.001, 1st- and 2nd-trimester vs 
postpartum 
 0.02, 3rd- trimester vs postpartum 
Box-Cox transformation of AUC_COWS; Log transformation of AUC_BUP 
*: Two patients terminated study earlier and the AUC of COWS score were not able to calculate.
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Figure 6-2. BUP plasma concentration vs Clinical Opioid Withdrawal Scale score.  
The dot represents COWS score vs BUP plasma concentration that were measured at the same 
time point. The matrix plot suggests that there is no simple linear correlation between COWS score 
and buprenorphine plasma concentration. 
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Figure 6-3. The changes of AUCs of COWS score from baseline vs BUP AUC.  
The AUC of COWS score at baseline were calculated by applying COWS score at trough to the 
entire dose interval. The dot represents the change of area under the time course of COWS score 
vs area under the time course of BUP plasma concentration during one dose interval in one PK 
study occasion in one patient. The matrix plot suggests that there is no simple linear correlation 
between the change of the AUC of COWS score and buprenorphine plasma concentration. 
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6.4.3   Buprenorphine induced miotic effect 
6.4.3.1  Basic exposure and response exploration 
 
Before modeling analysis, we did some basic plots to identify the relationship between 
buprenorphine exposure and pupillary diameter (Figure 6-4, 6-5 and 6-6). 
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Figure 6-4. BUP plasma concentration vs pupillary diameter 
The dot represents pupillary diameter with BUP plasma concentration that were measured at the 
same time point. The matrix plot between pupillary diameter and buprenorphine plasma 
concentration suggests that the miotic effect induced by administration of BUP is probably via an 
Emax relationship.  
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Figure 6-5. BUP exposure (AUC) vs the AUC of pupillary diameter 
The dot represents the area under the time course of pupillary diameter vs the area under the time 
course of BUP plasma concentration during a dose interval in one PK study occasion in one patient. 
The matrix plot suggests that there is no simple linear correlation between the AUC of pupillary 
diameter and the AUC of buprenorphine. 
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Figure 6-6. Time course of pupillary diameter following SL administration of BUP by study 
occasion 
Red, green and blue curves represent study at the 1st- and 2nd-trimester, 3rd-trimester and 
postpartum, respectively. 
N = 19 (2, 9 and 8 patients completed study in 6, 8 and 12 hrs, respectively), 18 (4,1 and 13 patients 
completed study in 6, 8 and 12 hrs, respectively), and 14 (3 and 11 patients completed study in 6 
and 12 hrs) at the 1st-half, 2nd-half of pregnancy and postpartum, respectively. 
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6.4.3.2 Model analysis 
The modeling of buprenorphine PK has been reported in Chapter 5. The results of the 
population PK /PD model showed that a hypothetical effect compartment best described 
buprenorphine induced miotic effect (Figure 6-7.). Linking pupil diameter sizes to predicted 
buprenorphine concentrations in a hypothetical effect compartment resulted a drop in AIC of 29.4 
compared to a sigmoidal Emax model. As the effect compartment was a hypothetical compartment, 
there was no mass transfer between central compartment and the hypothetical effect compartment. 
The differential equation for the hypothetical effect compartment is listed below. 
        𝑑𝑑𝑑𝑑7
𝑑𝑑𝑑𝑑
 = 𝑘𝑘𝑅𝑅0 ×  
𝑑𝑑2
𝑉𝑉2
 - 𝑘𝑘𝑅𝑅0 ×  𝑋𝑋7 
Where X2 is the amount of buprenorphine in the central compartment. X7 is the 
concentration of buprenorphine in the hypothetical compartment. V2 was the apparent volume 
distribution of buprenorphine in the central compartment and t represented time. Ke0 was the 1st-
order rate constant of the transfer of the concentration of BUP from central compartment to the 
hypothetical effect compartment. 
The results of the population PK /PD modelling analysis are shown in Table 6-2. The model 
estimated that buprenorphine was very potent in inducing miotic effect with a value of EC50 at 
0.63 ng/mL. The baseline pupillary diameter was estimated as 9.65 mm, which represented the 
typical pupil diameter size in an opioid addicted patient without buprenorphine exposure. The 
transfer of BUP from central compartment to the hypothetical effect compartment was modeled 
by 1st-order kinetics. The estimated rate constant of distribution of BUP from the central 
compartment to the hypothetical effect compartment was 0.723 hr-1, which indicates that the 
transfer half-life between plasma and effect site was approximately 57 min (ln2/ke0). All of the 
215 
typical values and variance were estimated precisely, as the relative standard errors were all within 
30%. 
6.4.4  Model evaluation 
In the goodness-of-fit plots, the observed pupillary diameter against population predicted 
concentration or individual predicted pupillary diameter were clustered towards the lines of 
identity. The conditional weighted residuals data were symmetrically distributed around the line 
of zero and majority of the residuals were within the range of 2 times the standard deviations 
(Figure 6-8).  
The VPC plot displayed that the 5th, 50th, and 95th percentiles of the observed pupillary 
diameter were within 95% predicted interval from 1000 simulated replicate datasets. Also, most 
of the observed pupillary diameter were within the predicted 95% intervals as shown in Figure 6-
9.  
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Figure 6-7. Schematic diagram of the final population pharmacokinetic /pharmacodynamic model 
k12, first-order absorption rate constant; k23 and k32, rate constant for distribution of buprenorphine between central and peripheral 
compartment; k20, first-order elimination rate constant; k41, rate constant for the distribution of buprenorphine from gall bladder to dose 
compartment; ke0, rate constant of distribution of BUP from central compartment to the hypothetical effect compartment; GB, gall 
bladder
k12 
    Dose Central CMT 
  Peripheral CMT 
k20 
  Gall Bladder 
Hypothetical 
Effect CMT 
ke0 
Pupillary 
Constriction 
ke0 
Pupil size = 𝐸𝐸0 - 
1
100
 × 𝐸𝐸0 × (𝐼𝐼𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐴𝐴𝑒𝑒𝛾𝛾𝐼𝐼𝐴𝐴50𝛾𝛾 + 𝐴𝐴𝑒𝑒𝛾𝛾 ) 
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Table 6-2.  Parameter estimates of final population pharmacokinetic /pharmacodynamic 
model for buprenorphine following sublingual administration in pregnant women 
Parameter Final model estimate (RSE %) Bootstrap (n=500) 
Median (95% CI) 
Population typical value 
Emax (%) 82.9 (4.2) 69.9 (36.1 – 96.4) 
EC50 (ng/mL) 0.63 (16.3) 0.65 (0.29 – 1.63) 
Gamma 0.396 (15.3) 0.518 (0.253 – 1.479) 
Baseline (mm) 9.65 (0.3) 9.16 (6.67 – 9.99) 
ke0 (hr-1) 0.723 (27.2) 0.722 (0.366 – 1.157) 
Interindividual variability (expressed as % CV) 
Baseline 18.8 (18.5) 15.9 (0.1 – 24.5) 
Gamma 68.8 (28.2) 80.2 (44.0 – 126.6) 
Interoccasion variability (expressed as % CV) 
Baseline 9.7 (20.5) 9.2 (4.3 – 15.5) 
Residual variability  
Additive error (mm) 0.24 (9.3) 0.34 (0.19 – 0.28) 
CI: confidence interval; Emax: percentage of maximum changes of buprenorphine induced miotic 
effect compared to baseline pupillary diameter; IC50: buprenorphine concentration to product a 
half-maximal effect; Gamma: the shape of the sigmoidal factor; Baseline: pupil diameter size in 
opioid addicted patient without buprenorphine exposure in the body of patients; ke0, rate constant 
of distribution of BUP from central compartment to the hypothetical effect compartment. 
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Figure 6-8. Goodness of fit diagnostic plots for buprenorphine population PK /PD final 
model fit.  
 
(A) Individual predicted pupil diameter vs. observed pupil diameter. (B) Population predicted 
pupil diameter vs. observed pupil diameter. (C) Conditional weighted residuals vs. population 
predictions (D) Conditional weighted residuals vs. sample collection time after a dose. The solid 
black lines in (a) and (b) represent the line of identity and those in (c) and (d) represent the line y 
= 0. The solid red lines in each panel represent loess smooth of the data.  
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Figure 6-9. Predictive performance of the final model using prediction-corrected visual 
predictive check plots.  
The model predicted pupil diameter were plotted against observed pupil diameter at each time 
point after a dose. Y-axis, Dependent variable represented pupil diameter; x-axis, Independent 
variable represented time after a dose. Open dots represented observed pupil diameters, solid blue 
lines represented the 5th, and 95th percentiles of observed pupil diameters; the solid red lines 
represented the 50th percentiles of the observed pupil diameter; shaded area represented the model 
predicted 95% confident intervals surrounding the 5th, 50th, and 95th percentiles from 1000 
simulated datasets.  
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6.5 Discussion 
In the present analysis, we evaluated the pharmacodynamics of buprenorphine in pregnant 
women. A linear mixed effect model analysis indicated that the AUCs of COWS scores in a dosing 
interval were significantly higher during pregnancy compared to the values during the postpartum 
period, which may be due to the significantly lower buprenorphine exposure in pregnant women 
that is observed in the clinical studies. A population PK /PD modeling analysis demonstrated that 
pupillary constriction was induced after administration of buprenorphine. The relationship 
between pupillary diameter and buprenorphine concentration was described by a sigmoidal Emax 
model with a hypothetical effect compartment. A time delay between buprenorphine plasma 
concentration and pupillary constriction indicates that there was a temporal dissociation of the 
distribution of buprenorphine between central and biophase compartment. The equilibrium half-
life was 57 mins. The temporal dissociation between the time courses of buprenorphine plasma 
concentration and miotic effect may be due to the transfer of buprenorphine from blood to central 
nervous system. The IC50 of BUP was not significantly different during pregnancy and postpartum 
in the PK/PD model analysis of buprenorphine concentration and pupillary diameter, which 
suggested that there might be no significant changes in the sensitivity or number of µ-opioid 
receptors during pregnancy compared to non-pregnant women. 
As the two BUP clinical studies were observational studies, the doses of BUP administered 
in study participants were prescribed for clinical purposes by caregivers of each individual patient. 
We used observed, rather than dose-normalized, AUC of BUP plasma concentration to evaluate 
the exposure of BUP in pregnant women. Using the observed AUC enables us to assess if the 
exposure of BUP is comparable in pregnant and non-pregnant women under the current clinic 
practice. The results revealed that the exposure of BUP as measured by the AUC in a dose interval 
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at steady state were significantly lower during pregnancy compared to the exposure during 
postpartum period.  
The pharmacodynamic effect of buprenorphine inhibiting opioid withdrawal were assessed 
by COWS score in the two BUP clinical studies. The AUCs of COWS scores in a dosing interval 
of BUP were significantly higher during pregnancy than during postpartum. We also observed 
large interindividual variabilities in COWS scores. At prescribed doses, BUP is able to minimize 
opioid withdrawal symptoms and cravings in patients and eventually to help patients function 
normally. Lower the COWS score, better the patients feel; higher the COWS score, less satisfied 
the patients are. The observed significantly greater COWS scores during pregnancy compared to 
postpartum is likely the result of the lower buprenorphine exposure in pregnant women. A matrix 
plot suggested that that there was no relationship between COWS score and BUP plasma 
concentration. Further PK/PD analysis to study the correlation between BUP concentration and 
COWS score is needed.  
As a substrate of µ-opioid receptor, buprenorphine binds to µ-opioid receptor in the central 
nervous system. The pharmacological effects associated with BUP binding to µ-opioid receptors 
include pain modulation, euphoria, pupillary constriction, etc. In the two BUP clinical studies, we 
observed that following administration of BUP miosis occurred and the sizes of pupillary diameter 
gradually returned back to the values of baseline at the end of a dose interval. Pupillary size is 
determined by the dilation or constriction of iris through sympathetic and parasympathetic nervous 
system. Opioids induced pupillary constriction has been observed in human, rabbits and dogs. 
Whereas, pupillary dilation has been seen in rats, mice, and cats. It has been shown that the opioid 
induced miosis or mydriasis are opioid receptor-mediated as these changes can be blocked by µ-
opioid receptor antagonist, naloxone [25]. Currently, the exact site of action opioid mediated 
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pupillary diameter change is not clear; however, it is believed that the action site should be within 
the brain as no pupillary effect was observed by intraocular administration of morphine and the 
effective dose of morphine following an intracerebroventricular injection was hundredths of the 
intravenous administration [26, 27]. The possible mechanism of the pupillary constriction by 
opioids may be through the suppression of the inhibitory process to Edinger-Westphal nucleus, a 
place in the midbrain that regulates signal to iris muscle resulting in pupillary constriction [28, 29]. 
Several studies have observed that higher plasma concentration of morphine and methadone results 
in more pronounced effects on pupillary constriction or dilation in human and rats [30-35].  
The population PK/PD modelling analysis of BUP concentration and pupillary diameter 
revealed that the miotic effect induced by administration of BUP can be described by an Emax 
relationship. The population PK/PD model estimated the concentration of BUP to induce half 
maximal constrictive effect of pupillary diameter to be 0.63 ng/mL. The small value of IC50 
estimated by the model is consistent with high potency of buprenorphine for µ-opioid receptors as 
compared with other opioids. The IC50 of morphine and codeine for the miotic effects were 4.56 
and 8.44 ng/mL [334]. The IC50 of BUP was not significantly different during pregnant and 
postpartum in the PK/PD model analysis, which suggested that there might be no significant 
changes in the sensitivity or number of µ-opioid receptors during pregnancy compared to 
postpartum. Lack of significant changes in the IC50 of BUP during pregnancy and postpartum 
might be a result of low power to identify statistically significant difference due to small patient 
sample sizes in the two BUP clinical studies. Clinical studies in larger patient population are 
needed to validate these findings from the present study. 
The present population PK/PD modelling analysis of the relationship between pupillary 
diameters following administration of BUP only included BUP plasma concentration. Potential 
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miotic effects induced by the metabolites of BUP were not incorporated into the pharmacodynamic 
model. After administration, buprenorphine is extensively metabolized to norbuprenorphine, and 
norbuprenorphine is further metabolized to norbuprenorphine glucuronide. In addition, a portion 
of buprenorphine is directly conjugated to buprenorphine glucuronide. In vitro study showed that 
both norbuprenorphine and buprenorphine glucuronide also bind to mu-opioid receptors [95]. 
However, norbuprenorphine was found to be a substrate of P-glycoprotein, which may result in a 
limited exposure of norbuprenorphine in the brain [291]. The exposure of norbuprenorphine in the 
brain is limited based on the reported data from postmortem brain samples. In 6 overdose death 
cases, the concentrations of norbuprenorphine was 5.8 ng/g (BUP concentration was 151 ng/g) in 
one postmortem brain sample, and were not detectable in the other 5 postmortem brain samples 
(BUP concentration in these postmortem brain samples ranged 7.1 – 76.1 ng/g) [292]. Studies have 
found that morphine-6-glucuronide can induce pupillary constriction, but it was 22 times less 
potent than morphine [335]. Similar to morphine-6-glucuronide, as a substrate of mu-opioid 
agonist, the IC50 of buprenorphine glucuronide was higher than buprenorphine (4.9 pM vs 2.7 pM) 
[95]. Considering that only a small portion of the administered dose of BUP is converted to BUP 
glucuronide and that buprenorphine glucuronide is more polar, the concentration of buprenorphine 
glucuronide might be limited in the brain. Taken together, it is anticipated that the contribution 
towards the pharmacological effects in the brain by the metabolites of BUP should be very limited. 
In clinical study 1, pupil diameters were only collected at trough, 4, 8 and 12 hours after a 
dose of buprenorphine. In the second clinical study, the dose frequency of buprenorphine were 
three times a day or four times a day for most of the study participants. Only limited pupillary 
diameter sizes were collected at 10 and 12 hours after a BUP dose, which made the population PK 
/PD model inadequate to describe the time courses of pupil diameter after 10 hours following a 
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buprenorphine dose. In addition, we were unable to collect the true baseline of the pupil diameter 
when there was no buprenorphine exposure in the patients. The baseline pupil diameter was 
estimated by the model, which were predictions of the pupil diameter sizes when there was no 
buprenorphine in the patient.  
Large interindividual variability was found in pupillary diameter in the clinical studies. The 
model estimated that the coefficient of variance of the shape of the sigmoidal Emax model was 
68.8%. Also, adding interoccasion variability to the baseline pupil diameter improved the model 
fit significantly. Although pupillary diameter is correlated with administration of BUP as shown 
in this modeling analysis, pupillary diameter may not be a meaningful biomarker to infer plasma 
concentration of buprenorphine in maintenance therapy as there is no direct link to the plasma 
concentration of BUP, and there is large interindividual and interoccasion variabilities. Further 
investigation of reliable and readily measurable biomarkers that are able to objectively assess 
opioid withdrawal to optimize dosing in pregnant women is warranted.   
6.6 Conclusions 
In the present study, we observed significantly lower plasma exposure of BUP and 
significantly higher AUC of COWS score in a dosing interval of BUP during pregnancy compared 
to the values during the postpartum period under the current dose regimen in pregnant women. 
There were no direct correlations between COWS score, pupillary diameter and the plasm 
concentration of BUP. The IC50 of BUP was not significantly different during pregnant and 
postpartum in the PK/PD model analysis of pupillary diameter. The results suggest an increase in 
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BUP doses may be needed during pregnancy in order to maintain a comparable BUP exposure and 
therapeutic effects of BUP in treating opioid use disorder. 
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  SUMMARY AND FUTURE DIRECTIONS
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7.1  Summary and Clinical Inference 
Ideally, it is better to avoid medications during pregnancy because of the concerns for fetal 
safety. Pregnant women, however, may take medications to treat pregnancy related complications, 
such as nausea and vomiting, gestational diabetes, preeclampsia, hypertension, depression, and 
preterm delivery. Pregnant women may also take medications because of chronic preexisting 
illnesses, and substance abuse disorder. A survey showed that 96% of the pregnant women 
received at least one medication during their pregnancy and more than 62% of them used over the 
counter medications [336]. The average number of medication used during pregnancy increased 
from 2.5 in 1970’s to 4.2 in 2000’s [337]. However, limited data exists on changes in the PK/PD 
of drugs in pregnant women. Ironically, dosage regimens that are used in pregnancy are based on 
the recommendations for non-pregnant women and men, because pregnant women are normally 
excluded from clinical studies during drug development due to fetal safety issues. Use of 
medications during pregnancy which are not titrated for pregnancy induced alterations in 
physiological conditions may lead to therapeutic failure or drug related toxicities.  
Pregnancy can alter drug disposition. Pregnancy induces many physiological changes 
including the development of placental-fetal compartment, increase in renal filtration, increase in 
fluid volume, increase in hepatic portal blood flow, as well as changes in the expression and 
activity of several drug metabolizing enzymes [125, 145, 147]. These pregnancy-induced 
physiological changes can impact drug absorption, distribution, metabolism, and elimination 
[148]. Specifically, pregnancy results in a decreased rate of absorption of certain drugs due to 
decreased gastric emptying and decreased intestinal motility. The exposure of certain drugs used 
during pregnancy may be decreased or increased depending on how the activity of drug 
metabolizing enzymes and transporters in the gut are altered during pregnancy. Pregnancy leads 
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to an increased volume of distribution because of the increased body fat, total body water, and 
blood volume. Pregnancy effect on metabolism of drug is drug specific. For example, the 
metabolism of drugs mediated by cytochrome P-450 (CYP) 2C9, CYP2D6, CYP3A4, uridine 5'-
diphospho-glucuronosyltransferase (UGT) 1A4, and UGT2B7 are enhanced, whereas the 
metabolism of substrates of CYP1A2 and CYP2C19 are decreased [158]. Taken together, the 
physiologic and PK changes associated with pregnancy may result in an altered systemic exposure, 
and ultimately, lead to alterations in the efficacy and toxicity of drugs used in pregnant women. 
Several clinical studies have found significant changes in systemic exposure of certain drugs used 
during pregnancy [161-163]. Recent NICHD initiatives have focused on gathering more 
pharmacological data on drugs used in pregnancy. However, clinical studies in pregnant women 
are challenging and difficult to perform. Modeling and simulation has the potential to predict drug 
exposure in the presence of physiologic changes seen in pregnant women that can alter drug 
elimination and drug exposure and therefore drug response.  This body of work is one of our first 
attempts to understand the pharmacokinetic and pharmacodynamic changes induced by pregnancy 
by combining small cohort clinical studies with different modeling approaches. We illustrated our 
approach using buprenorphine, a treatment option for substance abuse disorder in pregnant 
women.  
In Chapter 2, we report the development and validation of a rapid, sensitive, and selective 
method for the determination of buprenorphine and its three metabolites, norbuprenorphine, 
buprenorphine glucuronide, and norbuprenorphine glucuronide, in human plasma using ultra 
performance liquid chromatography with tandem mass spectrometry (UPLC–MS/MS). A sample 
volume of 200 µL of plasma was sufficient for quantification of BUP and its metabolites. Protein 
precipitation was applied to process plasma samples prior to chromatography. Deuterated 
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buprenorphine-D4, norbuprenorphine-D3, buprenorphine-D4-3-β-D-glucuronide, 
norbuprenorphine glucuronide-D3, were used as the internal standards (IS). Chromatographic 
separation was performed using Acquity UPLC Ethylene Bridged Hybrid (BEH) C18 1.7 µm 
column (2.1x100 mm) with a mobile phase consisting of [A] 5% Acetonitrile in water containing 
ammonium acetate (2 mM) and formic acid (0.1%), and [B] Acetonitrile containing ammonium 
acetate (2 mM) and formic acid (0.1%) delivered at a flow rate of 0.3 mL/min in a gradient elution. 
The total run-time was 7 min, with buprenorphine, norbuprenorphine, buprenorphine glucuronide 
and norbuprenorphine glucuronide eluting at 3.3, 1.64, 1.35, and 0.84 min, respectively. The 
analytes were detected by a XEVO TQS mass spectrometer in positive electron spray ionization 
(ESI) mode using multiple reaction monitoring (MRM). The assay was linear over the range of 
0.05 – 100 ng/mL for buprenorphine, 0.2 – 100 ng/mL for norbuprenorphine, 0.2-200 ng/mL for 
buprenorphine glucuronide and norbuprenorphine glucuronide. The intra-day and inter-day 
accuracies expressed as percentage of the nominal concentrations were within 98.2-108.0 %. The 
intra-day and inter-day precision determined by the coefficient of variations were within 9 %. No 
significant matrix effects were observed for buprenorphine or the three metabolites in plasma 
samples. Buprenorphine and the three metabolites were stable under various storage and 
experimental conditions. This validated method was successfully applied to a clinical 
pharmacokinetic study after sublingual administration of buprenorphine to pregnant women at 
different trimesters and during postpartum. We observed a lower exposure of buprenorphine 
during pregnancy compared to postpartum. The AUC ratios of metabolites to parents demonstrated 
that CYP- and UGT- mediated buprenorphine metabolism were altered during pregnancy 
compared to postpartum, which may partially explain the lower exposure of buprenorphine during 
pregnancy.  
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In the next step we applied PBPK and PopPK approaches to evaluate the impact of 
pregnancy on BUP PK. In Chapter 3, we reported the process of building and validating a full-
PBPK models of intravenous (IV) BUP in healthy non-opioid dependent and opioid dependent 
patient populations across a wide range of BUP doses. The full-PBPK models incorporate data on 
enzymatic metabolism of BUP and its distribution into 13 major tissues in the body following IV 
dosage. BUP PBPK IV models was able to predict BUP exposure in healthy population in the dose 
ranges of 4 to 32 mg. The predicted concentration-time profiles in the study-matched virtual patient 
population are consistent with the observed data across 5 independent studies in healthy non-opioid 
dependent and opioid dependent patient populations. The predicted IV BUP PK parameters fell 
within 85%-115% range of the corresponding PK parameters calculated from the IV BUP studies. 
BUP SL PBPK model was built by introducing SL absorption component to the validated IV BUP 
PBPK model, and validated through published clinical studies in healthy non-opioid dependent 
and opioid dependent patients. We performed inter-study and intra-study validations by comparing 
the mean area under plasma concentration-time curve (AUC, represent systemic exposure after a 
dose) of the predicted and observed data. Model performance was assessed by intra- and inter-
study validations. For the intra-study validations, we used the clinical PK data from different 
dosing ranges from the same study that was used to build the PBPK profiles. For inter-study 
validations, we used data from several model naïve clinical PK studies that were not used in model 
building. For the validations, we performed visual plots of fitted and the predicted against the 
observed mean concentration-time profiles. The 5th to 95th intervals of the predicted concentrations 
were calculated to show the overall inter-patient variability. PBPK models of IV and SL BUP were 
developed and validated using 14 independent BUP PK studies in non-pregnant subjects (5 
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intravenous single dose, 5 SL single dose, and 4 SL multiple dose). We then adapted this validated 
SL BUP PBPK model to pregnancy-based model by incorporating physiological changes across 
trimesters that may impact BUP exposure, including increase in the expression CYPs 3A4, 
increase in cardiac output, plasma volume, and red blood cell volume, and decrease in hematocrit, 
and albumin. The BUP SL PBPK pregnancy model was validated with our two in-house 
prospective clinical trials in pregnant women in three trimesters and postpartum. The model 
predicted decreased BUP exposure in all three trimesters, compared to the postpartum period. The 
model predictions were consistent with the observations in the 1st, 2nd and 3rd trimester in a 
prospective pilot BUP PK study in pregnant women (Chapter 4). 
 
We also applied nonlinear mixed effect model to explore population PK parameters 
including clearance, and volume of distribution of BUP, as well as between subject variability and 
between occasion variability (different trimesters) to study alteration of BUP metabolism during 
pregnancy. Specifically, we used first-order conditional estimation with interaction method to 
explore whether 1 or 2 compartment model fits the clinical data best. For the discrimination 
between different base models, we used AIC and certain diagnostic plots. As BUP was dosed via 
sublingual administration in the study, we also explored whether adding a lag time or additional 
absorption compartment through separate or combined sequential, parallel or linked zero and first 
absorption model would improve model fitting. After finalizing the base model, we used stepwise 
forward/backward method to explore categorical and continuous factors, including pregnancy, 
gestation weeks, and body weight, age that may influence BUP pharmacokinetics. Simulation 
based diagnostic methods, such as visual predictive check (VPC) and bootstrap were employed to 
evaluate the covariate models. A two-compartment model with 1st-order absorption containing 
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EHC and 1st-order elimination best described the absorption and disposition of buprenorphine 
following sublingual administration. Pregnancy was identified to be associated with significant 
differences in BUP PK with the apparent clearance of buprenorphine being increased 1.64-fold 
during pregnancy compared to the postpartum period. None of the other patient covariates 
explained interindividual variability in BUP PK in pregnant women (Chapter 5).  
Lastly, we applied PK /PD analysis to evaluate the time course of the effect of 
buprenorphine on COWS score and pupillary diameters and to characterize the pharmacokinetic 
/pharmacodynamic properties of buprenorphine in order to optimize buprenorphine dosing in 
pregnant women. We observed significantly lower plasma exposure of BUP and significantly 
higher AUC of COWS score in a dosing interval of BUP during pregnancy compared to the values 
during the postpartum period under the current dosing regimen in the pregnant women. There were 
no direct correlation between COWS score, pupillary diameter and the plasma concentration of 
BUP. The relationship between pupillary diameter and buprenorphine concentration was described 
by a sigmoidal Emax model with a hypothetical effect compartment. The model estimated that 
buprenorphine was transferred from the central compartment to a theoretical biophase 
compartment with a 1st-order transfer kinetics at a rate constant at 0.723 hr-1. The estimated 
maximal effect (Emax) and buprenorphine concentration at the theoretical effect site exerting a half-
maximal effect (IC50) were 82.9 % and 0.63 ng/mL, respectively. The model analysis revealed that 
buprenorphine was very potent in producing miotic effect. The population PK /PD modeling 
analysis demonstrated that pupillary constriction was induced after administration of 
buprenorphine. The pupillary diameter was associated with predicted buprenorphine concentration 
at a hypothetical effect compartment. The IC50 of BUP was not significantly different during 
pregnancy and postpartum in the PK/PD model analysis of pupillary diameter. The findings from 
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the modeling analysis were in accordance with the pharmacological mechanism of buprenorphine 
as a mu-opioid agonist (Chapter 7). 
To conclude, an integration of small cohort of clinical studies, and model-based strategies 
such as PBPK and population PK/PD can facilitate clinical decision making in optimize doing of 
medications used in pregnant women.  
 
Primary contribution of the current work 
 
• A simple, selective, rapid and sensitive UPLC-MS/MS assay to simultaneously quantify 
plasma concentrations of buprenorphine, norbuprenorphine, buprenorphine glucuronide 
and norbuprenorphine glucuronide using a small volume of human plasma was developed 
and validated. This methodology was applied in a BUP pk study in pregnant women. 
• Analysis of BUP metabolite to BUP parent molar concentration ratio demonstrated 
alterations in CYP- and UGT- mediated metabolic pathways during pregnancy. 
• Physiologically-based pharmacokinetic models of IV and SL BUP were developed and 
validated using 14 independent BUP PK studies in non-pregnant subjects. 
• A BUP SL PBPK pregnancy model was validated with our two in-house prospective 
clinical trials in pregnant women at three trimesters and postpartum. 
• A population PK model was developed and the model –based analysis indicated the 
apparent clearance of buprenorphine to be increased 1.64-folds during pregnancy 
compared to the postpartum period. 
• In the PK/PD analysis, we observed significantly lower plasma exposure of BUP and 
significantly higher AUC of COWS score during a dosing interval of BUP during 
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pregnancy compared to the values during the postpartum period under the current dose 
regimen.  
• A population PK/PD model was developed to describe the time course of the changes in 
pupillary diameter with BUP concentrations. The IC50 of BUP was not significantly 
different during pregnant and postpartum in the PK/PD model analysis of pupillary 
diameter. 
 
Clinical implications 
 
• The clinical study, PBPK and PopPK modeling have identified that pregnancy is associated 
with increased BUP apparent clearance and decreased BUP exposure.  
• To optimize BUP dosing in pregnant women higher doses or more frequent dosing are 
warranted (eg. double dose or TID, QID dosing). 
• PBPK and PoPPK modeling and simulation can be used to predict drug exposure and 
response during pregnancy. 
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7.2 Limitations 
• A relatively small number of patients (4) were enrolled during the 1st-trimester in 
the clinical studies. The time course of buprenorphine in the 1st trimester obtained 
from the 4 patients may not represent the general population in the 1st trimester. 
Additional patients are being enrolled in the 1st trimester in an ongoing clinical 
study and this will be used for further validation. 
• Nausea is a common problem in pregnant women. Patients in the two clinical 
studies broke the SL tablet into smaller pieces to reduce the nausea and discomfort 
of holding the medication under the tongue. Breaking up a tablet decreases the 
disintegration and dissolution time, and can lead to a faster drug absorption. This 
may be a reason for the high variability observed in Tmax in the clinical studies. 
• In the analysis of the alterations of CYP- and UGT-mediated metabolism of 
buprenorphine, we observed greater mean ratios of AUC of metabolites to parent 
in both metabolic pathways. However, the ratios of AUC of metabolites to parent 
were decreased in some patients during pregnancy compared to the ratios at 
postpartum, especially in the CYP-mediated N-demethylation pathway. The 
decreases in the AUC ratios suggests that there is a decrease in the activity of that 
metabolizing pathway in these patients, which is not in agreement with 
observations in other studies. The changes in the directions of enzyme activities in 
these patients may be due to other factors such as altered compensatory effect of 
other metabolic pathways or potential drug interactions. In the clinical studies, we 
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did not analyze genotypes of all of the drug metabolizing enzymes that are 
responsible for the metabolism of buprenorphine and its impact is currently not 
clear. Genotypes of the drug metabolizing enzymes in the patients are being 
investigated in an ongoing study. 
• The primary challenge in building a comprehensive fetal compartment is the limited 
information on the fetal physiological development and drug exposure in the fetus 
during pregnancy. In SimCyp®, the fetal-placental unit is considered as a combined 
compartment in pregnant women. The fetal-placental unit is simplified as a 
homogenous organ with the assumption that the components of the unit have 
similar characteristics of blood perfusion and drug partitioning. So we were not 
able to estimate BUP exposure in the fetus in this study.  
• In the development of PBPK model, the brain was modelled as a perfusion-limited 
compartment due to the lack of information regarding active and passive transport 
of buprenorphine in the brain. In the PBPK model of BUP, the availability of µ-
opioid receptor was assumed to have direct relationship with the plasma 
concentration of buprenorphine. The biological processes such as biophase 
distribution, drug-receptor interaction and signal transduction were not included in 
the simulation. 
• In the clinical study 1, pupillary diameters were only measured at trough, 4, 8 and 
12 hours after a dose of buprenorphine. In the second clinical study, the dosing 
frequencies of buprenorphine were three times a day or four times a day in most of 
the study participants. Only limited pupillary diameter sizes were collected at 10 
and 12 hours after a BUP dose, resulted in inadequate description of the pupillary 
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diameter after 10 hours following a buprenorphine dose in the PK/PD model. In 
addition, due to patient safety concerns we were unable to collect the true baseline 
pupillary diameter when there was no buprenorphine in patients. The baseline 
pupillary diameters were estimated by the model, which were predictions of the 
pupil diameter sizes when there was no buprenorphine in the patient.  
 
7.3 Future Directions 
• Impact of plasma protein in binding changes: The unbound drug concentration is 
determined by the unbound fraction of drug and the total drug concentration in plasma. The 
decrease in the total concentration of buprenorphine and increase in the unbound fraction 
of buprenorphine may result in no changes in the unbound plasma concentration of 
buprenorphine during pregnancy.  As only unbound drug is able to cross blood brain 
barrier, unbound buprenorphine concentration in the brain may not be different during 
pregnancy compared to the levels in non-pregnant women. We will measure the unbound 
fraction of buprenorphine in plasma to evaluate the changes of unbound concentration of 
BUP in pregnant women. Animals studied are being performed to evaluate the effect of 
pregnancy on brain distribution of BUP and its metabolites. 
• Exposures at various trimesters: Currently, limited numbers of pregnant women have been 
studied. A clinical BUP PK/PD study in pregnant women is ongoing.  More patients will 
be enrolled in the clinical study, especially patients in the 1st trimester. These data will be 
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added to the model to further validate and evaluate application of PBPK model at various 
trimesters in pregnancy.  
• Fetal exposure: The present PBPK model has been developed to predict the plasma 
concentration of BUP in the mother. A PBPK model will be developed to predict BUP 
exposure in the fetus to understand the association between fetal BUP exposure and NAS. 
• Metabolic pathways in pregnancy: The BUP metabolite to parent ratio appears to be altered 
perhaps due to the alteration of CYP- and UGT- mediated pathway of BUP during 
pregnancy. With more patient enrolled in the current clinical study, we will develop a 
simultaneous BUP parent/metabolite PBPK and PopPK model to quantify the changes of 
CYP3A4 and UGTs mediated metabolic pathways to better understand the modulations of 
the activities of these enzymes in pregnancy. 
• There was a general trend for an increase in N-demethylation and glucuronidation pathway 
in pregnancy. However, in a few subjects the 𝐴𝐴𝐴𝐴𝐴𝐴 𝑁𝑁−𝑑𝑑𝑅𝑅𝑐𝑐𝑅𝑅𝑑𝑑ℎ𝑦𝑦𝑦𝑦𝑑𝑑𝑑𝑑𝑅𝑅𝑑𝑑 𝑁𝑁𝐴𝐴𝑃𝑃
𝐴𝐴𝐴𝐴𝐴𝐴 𝑁𝑁𝐴𝐴𝑃𝑃   decreased in 
pregnancy. The reason for this should be further evaluated. We will further study the 
alterations of the activities of CYP3A4 during pregnancy and postpartum in study patients 
by analyzing the changes in the metabolism of endogenous compound, the ratio of 4β-
hydroxycholesterol/ cholesterol. 
• The enzymes responsible for metabolism of BUP (CYPs and UGTs) are known to be 
polymorphic. Genotypes of CYPs and UGTs in these patients will be determined. The 
impact of genotype on the magnitude and direction of change in exposure during pregnancy 
will be evaluated in future studies. 
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• The exact contributions of CYPs and UGTs to the metabolism of BUP are unknown. An 
in vitro study will be performed to evaluate simultaneous biotransformation of BUP 
through the two pathways in hepatocytes. 
• Additional work of BUP PBPK model: to further validate BUP PBPK model in liver 
disease population and drug-drug interaction studies using clinical data; to develop a 4-
compartment BUP brain PBPK model in rats and validate predicted BUP concentration in 
the brain in rats with BUP PK study in rats; to extrapolate the 4-compartment BUP brain 
PBPK model in rats to human and predict BUP concentration in the brain in human. 
• Additional PK /PD analysis: Currently, only the primary PD effects (COWS score and 
pupillary diameter) of BUP have been evaluated in pregnant women. We will also evaluate 
the time course of the effect of buprenorphine on other physiological measurements such 
as hear rate, respiratory rate, blood pressure and galvanic skin temperature in the ongoing 
clinical studies. 
 
 
A better understanding of BUP PK /PD will facilitate better treatment protocols for pregnant 
women. 
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Appendix A 
Table 7-1Physiochemical and pharmacokinetic parameters used to develop buprenorphine profile in 
Simcyp® 
 Parameter Value Reference/Source 
Physiocochimical 
      MW (g/mol) 467.64 Pubchem/ DrugBank 
      Log Po:w 4.98 [70] 
      Compound type Diprotic Base 
      pKa1, pKa2 9.62, 8.31 [70] 
      B/P 0.55 [89] 
      fu 0.03 [338]/ Parameter optimization 
Absorption 
      Absorption model 1st order absorption model 
      fa 0.80 Parameter estimation tool 
      Ka (1/h) 2.34 Parameter estimation tool 
      Lag time (h) 0.7 Parameter estimation tool 
      Qgut (L/h) 8.12 Predicted 
      fuGut 1 User input 
      Permeability predicted via PSA 
PSA (Å):62.16 Pubchem/ DrugBank 
HBD: 2 Pubchem/ DrugBank 
Distribution 
      Distribution model Full PBPK model 
      Prediction method of Vss Method 1(Corrected 
Poulin-Theil) 
      Predicted Vss (L/kg) 2.48 
Elimination 
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Abbreviations to Appendix A.1: MW: molecular weight; logPo:w: logarithm of the octanol to water 
partition coefficient, pKa: negative logarithm of the acid dissociation constant, B/P: blood to 
plasma partition coefficient; fu: Plasma fraction unbound; PSA: polar surface area; HBD: number 
of hydrogen bond donors; Vss: apparent volume of distribution at steady state; Clint: intrinsic 
clearance. 
A.2
Table 7-2Key pharmacokinetic parameters of buprenorphine in non-pregnant subjects (range, or mean±SD) 
PK parameter Value Reference 
CL (L/h) 50-62.5 [74, 78, 87, 88] 
Bioavailability of SL dose 36±13% [78] 
Tmax(h) 0.75-1.5 [66, 69, 283] 
Cmax (ng/mL, mean ± SD) following 8 mg 
single SL dose  
2.88±1.14 [339] 
AUC 0-inf (ng*h/mL, mean ± SD) following 
8 mg single SL dose 
28.39±10.22 [339] 
Abbreviations: CL: Clearance, Tmax: Time to reach maximum concentration, Cmax: Maximum 
    Clearance type Enzyme kinetics 
    In vitro metabolic system Recombinant 
        CYP3A4 [268] 
            Vmax (pmol/min/pmol of 
 
10.4 
            Km (µM) 13.6 
CYP2C8 [268] 
 Vmax (pmol/min/pmol of isoform) 1.4 
            Km (µM) 12.4 
        UGT1A1 [281] 
            Clint (µL/min/pmol of 
 
0.0162 
        UGT1A3 [281] 
            Clint (µL/min/pmol of 
 
0.0155 
        UGT2B7 [281] 
            Clint (µL/min/pmol of 
 
0.0116 
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concentration, AUC0-inf: Area under plasma concentration-time curve from time 0 to infinite. 
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Appendix B  Clinical Opioid Withdrawal Scale 
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Clinical Opiate Withdrawal Scale (COWS) 
Flow-sheet for measuring symptoms over a period of time during buprenorphine induction. 
For each item, write in the number that best describes the patient’s signs or symptom. Rate on just 
the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the 
patient was jogging just prior to assessment, the increase pulse rate would not add to the score. 
Subject ID# |__|__|__|__|__|__|__|__|                       Date: ______________ 
Buprenorphine induction: 
Enter scores at time zero, 30min after first dose, 2 h after first dose, etc. 
 Times: ______ ______ ______ ______ 
Resting Pulse Rate: (record beats per minute) 
Measured after patient is sitting or lying for one minute 
0 pulse rate 80 or below 
1 pulse rate 81-100 
2 pulse rate 101-120 
4 pulse rate greater than 120 
Sweating: over past ½ hour not accounted for by room 
temperature or patient activity. 
0 no report of chills or flushing 
1 subjective report of chills or flushing 
2 flushed or observable moistness on face 
3 beads of sweat on brow or face 
4 sweat streaming off face 
Restlessness Observation during assessment 
0 able to sit still 
1 reports difficulty sitting still, but is able to do so 
3 frequent shifting or extraneous movements of legs/arms 
5 Unable to sit still for more than a few seconds 
Pupil size 
0 pupils pinned or normal size for room light 
1 pupils possibly larger than normal for room light 
2 pupils moderately dilated 
5 pupils so dilated that only the rim of the iris is visible 
Bone or Joint aches If patient was having pain 
previously, only the additional component attributed to 
opiates withdrawal is scored 
0 not present 
245 
1 mild diffuse discomfort 
2 patient reports severe diffuse aching of joints/ muscles 
4 patient is rubbing joints or muscles and is unable to sit still 
because of discomfort 
Runny nose or tearing Not accounted for by cold 
symptoms or allergies 
0 not present 
1 nasal stuffiness or unusually moist eyes 
2 nose running or tearing 
4 nose constantly running or tears streaming down cheeks 
GI Upset: over last ½ hour 
0 no GI symptoms 
1 stomach cramps 
2 nausea or loose stool 
3 vomiting or diarrhea 
5 Multiple episodes of diarrhea or vomiting 
Tremor observation of outstretched hands 
0 No tremor 
1 tremor can be felt, but not observed 
2 slight tremor observable 
4 gross tremor or muscle twitching 
Yawning Observation during assessment  
0 no yawning 
1 yawning once or twice during assessment 
2 yawning three or more times during assessment 
4 yawning several times/minute 
Anxiety or Irritability 
0 none 
1 patient reports increasing irritability or anxiousness 
2 patient obviously irritable anxious 
4 patient so irritable or 
Gooseflesh skin 
0 skin is smooth 
3 piloerrection of skin can be felt or hairs standing up on arms 
5 prominent piloerrection 
Total scores 
with observer’s initials 
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Score: 
5-12 = mild;
13-24 = moderate;
25-36 = moderately severe;
More than 36 = severe withdrawal
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